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CHAPTER 1 INTRODUCTION
Please note that part of content of this chapter is from a chapter of
Nanomedicine for Inflammatory Diseases, “Bridging the Gap between Bench and
Clinic; Asthma” is being copyedited and will be published in Nanomedicine for
Inflammatory Disease, Taylor & Francis Group, UK, 2016 (in process). The
authors of this book chapter include Rima Kandil, Dr. Olivia Merkel and me.
Rima Kandil and me are the joint first authors of this book chapter.
1.1 Gene therapy
Gene therapy is the in vivo delivery of therapeutic nucleic acids into cells
or tissue to treat or prevent a disease. Nucleic acid mediated therapies include: a)
replacing a malfunctioning gene with a functional wildtype gene; b) silencing a
mutated gene; c) supplementing a gene encoding a missing protein in cells; d)
boosting the immune response toward foreign infectious organisms1.

Gene

therapy is thought to be the solution for hard to cure diseases including genetic
diseases, cancer, neurodegenerative disease, immunodeficiency and HIV, and
extensive studies in pre-clinic research and clinical trials have been completed and
are going-on. Currently, gene therapy can be conducted via two different
approaches. One is the ex vivo approach, where nucleic acids are transferred into
autologous target cells collected directly from individuals. These gene- corrected
cells are returned back to the body and fight the disease. The other is the in vivo
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approach, where nucleic acids are directly administrated to patients for nucleic
acid delivery to target cells inside the body2.
By 2012, over 1800 gene therapy clinical trials were performed in 31
countries. Most of these trials (64.4%) focus on treatments of different cancers

3

since the five-year survival rates of certain cancers are still very low, such as liver
(17.5%), lung (17.7%) and pancreatic cancer (7.7%) according to a report from the
National Cancer Institute (2009-2013). Current pre-clinic research and clinical
trials for gene therapies of cancer include several strategies. The first one is the
replacement of mutated tumor suppressor genes such as p53. Advexin® is a gene
p53 encoding plasmid carried by an adenoviral vector. It showed antitumor
activity and improved survival in clinical trials for treatment of head and neck
cancer 4. Another approach is the supplement of a ‘suicide gene’ encoding a
viral/bacterial enzyme which can covert a pro-drug to an active drug in cancer
cells 5. Silencing of gene controlling tumorigenesis (e.g. proliferation and survival),
metastasis and drug resistance is also a common approach 6. In Chapter 4, our
study reports that silencing of GASC1, an epigenetic factor involved in
tumorigenesis, can inhibit the proliferation of basal-like breast cancer cells.
Gene therapy of inflammatory diseases only accounts for small potion in
gene therapy clinical trials (0.7%) 3. However, a large global market of drugs for
inflammatory diseases 7 encourage research groups and pharmaceutical companies
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to develop new therapies consequently increasing the number of pre-clinical
research approaches and clinical trials of gene therapy for inflammatory diseases.
For example, gene therapy approaches for asthma include DNA vaccines to induce
immune tolerance 8, delivery of antisense oligonucleotides 9, small interfering
RNA (siRNA) 10 and deoxyribozymes (DNAzyme) 11 for the selective silencing of
asthma related genes. Currently, there is one gene therapy approach for asthma in
clinical trial using SB010. SB010 is a DNAzyme which can cleave GATA-3, a
key factor in asthma pathogenesis. It can achieve anti-inflammatory effects and
improved lung function in asthmatic patient

11

. In Chapter 2 & Chapter 3, the

application of siRNA as novel therapies of asthma will be discussed.
1.2 Delivery of nucleic acids
1.2.1 Viral delivery system
Many viruses naturally have the ability to effectively transfer their genetic
material and express proteins in host cells as part of their replicate cycle.
Therefore, they offer the potential to deliver nucleic acids to mammalian cells for
gene therapy. In a viral delivery system, the gene which is essential for viral
duplication is deleted and replaced by a therapeutic gene. Viral delivery systems
show advantages, including high in vivo transduction efficiency and constant
expression of the target gene

12

. Viral vectors, including adenovirus, retrovirus,

adeno-associated virus, herpes simplex virus and lentivirus, are the most common

4

delivery system of nucleic acid in clinical trials of gene therapy 3. The number of
gene therapy clinical trials increased dramatically since the first gene therapy was
approved in 1990. The first trial aimed to treat a kind of severe combined immune
deficiency (SCID) which lacks a gene encoding adenosine deaminase (ADA).
Patients were administrated autologous T cells transduced by retroviral vectors
carrying genetic material encoding ADA. Even though this trial only showed
modest results, it demonstrated the feasibility and potential of gene therapy in
clinical use 13. However, concerns regarding safety of viral vector from the public
and from researchers arose while increasing numbers of clinical trials of gene
therapy have been approved. One of the major setbacks of gene therapy was the
case of Jesse Gelsinger. In 1999, 18-year-old Jesse Gelsinger, who suffered from a
metabolic disorder due to partially defect ornithine transcarbamylase (OTC),
entered a clinical trial of gene therapy aiming to supplement OTC using an
adenoviral vector containing genetic material encoding OTC. Tragically,
Gelsinger died from a severe and unexpected immune reaction to the viral vector.
In 2000, the United States Food and Drug Administration (USFDA) stopped this
trial and some other trials employing gene therapy. The FDA announced new
programs and restrictions, including the Gene Therapy Clinical Trial Monitoring
Plan and the Gene Transfer Safety Symposia, to protect patients better 14. Another
common viral vector, retrovirus vector, was used in a clinical trial to treat 11
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children who had severe combined immunodeficiency (SCID)-XI disease which
was the first success in gene therapy 15. However, 5 children developed leukemialike illness which was believed to be due to insertion of the retrovirus vector
which triggered the expression of proto-oncogenes 16. Extensive efforts have been
devoted to improve the safety of viral vectors and promising progress has been
made. Several new drugs for gene therapy were approved. Genedicine, an
adenoviral vector carrying wildtype p53 gene, is the first gene therapy drug in the
clinic for treatment of head and neck squamous cell carcinoma approved by the
China Food and Drug Administration (CFDA). Another drug for gene therapy is
Glybera, an adeno-associated virus carrying gene encoding human lipoprotein
lipase (LPL), approved by the European Medicines Agency (EMA) and USFDA
for treatment of lipoprotein lipase deficiency. Despite the improved safety of viral
vectors and the success in the clinic, concerns of potential severe side effects, such
as immunogenicity and carcinogenesis, caused by viral vectors never vanished and
additional care is taken regarding the approval of gene therapy using viral vectors.
On the other hand, the complexity of viral vectors manufacture and limited DNA
packaging capacity also limit the large scale clinical use 17.

6

1.2.2 Non-viral delivery system
1.2.2.1 Challenges of delivery of nucleic acids
Because of the limitations and concerns mentioned above, the application
and development of non-viral delivery became more popular. Non-viral vectors
demonstrate many advantages compared to viral vector. First of all, non-viral
vectors have better and tunable safety profiles than viral vectors. Biocompatible
materials can be selected to achieve less immunogenicity and toxicity. Non-viral
vectors can be also synthesized by biodegradable materials to reduce the toxicity
and accumulation in the body. Moreover, applications of non-viral vectors for
gene therapy can avoid insertional mutagenesis. Non-viral vectors have larger
capacity for delivery of nucleic acid and are less complicated in their manufacture
process which makes it easier for scaling up the production. More importantly,
because the relatively simple chemical structure of non-viral vectors, such as
polymer-based materials, various modifications have been done to achieve
efficient and selective gene delivery, better safety and optimal pharmacokinetic
profiles 18. For example, non-viral vectors are commonly modified with targeted
ligands such as folic acid

19

and transferrin

20

to achieve cell/tissue specific

delivery. PEGylating non-viral vectors has been utilized to increase the
biocompatibility and circulation time
accumulation

22

21

and to achieve tissue specific

. Despite the numerous studies which have been performed to
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develop and optimize non-viral vectors, their gene delivery efficiency is still
relatively poor especially compared to their viral counterparts. Consequently, only
a few non-viral vectors are mature enough to enter clinical trials 18.
Non-viral vectors will encounter various challenges when they are applied
to deliver nucleic acids systemically. Nucleic acids are easily degraded by
endogenous nucleases in the circulation. The half-life of nucleic acids in the blood
stream is short, for instance, the half-life of naked plasmid DNA injected
intravenously (i.v.) has been reported to be 10 minutes in mice. Nucleic acids
carried by non-viral vectors are not readily degraded by nucleases and have longer
circulation half-lives. Chemical modification in nucleic acid can also facilitate to
protect them against the cleavage by nuclease and increase their in vivo stability.
Common modification include incorporation of 2’-O- methyl to replace the 2’OH group in the ribose in siRNA and combination of 2-thiouridine and 5methylcytidine in mRNA 18.
Non-viral vectors need to overcome several biological barriers to deliver
nucleic acids to target cells/tissues. Most non-viral vectors contain polycations or
cationic lipids to condense nucleic acids which have negatively charged backbones.
Nucleic acids can electrostatically interact with non-viral vectors and form
polyplexes or lipoplexes which commonly have a net positive surface charge. This
positive charge can induce non-specific association with non-target cells and
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interaction with serum proteins in circulation. Vectors covered with a corona of
serum proteins are easily recognized and trapped by the reticuloendothelial system
(RES), such as liver, spleen and bone marrow. Consequently, only a small dose of
i.v. administrated cationic nanoparticles can be delivered and accumulate at the
target site. One of the strategies to reduce the positive charge and non-specific
delivery is to decorate the vectors with polyethylene glycol (PEG), a hydrophilic
and charge-neutral polymer. PEG shields the polyplexes/lipoplexes in the blood
stream and avoids non-specific delivery. Most importantly, it prevents interaction
with serum proteins and reduces accumulation in the RES which significantly
increases the circulation time of polyplexes/lipoplexes 23.
Another challenge is selective accumulation in the tissue of interest. The
behavior of non-viral vectors of nucleic acids in the body is highly dependent on
their size, shape and surface properties. Typical non-viral vectors carrying nucleic
acids, such as lipoplexes and polyplexes, are of spherical shape and in the
nanometer range. Large lipoplexes/polyplexes (> 200 nm) tend to accumulate in
liver and spleen and micrometer size particle (2-5 um) rapidly accumulate in the
capillaries of the lung. Therefore, particle sizes around 100 nm are preferred

24

.

Normal blood vessels have tight interendothelial junctions and prevent
extravasation of lipoplexes/ polyplexes from the blood stream. In certain cases,
such as inflammation and injury, leakage and dysfunction occur in the blood

9

vessel and lead to accumulation of lipoplexes/polyplexes at these sites. This
strategy is commonly utilized to target tumors. The blood vessels supporting
tumor growth are fenestrated, and tumors often lack efficient lymphatic drainage.
This phenomenon is termed the “enhanced permeability and retention (EPR)
effect”. Modifications in vectors to prolong circulation time, such as PEGylation,
can increase the accumulation at the tumor site. Another consideration is fluid
dynamics of lipoplexes/ polyplexes. Particles with spherical shape demonstrate
less lateral drift in the blood stream compared to non-spherically shaped particles
which result in lower association with endothelial cells and extravasation from the
blood stream 24.
Once the lipoplexes/polyplexes reach their selective site, even if some
hydrophobic vectors can diffuse directly through the cellular membrane, most
vectors require active internalization. Ligand modification in vectors can enhance
cellular uptake via receptor mediated internalization. Moreover, vectors equipped
with cell penetration peptides, such as trans-activating transcriptional activator
(TAT) from the human immunodeficiency virus 1 (HIV-1), can also mediate
efficient cellular uptake. Endocytosis of lipoplexes/polyplexes involves formation
of intracellular vesicles termed endosomes. Endosomes eventually merge with
lysosomes, which are vesicles that contain a highly acidic and enzyme rich
environment and are capable of degrading the vectors and therapeutic nucleic

10

acids. Therefore, escape from the endosome is required for vectors to avoid
degradation and to release nucleic acids into cytoplasm. To facilitate endosomal
escape, the vectors can be modified with endosomolytic peptides, such as melittin,
to disrupt the endosomal membrane

25

. Cationic polymers which have a high

buffer capacity, such as poly ethyleneimine (PEI), can absorb protons and lead to
an increased influx of counter ions (chloride) and water. Eventually, the increased
osmotic pressure leads to bursting of the endosome and the release of materials
inside the vesicles. This theory is called “proton sponge effect”. Another reason
why cationic polymers and lipids can achieve efficient endosomal escape is called
“flip-flop”

mechanism.

The

polymer/lipid

with

positive

charge

can

electrostatically interact with vesicle membranes with negative charge and lead to
membrane flipping and destabilization 23.
Different kinds of therapeutic nucleic acids face different challenges in the
cytosol. Plasmid DNA (pDNA) needs to be delivered into the nucleus and requires
access to the transcriptional machinery to express protein. Direct microinjection of
pDNA carrying the thymidine kinase genetic information into nuclei of cells
lacking thymidine kinase induces thymidine kinase expression in 50-100% of the
cells. However, little activity of thymidine kinase was observed in the cells
microinjected with pDNA into the cytoplasm. Furthermore, pDNA can express
proteins efficiently in fast proliferating and dividing cells, since during mitosis the

11

nuclear envelope breaks down and the nucleus becomes more accessible to pDNA
in the cytoplasm. In contrast, pDNA transfection results in poor protein expression
in slow dividing cells due to their nucleic envelope being intact. These studies
indicate that the nuclear envelope is the major barrier for delivery of pDNA to the
nucleus. To overcome this barrier, modification with nuclear localiztion signal
(NLS) sequences in non-viral vectors have been prepared and result in enhanced
nuclear delivery efficiency and protein expression

26

. Small interfering RNA

(siRNA) requires to be successfully incorporated into the RNA-induced silencing
complex (RISC) to achieve gene silencing. The least stably hybridized 5’ terminal
of siRNA tends to load into the RISC, therefore, modification of the 5’ end of
siRNA is not recommended

18

. Application of longer double stranded RNA

(dsRNA) to trigger gene silencing results in higher gene silencing efficiency.
Synthetic long dsRNA (25-30 base pair) demonstrated 100-fold higher gene
silencing efficiency compared to corresponding shorter siRNA (21 bp). It is
believed that long dsRNA is a substrate of Dicer, a RNase-III class
endoribonuclease, involved in RNA interference. Dicer can facilitate siRNA
loading into the RISC and plays a role in RISC assembly. Therefore, more
efficient gene silencing can be achieved when its substrate, long dsRNA, is
provided to Dicer compared with delivery of conventional synthetic siRNA (21 bp)
to RISC 27.
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1.2.2.2 Synthetic non-viral vector
Non-viral vectors include polymers, cationic lipids, synthetic peptides,
RNA/DNA chimera and inorganic nanoparticles (e.g. gold, magnesium)

28

. This

section will focus on introducing the application of polymeric vectors for gene
delivery.
There are three strategies of how polymeric vectors can carry nucleic acids:
encapsulation, adsorption and electrostatic interaction. Nucleic acids can be
encapsulated into biodegradable polymers, such as poly lactide-co-glycolide
(PLGA), poly lactic acid (PLA) and poly beta-amino esters, to prevent enzymatic
degradation in vivo and to achieve controlled release. The backbone of
biodegradable polymers usually contains ester linkages which can be hydrolyzed
and cleared easily in the body. The kinetics of nucleic acid release is tunable via
adjustment of the hydrolysable parts in the polymer

29

. PLGA is a popular

biodegradable polymer for gene delivery since it is approved for human use
worldwide. PLGA can successfully encapsulate plasmid DNA, a relatively large
nucleic acid, and achieve efficient transfection

30

. Small nucleic acid such as

siRNA can be also encapsulated into PLGA. However, there are several
challenges in this process including leakage of siRNA from PLGA particles, low
loading efficiency and encapsulation efficiency

31

. Moreover, degradation of

nucleic acids may happen during the encapsulation process since they are exposed
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to organic solvents and sonication or long term solvent evaporation may be
required. Degradation may also happen inside the particle due to the low pH
environment caused by hydrolyzation of esters in the polymer

29

. To overcome

these limitations, an adsorption loading strategy has been developed. Adsorption is
a technique that combines both encapsulation and electrostatic interaction
strategies. A cationic polymer can be incorporated into a biodegradable polymer 32
or adsorbed onto the surface of formed particles

33

. Therefore, nucleic acids can

efficiently be loaded by the cationic moiety to avoid the harsh encapsulation
process and hydrolyzation environment

29

. The most common strategy to pack

nucleic acids using polymers is electrostatic interaction. This technique takes
advantage of the anionic nature of nucleic acids, contributed by the phosphate
group connecting the ribose molecules. Nucleic acids can electrostatically interact
with cationic polymers and form particles suitable for efficient gene delivery 29.
Many cationic polymers are exploited for gene delivery including poly- Llysine (PLL), acrylate based polymers, poly(amino-ester) based polymers,
polyamidoamine (PAMAM) dendrimers and PEI based polymers. For example,
PLL is a biodegradable polymer which is one of the first cationic polymers to be
utilized in gene transfer. Despite the favorite biocompatibility of PLL, the short
half-life in circulation and low transfection efficiency limit its use. PAMAM
dendrimer is a symmetric macromolecule which has repetitive units of amido-
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amines and primary amines located at the terminal surface. The controlled
synthesis process of PAMAM dendrimers results in its narrow molecular weight
range and defined spheroidal shape. Surface primary amine can efficiently
condense nucleic acids and can easily be chemically modified with functional
groups (e.g. targeting ligands, PEG, cyclodextrin). More importantly, large
amount of internal tertiary amino group can serve as “proton sponge” to buffer pH
change in endosome resulting better endosomal escape 34.
Among the cationic polymers, PEI is one of the most extensive studied
polymers for gene delivery and is considered as the gold standard transfection
reagent. PEI can be synthesized in different molecular weight and structure such
as linear and branched. PEI usually contains primary amines and secondary
amines as well as tertiary amines if its structure is branched. This amine rich
structure renders PEI the ability to efficiently compact nucleic acids and protect
them from degradation. Similar to PAMAM dendrimers, PEI has a large buffer
capacity leading to high transfection efficiency. Researchers

have

developed

various PEI based polymers to achieve better transfection efficiency and better
biocompatibility. S. Kim et al. reported that low molecular weight PEI (2000 Da)
conjugated with hydrophobic lipids such as cholesterol and myristate
demonstrated enhanced transfection efficiency of plasmid DNA encoding βgalactosidase in 293 cell lines. The exact mechanism of how lipid modification of

15

PEI increases transfection efficiency is still unclear. It is hypothesized that the
hydrophobic lipid increases the association with the lipophilic cell membrane

35

.

Other hydrophobic modifications have been used for PEI, including phospholipids
36

, alkanes 37, fatty acids
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and hydrophobic poly (amino acids) 39. M. Zheng and

her co-workers described that grafting PEI with poly-caprolactone-b-PEG (PCL-bPEG) increased the buffer capacity of copolymers compared to non-modified PEI
and resulted in corresponding enhanced transfection efficiency. Biodegradable
PCL served as a linker between PEI and PEG. Moreover, the hydrophobicity of
PCL is believed to facilitate the association between the PEI-PCL-PEG
copolymers and the cellular and endosomal membrane

40

. To increase the

endosomal escape, endosomolytic peptides modifications (e.g. mellitin

41

and

truncated HGP 42) and cell penetration peptide modifications (e.g. TAT 43) in PEI
have been developed and demonstrated enhanced transfection efficiency. One of
the limitations of endosomolytic peptides is their lytic activity under physiological
conditions which can lead to destabilizations of plasma membrane and cell lysis. S.
Boeckle et al. developed a PEI based polymer equipped with mellitin analogs. The
neutral glutamines in mellitin (Mel) were replaced by glutamic acid residues
resulting in high lytic activity at endosomal pH (pH 5) rather than physiological
pH (pH 7). Different mellitin analogs (MA) were conjugated to PEI at cysteine
modified C-termini (CMA-PEI). At endosomal pH 5, strong erythrocyte lysis was
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observed after the treatment with CMA-2-PEI and CMA-3-PEI but not with
CMA-4–PEI, CMA-1-PEI and Mel-PEI. Accordingly, CMA-2–PEI and CMA-3–
PEI mediated more efficient transfection of plasmid DNA encoding a reporter
protein Luciferase in 4 different cell lines (CT 26, HeLa, Neuro2A and A-10 cells)
compared to Mel-PEI, unmodified PEI, CMA-1-PEI and CMA-4-PEI. However,
increased corresponding toxicity was observed at high DNA doses (4 and 8 μg/ml)
41

. Another attempt to attenuate the toxicity of Mel under physiological condition

has been approached by the same group. M. Meyer et al. utilized dimethyl maleic
anhydride (DMMAn) to reversibly react with the lysines in Mel which could
reduce the lytic activity. Since the DMMAn can be cleaved from Mel in acidic
environment, this modified Mel (Mel-DMMAn) is believed to only demonstrate
lytic activity in the endosomal environment. The author conjugated Mel-DMMAn
to PLL and evaluated the transfection efficiency of plasmid DNA encoding
luciferase in Neuro2A cells. As expected, Mel-DMMAn-PLL induced less
erythrocyte lysis and cytotoxicity compared to Mel-PLL. Moreover, it mediated
higher luciferase expression compared to Mel-PLL and unmodified PLL at
different polymer and nucleic acid ratios (N/P ratios) 25. We were able to modify
25k Da PEI with Mel-DMMAn following the same strategy. This Mel-DMMAnPEI can deliver siRNA against green fluorescent protein (GFP) and mediate
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significantly more GFP knockdown compared to unmodified PEI in H1299 cells, a
lung cancer cell line, expressing GFP (Figure 1).
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Figure 1 GFP knockdown in H1299 using Mel-DMMAn-PEI. The GFP
knockdown mediated by PEI and Mel-DMMAn-PEI polyplexes containing siRNA
against GFP or scramble siRNA (NC) in H1299/GFP cells. Polyplexes were
prepared with 50 pmol of siRNA at N/P= 5 and transfected for 48 h. The MFIs
were quantified by flow cytometry. (Data points indicate mean +/- SD, n= 3. Oneway ANOVA, Newman-Keuls post-test, *** p <0.001).
To increase the selectivity to certain tissue/cells. PEI has been modified
with different targeting moieties. For example, to target cancer cells, transferrin 44,
folic acid

19a

, tripeptide motif Arg-Gly-Asp (RGD) in vitronectin, fibronectin and

fibrinogen 45 and epidermal growth factor (EGF) 46 were conjugated to PEI or PEI
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based polymers. In 2009, our group demonstrated two different approaches to
conjugate RGD mimics to PEI. In the first one, RGD mimics with maleimide
modification were reacted directly with the primary amines in PEI-PEG. In the
other approach, a PEG linker containing two functional groups, orthopyridyldisulfide and succinimidyl propionic acid (NHS-PEG-OPSS) were used for
coupling the RGD mimetic. NHS functional groups can react with the primary
amines in PEI and the OPSS group can couple to the thiol group in the sulfhydryl
derivative of the RGD mimics. Different RGD-PEIs were evaluated MeWo cells, a
human malignant skin melanoma cell line, overexpressing integrin receptors and
A549 cells, a lung epithelial cell line, expressing low levels of integrin receptors.
Results suggested that RGD-PEI can preferentially bind to MeWo cells and
efficiently deliver radio labeled plasmid DNA into MeWo cells rather than A549
cells. RGD-PEI polyplexes containing plasmid DNA encoding luciferase also
mediated significantly higher luciferase expression in MeWo cells compared to
unmodified PEI47.
Despite the high transfection efficiency of PEI-based polymers, potential
toxicity induced by high density of cationic charges arose concern regarding
applying PEI in vivo. To avoid the toxicity caused by positive surface charge,
several ways were developed to shield the particle, including PEGylation, coating
with serum protein transferrin

44

or hydroxyl rich “skin”, termed “hydroxylation
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camouflage”

48

.

X. Luo et al. modified 25k Da PEI with 5-ethyl-5-

(hydroxymethyl)-1,3-dioxan-2-oxo (EHDO) via an aminolysis reaction. The
properties of PEI-EHDO directly depended on the hydroxylation degree on the
surface. A high percentage of hydroxyl substitution on polymer PEI-EHDO34.5%
yielded polyplexes with plasmid DNA and demonstrated reduced surface charge
compared to unmodified PEI and PEI-EHDO19.9% polymer with lower percentage
of hydroxyl substitution. Accordingly, reduced cytotoxicity in 293T and Hela cells
and minimal hemolytic effects were observed after PEI-EHDO34.5% treatment.
Furthermore, less BSA protein was absorbed on the surface of PEI-EHDO34.5%
polyplexes compared to PEI and PEI-EHDO19.9

%

complexes, indicating a good

serum tolerance ability. This property lead to high efficiency of PEI-EHDO34.5% to
deliver plasmid DNA carrying luciferase gene in 293T and Hela cells in the
presence of serum 48.
On the one hand, the transfection efficiency and potential toxicity are both
related to the molecular weight of PEI. High molecular weight PEI (> 25k Da) can
mediate efficient transfection but demonstrates cytotoxicity. On the other hand,
low molecular weight PEI (600 – 25k Da) is less efficient and less toxic. To
reduce the potential toxicity, high molecular weight PEI synthesized from low
molecular weight PEI and crosslinked via reducible disulfide bonds or
inert/biodegradable polymers has been developed. These PEI based polymers are
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sensitive to redox stimuli. Glutathione (GSH) is a main reducing factor inside and
outside the cellular environment. The concentration of GSH in the extracellular
(2.8 µM) and intracellular (10 µM) environment differs strongly. Therefore, these
biodegradable polymers can breakdown once they enter cells, especially in the low
pH endosomal environment, and release their gene cargo

49

. Disulfide bond-

crosslinked low molecular weight PEI was first reported by M. Gosselin. The
author

crosslinked

800

Da

PEI

using

two

crosslinkers,

dithiobis-

(succinimidylpropionate) (DSP) and dimethyl-3,3′-dithiobispropionimidate 2HCl
(DTBP). The transfection efficiency of PEI-DSP and PEI-DTBP polyplexes
containing plasmid DNA encoding luciferase gene was evaluated in CHO cells.
The results suggested that transfection efficiency depended on the linker, crosslink
degree and N/P ratio. Crosslinked PEI at low N/P ratios (5 and 9) mediated less
luciferase expression compared to 25k PEI, while at high N/P ratios (13 and 18),
crosslinked PEI with crosslinking degree of 1 mediated comparable luciferase
expression to 25k PEI 50. Q. Peng et al. synthesized thiolated PEI (800 Da) which
can be oxidized by DMSO and yields disulfide crosslinked PEI (PEI-SS). Less
cytotoxicity of PEI-SS-PEI in Hela cells compared to 25k PEI was observed as
well 51.
Because of the promising properties of PEI, PEI is commonly used in proof
of concept studies or pilot studies for optimizing experimental conditions. In
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Chapter 3, 4 & 5, the application of branched PEI modified with targeteing
moieties to deliver siRNA for potential treatment of asthma and cancer will be
discussed.
1.3 RNAi for gene therapy
1.3.1 RNAi
RNA interference (RNAi) is endogenous sequence- specific mRNA
degradation process and first discovered in plant but later RNAi was reported as a
universal process in most eukaryotic organisms. On 1998, Andrew Fire and Craig
C. Mello discovered that double strand RNA (dsRNA) can efficiently suppress
expression of gene in the nematode worm Caenorhabditis elegans and later were
awarded the 2006 Nobel Prize in Physiology or Medicine for this contribution.
Many cellular components are involved in RNAi. Dicer is an enzyme
belonging to RNase III family and specifically cleaves dsRNA. Cleavage of Dicer
generate small interference RNA (siRNA) in a range of 21- 25 nucleotides. siRNA
is loaded in a protein complex termed RNA- induced silencing complex (RISC).
The sense strand (passenger strand) in siRNA is degraded in RISC while antisense
strand is integrated into RISC and serves as a guide strand. mRNA containing
complementary sequence of antisense strand can be recognized by siRNA/RISC
complex and cleaved by Argonaute 2 (Ago2), the component that has cleavage
activity in RISC. Another kind of small RNA (21-28 nucleotides) called micro-
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RNA (miRNA) can also induce gene silencing. A long miRNA precursor called
primary miRNA (pri-miRNA) is cleaved by an enzyme Drosha in the nucleus to
generate precursor-miRNA (pre-miRNA). The pre-miRNA is exported from
nucleus and incorporated into microribonucleoprotein complex (miRISC) or RISC
in some cases to cleave the mRNA containing complementary sequence (Figure 2).
miRNA and siRNA are in similar size range and both processed by Dicer followed
by gene silence. However, there are clear differences between siRNA and miRNA.
miRNA is single stranded but siRNA is found in double strands which is relative
more stable. The pair with mRNA of miRNA don’t require perfect complementary
match but do in siRNA induced gene silencing. Furthermore, many targets of
discovered miRNA haven’t been identified. Therefore, siRNA attracted extensive
attention to exploit its therapeutic application 52.
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Figure 2 Gene silence pathway.
1.3.2 siRNA for gene therapy
In 2001, S. Elbashir et al. first described that delivery of synthetic
siRNA against luciferase was sufficient to suppress the expression of luciferase in

24

different mammalian cell lines including HeLa (human), NIH/3T3 (mouse) and
CHO (Chinese hamster)

53

. Ever since, numerous siRNA sequences targeting

traditional non-drugable biological

molecules

have

been

in preclinical

development as potential therapies of difficult to treated diseases, and some have
entered clinical trials. Diseases which have been targeted by siRNA therapy in
clinical trials include cancer, ocular diseases, asthma, infectious diseases and skin
disorders. Local delivery of siRNA was the major administration approach in
initial clinical trials. Extensive effort has been put into the development of nonviral delivery systems of siRNA, increasing the number of clinical trials utilizing
systemic administration of siRNA and its vectors.
The first clinical trial of siRNA therapy was for the treatment of ocular
disease initiated by Opko Health Inc. In this trial, siRNA against vascular
endothelial growth factor (VEGF), named Bevasiranib, was administrated
intravitreally (IVT) to inhibit retinal neovascularization for the treatment of agerelated macular degeneration (AMD), a leading cause of blindness among people
age 60 and older, and diabetic macular edema (DME). However, its Phase III
results suggested that Bevasiranib can’t efficiently prevent vision loss in AMD.
Afterward, two other siRNA formulations, administrated IVT, for therapy of
AMD and DME which target VEGF receptor-1 (VEGFR1) entered clinical trials.
Neither formulation could achieve sufficient therapeutic effects to prevent vision
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loss. However, Macugen, a RNA aptamer against VEGF for AMD therapy, as the
only RNA therapy approved by the USFDA encouraged pharmaceutical
companies to keep exploiting this field. PF-655 is a siRNA formulation targeting
an upstream regulator, apoptosis stress-response gene RTP801/REDD1,
controlling VEGF production. Phase II results suggested that IVT administration
of PF-655 can improve the mean visual acuity. Another formulation of siRNA for
ocular disease is based on eye drops. SYL040012, a siRNA formulation against
β2-adrenergic-receptor (ADRB2), was developed by Sylentis, S.A. for treatment
of open angle glaucoma. It demonstrated well tolerability in patients with ocular
hypertension or glaucoma in a Phase I study. A completed Phase II study
suggested that SYL040012 (300 µg/ eye/ day) can significantly reduce intraocular
pressure compared to placebo. The same company initiated another clinical trial of
an siRNA eye drop formulation, SYL1001, targeting transient receptor potential
cation channel subfamily V member 1 (TRPV1) for alleviation of ocular pain
related to dry eye syndrome. Its recent Phase II results reported that one dose
(1.25 %) among four different doses (0.375%, 0.75%, 1.125% and 2.25%) can
alleviate ocular pain and hyperaemia compared to placebo 54.
An intranasal delivery formulation of siRNA against nucleocapsid protein
of respiratory syncytial virus (RSV), ALN-RSV01, was developed by Alnylam
Pharmaceuticals. ALN-RSV01 was proposed to be used in lung transplant patients
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with RSV infection. Phase II results indicated that ALN-RSV01 treatment
achieves a promising clinical outcome including reduction of incidence of
new/progressive bronchiolitis obliterans syndrome on day 90 and day 180 posttreatment. However, there hasn’t been a Phase III trial initiated since 2012 54b.
Another approach to locally deliver siRNA to the lung is inhalation.
ExcellairTM is an inhaled siRNA formulation targeting spleen tyrosine kinase
(Syk), an important factor involved in the inflammation process, for treatment of
asthma. As reported by ZaBeCor Pharmaceuticals, the Phase I study suggested
that ExcellairTM was well tolerated and safe. Furthermore, ExcellairTM treatment
can improve the lung function of patients with asthma and reduced frequency of
using immediate relief medication. The Phase II trial of ExcellairTM has been
announced in 2009, however, there have not been any results reported yet54b.
In 2007, Quark Pharmaceutical initiated the first clinical trial in which a
siRNA formulation was proposed to be systemically administrated in humans.
This siRNA therapy, QPI-1002, targets stress-response gene p53 for prevention of
Delayed Graft Function (DGF) in patients undergoing deceased donor kidney
transplantation. QPI-1002 treatment can reduce the incidence of DGF and reduced
the frequency of dialysis for 30 days post-transplant. A Phase III trial to evaluate
the safety and therapeutic efficacy of QPI-1002 in large groups of patients
(estimated 634 people) is currently recruiting participants54b.
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Currently, systemic siRNA therapies in clinical trials are mostly carried
by lipid nanoparticles (LNP). LNP preferentially accumulate in liver and kidneys.
Therefore, many clinical developments of siRNA aim to target hepatic genes.
TKM-ApoB is a siRNA therapy targeting apolipoprotein B (ApoB), the major
apolipoproteins in low-density lipoprotein particles (LDL) which are generated
primarily in the liver, for the treatment of hypercholesterolemia. This formulation
is administrated i.v. and therapeutic siRNA is carried by the first generation of
stable nucleic acid lipid particles (SNALP). Reduced ApoB/LDL was observed
after TKM-ApoB treatment, however, some patients experienced flu-like symptom
indicating potential immunostimulation by TKM-ApoB. Later, Alnylam
Pharmaceuticals initiated a clinical trial using the same carrier SNALP to pack two
sequences of siRNA against VEGF and kinesin spindle protein (KSP), important
factors involved in cell survival and proliferation, as therapy for primary and
secondary liver cancer. Successful suppression of VEGF has been achieved in
some patients who received siRNA treatment. A liver targeted strategy has been
developed to more selectively deliver siRNA to the liver with lower doses and
reduced toxicity. siRNA conjugated with triantennary N-acetylgalactosamine
(GalNAc) can trigger internalization of hepatocyte-restricted asialoglycoprotein
receptor (ASGPR). A GalNAc conjugated siRNA (ALN–PCS02)

targeting

proprotein convertase subtilisin/kexin type 9 (PCSK9), an enzyme specifically
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degrading LDL receptor, was developed by Alnylam Pharmaceuticals for
treatment of hypercholesterolemia. In a Phase I trial, a single dose of i.v.
administration of ALN–PCS02 can reduce PCSK9

by 70% and LDL in

circulation by 40%. A subcutaneous administrated formulation of the drug, ALN–
PCSsc, entered a Phase I study to evaluate its efficacy in terms of reducing blood
LDL. Treatment of ALN–PCSsc was well tolerated and can achieve up to 83%
reduction of LDL. More importantly, Phase I results suggested a potential for a biannual dosing 54b.
Application of siRNA therapies in cancers attracts large attention since
there is no effective treatment for some cancers which lead to high mortality rates.
A siRNA carried by anionic liposomes and targeting breakpoint cluster region–
Abelson murine leukemia oncogene (bcr-abl) tyrosine kinase was proposed as
therapy of Chronic Myeolid Leukemia (CML). A patient with imatinib-resistant
CML received siRNA formulation i.v. (10 μg/kg body weight) on day 426 posttransplantion of blood stem cells. Additionally, 300 μg siRNA was injected into
one subcutaneous CML node. Later, 2 additional doses were given to the patient
within 32 days after the first dose. The siRNA treatment transiently slightly
reduced the bcr-abl mRNA in CML cells and ex vivo results suggested that the
treatment can inhibit proliferation and induce apoptosis in CML cells. However,
ex vivo transfection results also suggest that CML cells may develop resistance to
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siRNA application

55

. Ligand coated nanoparticles have been applied to increase

the delivery efficiency of siRNA targeting tumors in the clinic.

Calando

Pharmaceuticals developed a delivery system containing three components in the
carrier including 1) a cationic cyclodextrin based polymer to carry siRNA, 2) an
adamantane polyethylene glycol could enhance the stability in the blood stream
and 3) a human transferrin to target the tumor. This formulation CALAA-01
targeting the M2 subunit of ribonucleotide reductase, an important factor involved
in cancer cells proliferation, was evaluated in the clinic for treatment of relapsed
or refractory cancers/solid tumors. The siRNA induced mRNA cleavage was
confirmed by a rapid amplification of complementary DNA ends (RACE) PCR.
However, two patients experienced dose-limiting toxic events. Moreover, no
objective anti-tumor effect was observed, and 29% patients showed increased
tumor sizes which lead to termination of this trial. Despite more optimization still
being required to achieve efficient in vivo gene knockdown using nanoparticle,
this trial demonstrated the feasibility to systemically administrate ligand guided
polymeric nanoparticles 56.
1.4 Transferrin receptor
Transferrin (80k Da) (Tf) is a glycoprotein present in serum and contains
two subunits linked by a spacer. Tf can deliver iron into cells mediated by
interaction with its receptor, the transferrin receptor (TfR). Iron is a factor
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involved in essential cellular procesess including DNA synthesis and metabolism.
Therefore it is essential for cell proliferation and differentiation. Dietary iron is
taken up through the intestine and becomes the oxidized form Fe

3+

. However,

cellular processes require Fe 2+ and Fe 3+ can be toxic to the cells. Tf can bind Fe 3+
and transport it as a non-toxic complex in circulation. Each subunit of Tf can bind
to one iron ion, therefore, there are two forms of Tf/iron complexes, monoferric Tf
and diferric Tf (holo-Tf). Additionally, apo-Tf represents Tf that is not bound with
iron or other metals. Tf/ iron complexes demonstrat higher binding affinity with
TfR compared to apo-Tf. For example, the association constant of holo-Tf with
TfR is 500 fold higher than apo-Tf with TfR.
TfR is a transmembrane receptor that can mediate endocytosis of Tf/iron
complexes. Holo-Tf can bind to TfR and be endocytosed in clathrin-coated pits.
The pH is reduced inside the endosome leading to a conformation change of holoTf. Consequently, Fe

3+

is released from holo-Tf and reduced to Fe

2+

in the

endosomal environment before it enters the cytoplasm. Apo-Tf/ TfR complexes
are recycled back to the cell surface and apo-Tf is readily dissociated from TfR
due to its low affinity. The expression of TfR is regulated by the intracellular iron
level. Cellular events, such as DNA synthesis that consume iron lead to reduced
intracellular iron levels eventually resulting in an upregulation of TfR. TfR is
universally expressed at low level in most cells/ tissues and upregulated in certain
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cells such as actively proliferating cells, vascular endothelium of brain capillaries,
and activated peripheral blood mononuclear cells. Additionally, upregulation of
TfR is also observed in various cancer cells including glioma, breast cancer, lung
adenocarcinoma and lymphoma.
1.4.1 TfR and diseases
Tf has been utilized as a targeted ligand for selective delivery of therapeutic
cargos in various diseases. Conventional therapies of cancer can eliminate cancer
cells but also commonly cause toxic effects in normal cells/ tissue. Since TfR is
often upregulated in cancer cells, Tf or TfR targeted moieties have been
conjugated to chemotherapies, toxic proteins and large molecules including
liposomes and nanoparticles. For example, Cisplatin, an anti-cancer drug
interrupting DNA synthesis, is a common chemotherapy used in various cancers
including breast cancer, brain tumors and lung cancer. To reduce the side effect
and increase tumor selectivity, Cisplatin conjugated with Tf (MPTC-63) was
developed and evaluated in pre-clinical research and clinical trials. MPTC-63
demonstrated higher cytotoxicity in Hela cells compared to non-modified cisplatin.
In a murine tumor model, suppressed growth of the tumor and reduced metastasis
of the tumor in the lung were observed in the MPTC-63 treated group. Later, in a
Phase I clinical trial, MPTC-63 treatment achieved positive response in 36% of
patients with advanced breast cancer57. Polymers and liposomes are common non-
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viral carriers for therapeutic cargos such as chemotherapies, macromolecules (e.g.
DNA, RNA and proteins). A Tf modified liposome encapsulating oxaliplatin (LOHP), MBP-426, was developed to increase the circulation time and tumor cell
selectivity by targeting TfR eventually to achieve enhanced anti-tumor efficacy.
Safety and pharmacokinetics of MBP-426 were evaluated in a Phase I clinical trial
and a favorable safety profile was achieve 57b, 58. Currently, an ongoing Phase Ib/II
trial is evaluating the therapeutic efficacy of MBP-426 combined with leucovorin
and 5-fluorouracil in patients with advanced or metastatic solid tumors. SGT-53 is
another TfR targeted liposome under clinical evaluation. SGT-53 is a liposome
formulation decorated with antibody fragments that target TfR and carrying DNA
encoding p53. A phase I clinical trial suggested that SGT-53 is well tolerated in
patients bearing advanced solid tumors. SGT-53 demonstrated targeted delivery to
tumor cells and achieved anti-tumor activity. There are 4 active clinical trials of
SGT-53 ongoing to evaluate its efficacy in refractory or recurrent solid tumors57b.
The blood–brain barrier (BBB) is a barrier that separates the circulation
system from the brain and prevents most macromolecules from entering the brain.
Certain receptors, such as TfR, are expressed on the endothelium of brain
capillaries for the introduction of essential nutrients and proteins (e.g. Tf).
Therefore, TfR has been exploited extensively in preclinical studies as a potential
entry for therapeutic reagent, particularly for macromolecules, to the brain. For
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proof of concept studies, a mouse monoclonal antibody against rat TfR, OX26, has
been conjugated to various molecules including neuroprotective agents,
neurotrophic factor and liposomes for brain delivery. For example, brain-derived
neurotrophic factor (BDNF), a neuroprotective agent, was coupled to OX26 and
evaluated in a rat stroke model. Animals administrated i.v. with OX26-BDNF
demonstrated 243% improvement in their ability of motor function compared to
unmodified BDNF. This result suggested more efficient brain delivery was
achieved by OX26-BDNF. OX26 has also been utilized to decorate liposomes for
gene delivery to the brain. Intravenous delivery of OX26-liposomes carrying DNA
encoding β-galactosidase resulted in β-galactosidase expressed in the brain of rats
59

.
Activated T cells (ATCs) overexpress TfR and play an important role in

inflammatory diseases. Our group is the first to exploit the possibility to deliver
nucleic acids in a targeted manner to ATCs as potential treatment of inflammatory
diseases, for instance, asthma. We demonstrated that Tf modified PEI can
selectively deliver siRNA to human primary ATCs ex vivo 60 and ATCs in the lung
of asthmatic mice in vivo 61.
1.5 Conclusion & significance
In the following chapters of this dissertation, I will discuss the most
important findings in my development and optimization of TfR targeted polymers
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for delivery of siRNA in various diseases. In Chapter 2, the progress and current
status of application of siRNA therapies in asthma is summarized. In Chapter 3,
the development and characterization of Tf conjugated PEI (Tf-PEI) as a potential
therapy of asthma is described. Also, the selective delivery of siRNA to ATCs is
confirmed ex vivo and in vivo. In this chapter, we proved the feasibility of
efficiently delivering siRNA to ATCs via TfR targeted strategy which would
benefit the development of a novel therapy for inflammatory diseases involving
ATCs. This approach could also be utilized to transfect ATCs in fundamental
studies since ATCs are difficult-to-transfect cells. Besides targeting ATCs in
asthma, the TfR selectivity of Tf-PEI is evaluated in breast cancer cells in
Chapter 4. Tf-PEI can achieve more efficient delivery of therapeutic siRNA
against GASC1, to basal-like breast cancer cells, an aggressive phenotype of
breast cancer, compared to unmodified PEI. In this chapter, we investigated a
potential siRNA therapy of basal-like breast cancer via suppressing a novel
epigenetic target, the histone demethylase GASC1. This potential treatment may
demonstrate a better safety profile in vivo due to its TfR selectivity and may be
combined with current anti-cancer therapy to achieve a better therapeutic outcome.
In Chapter 5, two peptides against TfR, alternative TfR targeting moieties, are
conjugated to PEI and both peptide-PEI conjugates are evaluated in lung cancer
cell lines. One of the targeted conjugate, HAI-PEI, demonstrated higher

35

transfection efficiency in lung cancer cells overexpressing TfR compared to
unmodified PEI. In this chapter, the feasibility of selectively delivering siRNA to
lung cancer cells overexpressing TfR using peptide-PEI was confirmed. This
peptide could be an alternative for holo-Tf to modify particles. Because of the high
stability of peptides and their ability to non-competitively bind to TfR, peptide
modified nanoparticles could be a better approach to achieve in vivo TfR targeted
delivery.

36

CHAPTER 2 PULMONARY DELIVERY OF SIRNA VIA
POLYMERIC VECTORS AS THERAPIES OF ASTHMA
Please note that part of the content of this chapter is from a review article,
“Pulmonary Delivery of siRNA via Polymeric Vectors as Therapies of Asthma”,
was published in Archiv der Pharmazie (Y. Xie, O.M. Merkel, 2015). The authors
of this article include Dr. Olivia Merkel and me. I am the first author of this
review article, searched the literature, and wrote the review.
2.1 Introduction
Asthma is one of the major worldwide public health problems affecting 334
million people
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and accounting for 250,000 annual deaths 63. It is estimated that

there would be additional 70 million asthmatic patients in 202562 and that the
global market for asthma and chronic obstructive pulmonary disease (COPD)
drugs would increase to $47.1 billion in 201764. Asthma can be effectively
controlled in most of the patients by current therapies including inhaled β2adrenergic receptor agonists, inhaled corticosteroids and injected immunoglobulin
E (IgE) antibody

65

. Nevertheless, compliance of inhaled corticosteroids is poor

due to the requirement of frequent inhalation and concerns of long-term side effect
66

. In contrast, common overuse of β2- adrenergic receptor agonists (CDC,2007)

increases the risk of systemic side effects 67. Moreover, there are 5-10% asthmatic
patients who lack adequate response to current therapies of asthma. The patients
within that group who also have common asthmatic comorbid conditions, such as

37

rhinosinusitis and chronic infections, will experience worse symptoms of asthma
and a higher risk of morbidity 68. Thus, it is necessary to develop safer and more
efficient additional treatments for asthma.
Asthma is a chronic inflammatory disorder and airway disease
characterized by limitation of airflow, airway hyperresponsiveness (AHR), mucus
hypersecretion and infiltration of inflammatory cells. In the pathogenesis of
asthma, common environmental stimuli (e.g. dust, pollen) are recognized
inappropriately by the immune system as antigen and consequently induce IgEdependent inflammatory response. The asthmatic symptoms are majorly driven by
inflammatory cells, for example, mast cells, eosinophils, dendritic cells,
lymphocytes, macrophage and their cytokines

69,70

. Dendritic cells, the most

efficiently antigen presenting cells (APCs), can present allergens to naïve T helper
cells (Th0) and promote the differentiation of T helper 2 cells (Th2). Th2 cells can
orchestrate the allergic response of asthma via secretion of Th2 interleukins (IL-4,
IL-5 and IL-13)

69

. For instance, IL- 4 can promote differentiation and

proliferation of Th2 cells and together with IL-13 stimulates B cells to proliferate
and produce IgE. IL-5 can recruit and activate eosinophils as well as maintain their
proliferation and survival. IL-13 is associated not only with IgE synthesis but also
with chemoattraction of eosinophils, AHR, airway remodeling and mucus cell
hyperplasia

69,70-71,72

. Other than Th2 cells, mast cells also contribute to asthmatic
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inflammation by secreting histamine, tryptase and prostaglandin D2 (PGD2) which
can induce potent bronchoconstriction, airway edema and lung fibroblast
proliferation as the result of IgE-dependent stimulation by allergens

69

. Another

essential type of inflammatory cells are eosinophils which can produce lipid
mediators and pro-inflammatory cytokines to directly damage epithelial cells,
induce bronchoconstriction and amplify inflammatory responses 73.
New drugs for asthma in pre-clinic research or clinic trails include new
bronchodilators and corticosteroids as well as inhibitors of novel therapeutic
targets, for example, kinase inhibitor and cytokine/chemokine blockage. siRNA
induced gene silence is thought to be an efficient approach to block the functions
of molecular targets. siRNA mediated therapies are post-transcriptional, transient
and based on sequence-specific gene silencing, hence they are believed to offer a
more potent and specific treatment with less side effects for different diseases

74

.

Pulmonary delivery of siRNA as a non-invasive and local administration can
reduce systemic side effects and prolong the lung retention period for the
treatment of lung diseases like asthma. Furthermore, rapid therapeutic effects and
lower dose requirement can be achieved due to the physiological properties of the
lung such as the large alveolar surface, absence of serum proteins and the presence
of a thin epithelium 75. Despite of the advantages of pulmonary delivery of siRNA,
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the biggest obstacle of clinical application of siRNA in asthma is the lack of
biocompatible vectors to efficiently deliver siRNA into target cells.
In this chapter, we will discuss the molecular targets for siRNA mediated
therapies and the formulation of siRNA applied in experimental asthma and will
summarize available siRNA delivery systems that are targeted to immune cells.
2.2 Therapeutic Molecular Targets of siRNA in Asthma
As described in the introduction, asthma is a very complex inflammatory
disease implicating numerous cells and cellular factors. The common therapeutic
molecular targets for RNAi therapy include cytokines/chemokines, transcription
factor, tyrosine kinase/ tyrosine kinase receptor, costimulatory molecules.
Additionally, new biological targets have been discovered, such as the transient
receptor potential cation channel (TRPV1)

76

, nerve growth factor

74b

, soluble

membrane N-ethylmaleimide-sensitive factor attachment protein receptor protein
(syntaxin4)77.
2.2.1 Cytokines and chemokines
It is known that cytokines/chemokines, particularly Th2 cytokines, play
prominent roles in airway inflammatory response and remodeling, thus, blockage
of cytokines/chemokines and their corresponding receptors by using siRNA has
been reported. Examples are the downregulation of suppressor of cytokine
signaling 3 (SOCS3)

78

, IL-479 and IL-5. Given that presence of eosinophils is
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implicated in airway hyperresponsiveness and remodeling and IL-5 is the most
important cytokine involved in eosinophils growth, activation as well as
recruitment, siRNA against IL-5 was applied to reduce inflammatory response in
ovalbumin (OVA)-induced murine asthma model.

Huang et al. showed that

intratracheal (i.t.) administration of lentivirus containing a siRNA against IL-5
expressing cassette (SEC4) to asthmatic mice for three consecutive days reduced
the expression of IL-5 in the lung by 50% quantified by real time PCR (RT-PCR).
Reduced eosinophilia was observed in SEC4 treated animals confirmed by less
eosinophils in the bronchoalveolar lavage fluid (BALF) cells and H&E staining
slides as well as less eosinophils chemoattractive cytokine (eotaxin) in the BALF.
Consequently, The AHR was significantly relieved according to non-invasive
whole body plethysmography (PenH) and invasive techniques 80.
2.2.2 Transcription factors
Blockage of a single mediator or receptor cannot achieve great therapeutic
effects due to the complexity of asthma. Therefore, the upstream molecules of the
inflammatory process have become more attractive therapeutic targets.
Transcription factors that control the production of cytokines/chemokines and are
involved in the growth and differentiation of major inflammatory cells were
reported as targets for siRNA mediated treatment, such as GATA-3, transducer
and activator of transcription 6 (STAT6), and receptor interacting protein 2
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(Rip2)81. GATA-3, a transcription factor highly expressed in Th2 cells, can
determine the differentiation of Th2 cells and promote the production of Th2
interleukins

82

. Antisense therapeutic intervention of GATA-3 in experimental

asthma has been achieved not only with siRNA. Finotto et al. reported that 200 µg
intranasally (i.n.) administrated GATA-3 anti-sense oligonucleotides for four
continuous days to mice with OVA-induced inflammation can achieve local antiinflammatory effects which were comparable to the positive control group treated
with the first-line drug dexamethasone

83

. This report of therapeutic effect of

blockage of GATA-3 in asthma is in line with the observation by Lee et al. who i.n.
delivered GATA-3 small hairpin RNA with a lentiviral vector (2.2×106 IFU) to
OVA-induced asthmatic mice 84. The only asthma therapy study involving GATA3 siRNA was published by Sel et al. To assess the efficacy of GATA-3 specific
DNAzyme (Gd21) to prevent and treat experimental allergic asthma, they i.n.
applied 200 µg Gd21 to mice with acute experimental asthma and compared to
animals that were i.n. treated with 200 µg siRNA against GATA-3 or GATA-3
anti-sense oligonucleotides. These treatments were alternative antisense strategies
in contrast to the DNAzyme. They concluded that Gd21 can more effectively
reduce the inflammation than GATA-3 specific oligonucleotide and siRNA
because these alternative antisense therapies showed a less efficient reduction of
the number of eosinophils in the BAL cells and decreased the IL-5/IFN-γ ratio less
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successfully 85. However, their results also showed that GATA-3 specific siRNA
treatment can reduce the number of mucus-producing goblet cells and AHR
comparably to the Gd21 treatment. In addition, the authors did not use any
delivery system for siRNA, anti-sense nucleotides or DNAzyme administration,
and “naked” nucleic acids were applied directly. The approach of delivering free
nucleic acids has been reported to lead to less efficiency in silencing genes in vivo
and in vitro compared with the delivery via any kind of vector. Therefore, the
therapeutic effect of GATA-3 siRNA or even anti-sense oligonucleotides is worth
to be further evaluated in vivo. STAT-6, another promising target, is the
transcription factor that controls the onset and maintenance of GATA-3 expression
and is involved in T cells differentiation and IgE production

86

. The anti-

inflammatory effect of i.n. administration of 100 µg siRNA against STAT-6 to
asthmatic mice was described by Darcan-Nicolasien et al. They showed a
decreased amount of infiltrated leukocyte in the BALF and reduced AHR in the
STAT-6 siRNA treatment group compared with animals treated with siRNA
against green fluorescent protein (GFP) which served as a negative control.
Additionally, decreased levels of IL-4, IL-5, IL-13 and less histological alterations
as well as less T cells infiltration were observed in lung tissue from the STAT-6
siRNA treatment group. However, the biodistribution of nanoparticles in the
central and peripheral area of the lung was majorly in airway epithelial cells
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instead of lymphocytes, where the expression of STAT-6 is most important in
asthma. This observation may lead to higher required doses to obtain efficient
therapeutic effects 87.
2.2.3 Tyrosine kinase / tyrosine kinase receptor
Other upstream targets are kinases involved in the inflammatory process
such as spleen tyrosine kinase (Syk) and the nuclear factor kappa-light-chainenhancer of activated B cells (NF-κB)88. Spleen tyrosine kinase (Syk) is widely
expresses in immune cells and can initiate or mediate various cellular signaling
pathways, including the development and maturation of B cells, proliferation of T
cells, and production of inflammatory mediators from macrophages and mast cells
89

. It was described by Stenton et al. that three i.n. aerosolized doses of Syk

antisense oligodexoynucleotides (ASO)/ liposome to OVA-induced asthmatic rats
can reduce the infiltration of leukocytes found in the BALF and inhibit the antigen
induced up-regulation of adhesion molecules in eosinophils, neutrophils and
macrophages. However, there was no statistical difference of pulmonary
inflammation between the Syk-ASO treatment and the saline treatment group
according to the histological analysis of lung sections, and two doses of Syk-ASO
treatments were not sufficient to inhibit the airway inflammation like three
treatments did. Therefore, Syk-ASO is not a very efficient anti-inflammatory
therapy but Syk was provento be a valuable target 90. Inspired by this study, Huang
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et al. i.n. instilled 10 µg siRNA against Syk on three consecutive days before the
induction of acute lung inflammation and correlated less infiltration of
inflammatory cells with the treatemnt91. Moreover, ExcellairTM (ZaBeCor, Bala
Cynwyd, PA, USA), a therapeutic siRNA against Syk, moved to Phase II clinical
trials as a new drug for asthma in 2009 and confirmed the potential of Syk as a
therapeutic target in asthma. A different potential target is the tyrosine kinase
receptor C-kit of which the ligand is stem cell factor (SCF). Wu et al. reported that
i.n. administration of methylation modified siRNA against C-kit (35 µg/day) for
three days to mice with experimental allergic asthma can significantly reduce the
levels of IL-4, IL-5 and SCF in the BALF and inhibit the infiltration of eosinophils
as well as histology alteration due to pulmonary inflammatory 92.
2.2.4 Costimulatory molecules
APCs can initiate and maintain the airway inflammatory response,
particularly a Th2-mediated response. The interaction between APCs and T cells
requires the facilitation of costimulatory molecules such as CD86 and CD4093.
Asai-Tajiri et al. reported that bone marrow derived dendritic cells (DCs) in vitro
transfected with siRNA against CD86 can lose their ability to activate Th2 cells. In
an OVA-induced murine asthma model, after i.n. administration of Texas Red
labeled CD86 siRNA (12.5 µg), it was observed that Texas Red-siRNA was able
to pass through the epithelial barrier and co-localized with DCs. With this
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biodistribution result in mind, they i.n. applied siRNA against CD86 (12.5 µg/ day)
for three days and achieved reduction of Th2 interleukins levels, less eosinophils
infiltration and reduced AHR. However, treatment of CD86 specific siRNA did
not reduce the goblet cell-mediated hyperplasia, indicating that higher dose of
CD86 specific siRNA may be required to alleviate sufficiently the symptoms of
asthma 94.
2.3 Targeted Polymeric Delivery of siRNA for asthma therapy
As summarized in Table 1, pulmonary delivery of siRNA is the most
common administration approach for the treatment of experimental asthma and the
majority of the formulations is either naked/modified siRNA or use lentiviral
vectors.
Table 1 Summary of biological molecular targets for siRNA therapies of asthma
Administration

Formulation/vector

Naked/Modified siRNA

Intratracheal
Lentivirus

Intranasal

Target Molecule

Ref

CD86

94

Rip2

81

IL-5

80

Nerve
factor

growth

74b

Atelocollagen

Syntaxin4

77

Lentivirus

GATA-3

84
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Naked/Modified siRNA

Intravenously

Plasmid

GATA-3

85

STAT-6

87

Syk

91

c-kit

92

SOCS-3

78

IL-4

79

CD40

93

Considering the large size, instability and negative surface charge, siRNA
is easily enzymatically degraded, phagocytically cleared, aggregates with serum
proteins, and does not readily cross physiological membranes22,95. Hence, viral or
non-viral carriers are needed, even though there are many reports in the literature
of pulmonary delivery of naked/modified siRNA96. Due to the safety issues of
viral vectors such as immunogenesis and insertional mutagenesis, non-viral
delivery vectors, particularly polymeric carriers, are more attractive and favorable
approaches to deliver siRNA. With the flexible and modifiable chemical structure,
polymeric carriers have the potential to overcome extracellular barriers including
instability in the blood stream, cell/tissue targeted delivery and biological
membranes as well as intracellular barriers like endosomal escape and cytoplasmic
siRNA release. Additionally, polymeric vectors can maintain a high capacity of
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siRNA loading, biocompatibility and the ability to co-deliver small molecular
drugs 97.
There are many polymeric delivery carriers that have been prepared and
optimized for pulmonary delivery of siRNA, such as polyethylenimine (PEI) and
chitosan

96

. However, administration of polymeric nanoparticles encapsulating

siRNA is limited in asthma therapy, due to the potential side effects induced by
non-specific cellular uptake and the difficulty to transfect differentiated immune
cells like lymphocytes in vivo. Receptor-ligand mediated targeted delivery of
siRNA could be a solution.
2.3.1 T cell targeted delivery systems
It is believed that Th2 cells can initiate and aggravate symptoms of asthma
via the production of Th2 interleukins. For this reason, there are many studies that
aim to block the effects of Th2 responses via RNAi. Currently, the most popular
lymphocytes transfection method is electroporation/nucleofection which, however,
is not suitable for in vivo application98. Moreover, T cells generally resist the
transfection of conventional polymeric or lipid-based (e.g.lipofectamine) vectors.
Therefore, the difficulty to efficiently transfect T lymphocytes hinders the clinical
application of RNAi in asthma.

Recently, a few polymeric siRNA delivery

systems specific for T lymphocytes have been discovered. CD7 is a surface
antigen of human T cells which rapidly internalizes upon binding of an antibody.
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To target and deliver nanoparticles encapsulating siRNA to T cells for the therapy
of HIV infection, Kumar et al. conjugated a CD7 specific single-chain variable
fragment with oligo-9-arginine peptide (scFvCD7-9R). Oligo-arginine is a
positively charged cell-penetrating short peptide which has been reported to
efficiently encapsulate siRNA and enhance the membrane permeability of
nanoparticles

99

. scFvCD7-9R was accordingly able to transduce FITC-labeled

siRNA selectively to primary human CD3+ T cells but not macrophages or B cells
in vitro. The in vivo specificity of nanoparticles was tested in two kinds of
humanized mice models implanted with human peripheral mononuclear cells (HuPBL and Hu-HSC). The i.v. injection of 50 µg siRNA against CD4 with
scFvCD7-9R on two consecutive days significantly reduced the expression of CD4
on activated CD3+ T cells in Hu-PBL mice as well as on the rest/naïve CD3+ T
cells in Hu-HSC mice. Additionally, to test the therapeutic effect, the authors
systemically administrated scFvCD7-9R encapsulating a mixture of anti-viral
siRNA including CCR5, Vif and Tat to Hu-PBL mice. Nanoparticles were shown
to protect Hu-PBL mice implanted mit HIV-seronegative donor’s PBMCs from
HIV-1 challenge and significantly inhibited the viral replication. Furthermore,
treatment of antiviral-nanoparticles of the Hu-PBL mice implanted with HIVseropositive donor’s PBMCs can protect the CD4+ cell loss compared with the
animals treated with nanoparticles encapsulating siRNA against luciferase, which
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served as a negative control. When PBMCs were exposed to nanoparticles in vitro,
negligible toxicity was confirmed by percentage of Annexin V positive cells and
production of IFN-γ. However, this scFvCD7-9R conjugate was optimized for i.v.
administration for the therapy and prevention of HIV infection so it remains to be
answered whether this conjugate can also efficiently and selectively deliver siRNA
to T lymphocytes through pulmonary administration. This study should be
highlighted because it demonstrates the feasibility to selectively deliver siRNA to
T lymphocytes in vitro and in vivo which could be potentially applied in different
inflammatory diseases like asthma and arthritis100. Another scFvCD7 conjugate
was described by Lee et al. who conjugated scFvCD7 with chitosan and measured
the in vitro transfection efficiency in T cell lines (Jurkat and A3.01 cells).
Chitosan is a biocompatible and biodegradable polymeric vector, and
chitosan/modified chitosan have been widely studied for pulmonary delivery of
siRNA. It is thus a promising candidate to deliver siRNA in asthma therapy. The
scFvCD7-chitosan/siRNA nanoparticles were around 300 nm in size and had a
slightly positive zeta-potential of +17 mV. There was significantly higher uptake
of scFvCD7-chitosan encapsulating FITC-siRNA compared with that of chitosan
in T cell lines and increased uptake was observed as the molar ratio of scFvCD7
per total chitosan increased. scFvCD7-chitosan nanoparticles prepared with
siRNA against CD4 were tested for in vitro gene silencing, and the CD4 gene
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knockdown efficiency was similar to that of Lipofectamine 2000 but significantly
higher than that of chitosan measured by flow cytometry and RT-PCR. However,
scFvCD7-chitosan condensed CD4 siRNA at a weight ratio of chitosan to CD4 at
40:1 indicating that the siRNA encapsulation efficiency of the conjugate was fairly
low. Additionally, scFvCD7-chitosan did not show better transfection efficiency in
T cells lines than Lipofectamine 2000, thus high doses of nanoparticles may be
required to achieve efficient gen silencing. Furthermore, the authors have not
performed any in vivo study, and the pulmonary delivery efficiency of siRNA via
scFvCD7-chitosan remains to be tested101.
In asthma pathogenesis, activated T cells, particularly Th2 cells, play an
essential role but not naïve T cells. However, CD7 is expressed on the majority of
mature T cells resulting in the fact that a CD7 targeted siRNA delivery system will
non-selectively deliver siRNA to both naïve and activated T cells. Therefore, a
pulmonary siRNA delivery system that can selectively transport siRNA to
activated T cells but not naïve T cells could achieve more efficient antiinflammatory effect and reduce potential side effects. In 2013, our group described
a selectively pulmonary delivery system of siRNA for activated T cells in which
the transferrin receptor (TfR) was targeted instead of CD7. TfR is an iron uptake
membrane receptor universally express at low level on most cells/tissues, in
contrast, it is overexpressed on highly proliferating and differentiating cells. It was
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reported that activated T lymphocytes highly express TfR to meet the iron
requirement for further differentiation and growth while naïve T lymphocytes do
not. For this reason, we linked transferrin (Tf), the native ligand which can trigger
TfR internalization, with low molecular weight PEI (LMW-PEI). PEI is the most
popular polycation for pulmonary delivery of siRNA, and applying low molecular
weight PEI can dramatically reduce the toxicity induced by the high density of
cations, which is the biggest obstacle limiting the clinical application of PEI. To
determine the selective delivery efficiency of Tf-LMW-PEI in vitro, primary
human activated T cells (ATC) or naïve T cells were transfected by Tf-LMW-PEI
encapsulating Alexa Fluor488-labeled siRNA. Flow cytometry quantified cellular
uptake of Tf-LMW-PEI/siRNA in ATCs was significantly higher than that of nonmodified LMW-PEI as well as Lipofectamine 2000. Additionally, the uptake of
Tf-LMW-PEI and LMW-PEI was minimal on naïve T cells compared with that on
ATCs indicating that the conjugate can distinguish ATCs from naïve T cells60. Our
group also determined the biodistribution of Tf-LMW-PEI formulated with Alexa
Fluor 647 labeled siRNA in OVA-induced asthmatic mice. Significantly higher
cellular uptake of Tf-LMW-PEI nanoparticles in CD4+ T cells in asthmatic mice
compared with that of LMW-PEI was observed. In addition, there was no
difference in terms of cellular uptake of Tf-LMW-PEI/siRNA, LMW-PEI/siRNA
and free siRNA-AF647 on CD4+ T cells in healthy control animals. In vitro and in
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vivo studies proved that Tf-LMW-PEI is another promising candidate for
pulmonary delivery of siRNA for asthma treatment.
2.3.2 Macrophage targeted delivery systems
Macrophages are the most abundant inflammatory cells in the lung and are
potentially involved in airway remodeling and eosinophilic inflammation in
asthma. However, macrophages can perform anti-inflammatory as well as proinflammatory effects, so the role of macrophage in asthma is not yet clear
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.A

delivery system of siRNA that targets macrophages can be not only a therapeutic
delivery vector but also a tool to facilitate the understanding of the role of
macrophage in asthma. Kim et al. described a siRNA delivery system targeting
macrophages through a macrophage expressing nicotinic acetycholine receptor
(AchR) that binds the peptide rabies virus glycoprotein (RVG). To target and
deliver siRNA to the macrophages in the nerve system for the treatment of
neuroinflammatory diseases, RVG was linked with nona-D-arginine residues
(RVG-9R). The authors first confirmed that RVG-9R can selectively deliver
FITC-labeled siRNA to primary splenic murine macrophage (CD11b+) in vitro.
Then the in vivo targeted delivery to peripheral and nerve system macrophages
mediated by AchR were shown by comparing the median fluorescent intensity of
CD11b+ macrophages from wild type or AchR knock out mice that had been i.v.
administrated with RVG-9R/FITC-siRNA. The therapeutic effect of RVG-9R
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prepared with siRNA against TNF-α was test in a lipopolysaccharide (LPS)induced murine inflammatory model. I.v. administration of RVG-9R/ siTNF-α
was reported to significantly inhibit the increased secretion of TNF-α in blood and
brain compared with RVG-9R/luciferase siRNA and was shown to protect the
neurons from LPS-induced apoptosis

103

. Another macrophage targeting system is

mediated by folic acid as it has been discovered recently that folate receptors are
upregulated on activated macrophage during the inflammatory process
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.

Inspired by this property, Yang et al. linked folic acid with chitosan (FA-chitosan)
to target macrophages for anti-inflammatory effects. Up to 62% in vitro gene
silencing was achieved with FA-chitosan nanoparticles prepared with siRNA
against GAPDH on LPS activated RAW 264.7 cells. The biodistribution of i.v.
injection of FA-chitosan encapsulating Cy5 labeled siRNA was monitored in a
murine subcutaneous inflammation model using an IVIS® 200 imagine system.
Accumulation of Cy5-siRNA/FA-chitosan nanoparticles was observed in the LPS
induced lesion site while no clear fluorescent signal was detected in the Cy5siRNA/chitosan group 105.
2.3.3 Targeted delivery systems for other cell types
Dendritic cells (DCs), the most efficient antigen presenting cells (APCs),
can initiate and maintain the inflammatory response; hence they are another
popular target cell type in asthma. A strategy to target DCs was described by
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Zheng et al who encapsulated siRNA in liposomes decorated with DC-specific
antibody DEC-205 which are so-called immunoliposomes (siILs). The siILs
prepared with siRNA against CD40 were shown to more efficiently silence the
expression of CD40 in DCs derived from bone marrow (BMDCs) compared with
GenePORTER® in vitro. The biodistribution of siILs encapsulating Cy3-labeled
siRNA after i.v. injection was observed on the tissue sections of liver, spleen and
kidney. was Accumulation of siILs/Cy3-siRNA in the spleen at 4 hours and even
stronger accumulation at 8 hours after injection was observed, but no detectable
siILs were found in the kidney at any time point. In contrast, naked Cy3-siRNA
was cleared through kidney soon after injection, suggesting siILs nanoparticles
may selectively accumulate in the DCs-rich tissues like the spleen and have a long
circulation time with slower clearance via kidney. The in vivo gene silencing of
siILs prepared with CD40 siRNA was determined in mice with inflammation
induced by keyhole limpet hemocyanin/complete Freund adjuvant. Significant
CD40 knockdown in DCs was achieved in animals treated with siILs/CD40
siRNA or naked CD40 siRNA compared to mice administered with siILs/ negative
control siRNA, IgG coupled non-targeted liposome and PBS. However, silencing
of CD40 expression induced by siILs/CD40 siRNA can last at least 12 days while
that induced by naked CD40 siRNA did not last this long. Meanwhile, the authors
also measured the expression of CD40 in B cells and concluded that the CD40
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silencing of siILs nanoparticles selectively happened in DCs106. In contrast,
another APC-targeted delivery system can transport siRNA to more than just DCs.
TLR9 is an endosomal location toll like receptor (TLRs) which can bind with CpG
oligonucleotides and facilitate the uptake of siRNA to the cytosol. This receptor is
as well expressed on various APCs including DCs, B cells and macrophages.
Uncontrollable growth of immune cells can result in blood cancer, for example, B
cells lymphoma. Immunosuppression is a common obstacle in cancer therapy, and
therefore, immune cells are important therapeutic targets in anti-cancer treatment.
To target and deliver siRNA to human hematopoietic cells for anti-tumor therapy,
siRNA against STAT3 was covalently linked to CpG oligonucleotides by Zhang et
al. The selective cellular uptake of CpG-Cy3-siRNA in primary human DCs,
monocytes and B cells was observed via flow cytometry but not in T cells and
natural killer cells. After intratumoral injection of the CpG-siSTAT3 in murine
subcutaneous tumor models (established by KMS-11, MonoMac6, MV4-11 or
A20 tumor cells), the in vivo gene silencing in tumor cells and the inhibition of
tumor growth were significantly higher than with the control CpG- luciferase
specific siRNA 107.
Except inflammatory cells, lung structure cells are thought to be therapeutic
targets for asthma. Beta2-adrenergic receptor (β2-AR) is abundant on bronchial
smooth muscle cells and is the target for β2-AR agonist bronchodilators. Therefore,
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Luo et al. conjugated β2-AR agonist salbutamol to guanidinylated chitosan (SGCS)
as a pulmonary delivery carrier of siRNA to improve the efficacy of gene silence.
SGCS formulated with siRNA against EGFP yielded nanoparticles with sizes of
around 100 nm and zeta-potentials of 2-4 mV. Nanoparticles were nebulized and
the aerosol was collected and was i.t. sprayed into the lung of EGFP transgenic
mice on three consecutive days. The in vivo GFP gene silencing of SGCS was
significantly better than that of non-targeted GCS determined by confocal
microscope and western blot 108.
2.4 Conclusion
In the last decades, many groups have tried to translate siRNA mediated
RNAi into a biocompatible, efficient and long term therapy to treat the airway
inflammation in asthma. Lots of novel therapeutic targets have been discovered
and numerous studies have been performed with the results of significant antiinflammatory effects. However, asthma is such a complex inflammatory disorder
which involves various factors, thus blockage of a single mediator or receptor
cannot efficiently relieve the symptoms. Accordingly, the delivery of siRNA
mixtures against multiple genes or against the upstream factors in the
inflammatory process such as transcription factors, kinases or costimulatory
molecules may be more effective. Furthermore, the lack of efficient and specific
siRNA delivery systems results in low therapeutic efficiency and high potential of
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side effects. Although, there are several ligand-receptor mediated targeted delivery
systems of siRNA that could potentially be applied in asthma, none of the current
immune cell targeted delivery systems has been optimized for asthma disease
except the Tf-LMW-PEI conjugate reported by our group. Therefore, further
studies and tests are required to develop an efficient siRNA delivery system for
asthma therapy.
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CHAPTER 3 TARGETED DELIVERY OF SIRNA TO
ACTIVATED T CELLS VIA TRANSFERRINPOLYETHYLENIMINE (TF-PEI) AS A POTENTIAL
THERAPY OF ASTHMA
Please note that part of the content of this chapter is from a research article,
“Targeted Delivery of siRNA to Activated T Cells via TransferrinPolyethylenimine (Tf-PEI) as a Potential Therapy of Asthma”, was published in
Journal of Controlled Release (Y. Xie, et al., 2016). The authors of this article
include Na Hyung Kim, Venkatareddy Nadithe, Dana Schalk, Archana Thakur,
Ayşe Kılıç, Lawrence G. Lum, David JP Bassett, Olivia M Merkel and me. I am
the first author of this research paper. I performed the experiments and wrote the
paper.
3.1 Introduction
siRNA mediated gene therapy could potentially be an alternative and safer
therapy for asthma. However, as discussed in Chapter 2, lack of an efficient in
vivo delivery system of siRNA and an effective molecular biological target limits
the clinic application of siRNA in asthma. Inflammation in asthma is driven by an
infiltration of inflammatory cells such as activated T cells (ATCs), eosinophils and
mast cells. Among infiltrated inflammatory cells, ATCs, specifically, T helper 2
cells (Th2) play a critical role in orchestrating pathological processes of asthma via
the production of Th2 cytokines

69-70, 109

. Therefore, blockage of the functions of
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Th2 interleukins (e.g. IL-5 110) or silencing of upstream transcription factors which
promote the production of Th2 interleukins (e.g. GATA-3

11

) have been

investigated as potential therapies of difficult-to-treat asthma.
Substantial investigations have been undertaken for applying siRNA to
silence asthma related genes in Th2 cells (e.g. IL-5

80

and GATA-3

111

).

Nevertheless, safe and effective delivery of siRNA is facing several challenges.
The hurdles are to overcome various physiological barriers including enzymatic
degradation, non-specific binding to non-target tissues or cells, negatively charged
cellular membranes, endosomal escape after endocytosis, and many more
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.

Moreover, delivery of siRNA to Th2 cells is particularly difficult because T cells
are in general resistant to non-viral vector-based transfection methods

98a

. T cells

do not actively endocytose nanoparticles because they do not express caveolin and
are devoid of caveolae
viral delivery systems
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. Conventional transfection approaches of T cells are

or electroporation

98b

. However, the fabrication of viral

vectors is time and cost consuming, and their potential safety issues limit their
clinical application 97a. On the other hand, electroporation is not a suitable method
for in vivo administration of siRNA
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. Various delivery systems have been

discovered to target T cells, including CD3 targeted polyethylenimine (PEI)
CD40L targeted liposomes
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, CD7 targeted chitosan

101

or oligo-arginine

116

,

100

.

However, their efficiency and potential systemic side effects for asthma therapy
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remain to be tested. Since CD7 and CD3 are pan T cell surface antigens and since
nanomedicines targeting these receptors were all applied through systemic
administration in their respective in vivo studies, it would be expected to observe
side effects with these strategies.
In order to avoid potential systemic side effects and to increase the
selectivity for activated T cells, the key mediators in asthma pathogenesis and
development, our group has developed a pulmonary siRNA delivery system based
on transferrin-polyethylenimine (Tf-PEI). This ligand-polymer conjugate takes
advantage of the increased expression of transferrin receptors (TfR) on T cells
after activation 118. TfR is a membrane protein expressed at low level on most cells
and can bind to the iron transport glycoprotein Tf, which consequently triggers
fast internalization 57b
. Previously, we showed that only activated primary T cells take up siRNA
delivered by Tf-PEI, while naïve T cells with a basal level of TfR expression
cannot be reached efficiently with the Tf-PEI conjugate for siRNA delivery

91

.

Low molecular weight PEI (5k Da) is used as a carrier of siRNA to facilitate
cellular internalization and endosomal escape

119

with minimal toxicity

51, 120

. N-

succinimidyl 3-(2-pyridyldithio) propionate (SPDP) as a crosslinker can introduce
a disulfide bond between Tf and PEI. Disulfide bonds are stable extracellularly but
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can be reduced in the endosome compartment 101 and allow PEI/siRNA polyplexes
to be released from the Tf/TfR complex prior to rapid recycling of TfR.
In this chapter, a pulmonary delivery system that can selectively and
efficiently deliver siRNA to activated T cells in the lung was developed and could
be potentially applied for asthma therapy. In the following present work, Tf-PEI
exhibited optimal physicochemical properties in terms of siRNA condensation
efficiency, size, zeta-potential and stability in the presence of lung surfactant and
mucin. In vitro studies revealed that Tf-PEI can efficiently deliver siRNA to
primary human ATCs or Jurkat cells and mediated significant gene knock down.
Biodistribution of Tf-PEI polyplexes formulated with fluorescently labeled siRNA
in a murine asthmatic model after intratracheal administration confirmed that TfPEI can selectively deliver siRNA to ATCs in vivo.
3.2 Material and Method
3.2.1 Materials
N- succinimidyl 3-(2-pyridyldithio) propionate (SPDP) was purchased from
Pierce (Rockford, IL), SYBR Gold dye and Lipofectamine 2000 were obtained
from Life Technologies (Grand island, NY), branched low molecular weight
(LMW) 5k Da PEI (Lupasol® G100) was from BASF (Ludwigshafen, Germany),
murine transferrin, picrylsulfonic acid solution (TNBS, 5% w/v), Dulbecco’s
phosphate

buffered

saline

(PBS),

dimethyl

sulfoxide

(DMSO),
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ethylenediaminetetraacetic acid disodium salt dehydrate (EDTA), type II mucin
from porcine stomach, and albumin from chicken egg white (OVA) were bought
from Sigma-Aldrich (St. Louis, MO). Chloroquine diphosphate was from MP
biomedicals (Santa Ana, California), human holo-transferrin was purchased from
EMD Millipore (Billerica, MA), 1,4-Dithio-DL-threitol (DTT, 99%) was obtained
from

Alfa

Aesar

(Ward

Hill,

MA).

Amine

modified

siRNA

pACCCUGAAGUUCAUCUGCACCACcg,
ACUGGGACUUCAAGUAGACGUGGUGGC),
phosphate-

dehydrogenase

(5´3´-

human

(GAPDH)

glyceraldehydesiRNA

pGGUCGGAGUCAACGGAUUUGGUCgt,

3(5´3´-

UUCCAGCCUCAGUUGCCUAAA- CCAGCA), and scrambled siRNA (5´pCGUUAAUCGCGUAUAAUACGCGUat,

3´-

CAGCAAUUAGCGCAUAUUAUGCGCAUAp) were purchased from Integrated
DNA Technologies (Coralville, IA) (indication of modified nucleotides: “p”
denotes a phosphate residue, lower case bold letters are 2´-deoxyribonucleotides,
capital letters are ribonucleotides, and underlined capital letters are 2´-Omethylribonucleotides). A 0.4% trypan blue solution in phosphate buffered saline
was purchased from HyClone GE healthcare (Buckinghamshire, UK).
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3.2.2 Synthesis of transferrin-polyethylenimine (Tf-PEI) conjugate
For the first reaction, 5k PEI (1 mg/ml) dissolved in HEPES buffered saline
(HBS) (20 mM HEPES, 150 mM NaCl, pH=7.5) was mixed with a 10-fold molar
excess SPDP (20 mM) in dry DMSO and stirred for overnight. A Tf solution (10
mg/ml, human or murine) was dissolved in HBS and stirred with a 5-fold molar
excess SPDP for 2 h. Purification of PEI-SPDP and Tf-SPDP were performed via
3,000 or 10,000 MWCO centrifugal filters (Millipore, Billerica, MA) with HBS/1
mM EDTA (pH=7.1), respectively. To estimate the concentration of SPDP in the
PEI-SPDP solution, 100 µl of 50-fold diluted PEI-SPDP solution was reacted with
1 µl of a 150 mM DTT solution for 30 min, and the pyridon-2-thion release was
measured spectrophotometrically at 343 nm in a 96-well UV plate (Corning).
Subsequently, a 10-fold molar excess DTT was mixed and reacted with the
remaining PEI-SPDP under nitrogen protection for 2 h. Reduced PEI-SPDP was
purified by 3,000 MWCO centrifugal filters with HBS/20 mM EDTA (pH=7.1).
For the coupling reaction, Tf-SPDP was added stepwise to PEI-SPDP and stirred
overnight at 4 C°. Purification of Tf-PEI was achieved on an ÄKTA FPLC system
(GE healthcare) equipped with 2 connected 1 ml HiTrap SP HP cation exchange
column (GE healthcare) as described before

121

. Free Tf was washed out with 0.5

M NaCl/20mM HEPES and Tf-PEI was eluted after initial binding to the column
after switching to 3 M NaCl/20 mM HEPES. Further purification and desalination
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was performed by 30,000 MWCO centrifugal filters (Millipore) with HBS. The
concentration

of

Tf

in

the

Tf-PEI

conjugate

was

determined

spectrophotometrically at 280 nm. To determine the concentration of PEI in TfPEI, a standard curve was generated by diluting PEI in a solution containing a
constant concentration of Tf. According to the standard curve, the concentration of
PEI in Tf-PEI conjugate was assessed at wavelength 405 nm using a TNBS
assay122.
3.2.3 Preparation of polyplexes
Polyplexes were prepared in either HBS or 5% glucose. An equal volume
of Tf-PEI or PEI was added to a defined amount of siRNA solution to yield
different amine to phosphate ratios (N/P ratios) and incubated for 20 min before
further measurement or transfection. Lipofecatmine 2000 (LF) lipoplexes
preparation was performed according to the manufacturer’s protocol. Briefly,
every 10 pmol siRNA were formulated with 0.5 µl LF. The amount of PEI or TfPEI needed at different N/P ratio for 50 pmol siRNA were calculated according to
the following equation: m (PEI in pg) = 50 pmol × 43.1 g/mol × N/P × 52
(protonable unit of PEI = 43.1 g/mol, number of nucleotides of 25/27mer siRNA =
52).
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3.2.4 Hydrodynamic size and zeta-potential measurement
For the measurement of size, PEI or Tf-PEI polyplexes were prepared with
50 pmol siRNA in HBS at different N/P ratios. The total volume of 100 µl
polyplexes was added into a disposal micro cuvette (Brand GMBH, Wertheim,
Germany) and the size was measured using a Zetasizer Nano ZS (Malvern
Instruments Inc., Westborough, MA). The measurement was set up at 173°
backscatter angle and 15 runs were performed three times for each sample. For
data analysis, 0.88 mPa*s for viscosity and 1.33 for refractive index were used
with the Zetasizer Software (Malvern). Subsequently, polyplexes were diluted
with Nanopure water (Thermo scientific) to 1 ml and transferred to a folded
capillary cell (Malvern) and zeta-potential measurements were performed three
times for each sample using the Zetasizer Nano ZS (Malvern).
3.2.5 SYBR gold dye binding assay
To measure siRNA condensation efficiency of the conjugates in
comparison to the unmodified polymer, siRNA in 5% glucose was distributed in a
FluoroNunc 96-wells white plate (Thermo Fisher Scientific, Waltham, MA) at a
concentration of 50 pmol/50 µl per well followed by adding 50 µl of different
concentration of either PEI or Tf-PEI to form polyplexes at different N/P ratios.
After 20 min incubation, 30 µl of 4 × SYBR gold solution was added to each well
and incubated for 10 min in the dark. SYBR gold fluoresces when it intercalates
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with free siRNA but not if siRNA is not accessible due to condensation and
protection by polymers. The fluorescence was quantified using a Synergy 2 multimode microplate reader (BioTek Instrument, Winooski, VT) at excitation
wavelength of 485/20 nm and emission wavelength of 520/20 nm. Fluorescence of
free siRNA (N/P=0) represents 100% of free siRNA.
To evaluate the stability of polyplexes, release of siRNA from polyplexes
in presence of lung surfactant Alveofact® (Boehringer-Ingelheim, Germany) or
mucin was determined by a modified SYBR gold assay

22

. While the surfactant

assay measures siRNA release from polyplexes by surface-active phospholipids,
the mucus assay determines polyplexes instability in presence of mucus
glycoproteins. Tf-PEI and PEI polyplexes were prepared with siRNA at N/P 7.5
and distributed in a 96-well white plate at a concentration of 50 pmol siRNA/100
µl per well. After 15 min incubation, 50 µl of 4 x SYBR gold solution was added
to each well and incubated for 10 min in the dark. Subsequently, 50 µl of a serial
dilution of Alveofact® or mucin was added (final concentrations: 0, 0.0005, 0.005,
0.05, 0.25, 0.5 mg/ml) and incubated for additional 20 min in the dark before
measurement of the fluorescence. To account for the autofluorescence of mucin,
free siRNA samples were prepared in the presence of according concentration of
mucin. The experiment was performed in replicates of three and fluorescence of
free siRNA represents 100% siRNA release.
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3.2.6 Cell culture
Peripheral blood mononuclear cells (PBMCs) were obtained from healthy
donors (KCI protocol 2007-012). This protocol was approved by the Wayne State
University Human Investigation Committee. PBMCs were cultured at a
concentration of 106 cells/ml in RPMI-1640 with HEPES & L-Glutamine cell
culture medium (Lonza, Walkersville, MD) supplemented with 10 % heat
inactivated fetal bovine serum (FBS) (v/v) (Sigma), 1 x penicillin/streptomycin
(pen/strep) (Corning, Corning, NY) and 2 mM L- Glutamine (Gibco® Thermo
Fisher Scientific). Peripheral resting T cells in PBMCs were stimulated with antiCD3 monoclonal antibody (OKT3, Ortho Biotech, Horsham, PA) at a final
concentration of 20 ng/ml and expanded with 100 IU/ml human recombinant
interleukin-2 (IL-2), Novartis). Jurkat cells, a human T lymphocytes cell line, were
a kind gift from Dr. Larry H. Matherly (Karmanos Cancer Institute). Jurkat cells
were cultured in the same media as primary T cells. A549 cells, a human epithelial
cell line derived from lung carcinoma, were obtained from ATCC (Manassas, VA,
USA) and cultured in DMEM media (Corning) supplemented with 10% FBS and
1× pen/strep. All cells were grown at a humidified atmosphere with 5% CO2 at 37
C°. Primary ATCs were frozen at -130 C° in 50% FBS, 40% growth media and 10%
DMSO on different post-activation days for later experiment.

68

3.2.7 Immunofluorescent staining
Human ATCs, harvested on different post-activation days, or Jurkat cells
were washed with PBS and 400,000 cells per sample were resuspended with 10 µl
50-fold diluted human FcR binding inhibitor (ebioscience, San Diego, CA) for 5
min on ice, followed by staining with 2 µl of PE labeled human CD71 antibody
(OKT9, ebioscience) or PE labeled mouse IgG1 isotype control antibody
(P3.6.2.8.1, ebioscience) for 30 min at 4 °C protected from light. Afterward, cells
were washed twice and resuspended with 400 µl ice cold PBS/2 mM EDTA before
they were analyzed with an Attune® Cytometer (Life Technologies). The cellular
suspensions were measured with 488 nm excitation and the emission filter set of
574/26 nm. On day 6 post-activation, ATCs were counterstained with a CD71
antibody and a PE-Cy7 labeled human CD3 antibody (UCHT1, Molecular probes).
The samples were measured with 488 nm excitation and emission filter of 574/26
nm and 640 LP in an Attune® Cytometer (Life Technologies). A viable
lymphocyte population was gated according to morphology based on forward and
sideward light scattering within which 10,000 events were evaluated. All results
are given as median fluorescent intensity (MFI). Data analysis was performed
using Attune® cytometer software (Life Technologies).
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3.2.8 Quantification of cellular uptake
Amine modified siRNA was labeled with succinimidyl ester (NHS)
modified Alexa Fluor 488 (AF488) (Life technologies) following the
manufacturer’s protocol and purified by ethanol precipitation and spin column
binding as described previously

123

. For uptake experiments, 50 pmol siRNA-

AF488 was prepared with Tf-PEI or PEI in 5% glucose at different N/P ratios (N/P
ratio: 5, 7.5, 10, 15, 20) or with LF. The day before the experiment, 400,000 ATCs
or Jurkat cells were seeded in 96 well plates (Thermo scientific) at a concentration
of 2×106 cells/ml and transfected with the polyplexes/lipoplexes for 24 h. Samples
were washed three times and resuspended in 400 µl PBS/2 mM EDTA. For initial
experiments, ATCs were transfected with low N/P ratio treatment groups were
analyzed using a BD LSR II flow cytometer (BD bioscience, San Jose, CA). For
later experiments, ATCs or Jurkat cells were transfected with high N/P ratios (10,
15, 20, or 5, 10, 20), and samples were analyzed using an Attune® Cytometer
(Life Technology) with 488 nm excitation and emission filter of 530/30. The cells
were gated according to morphology within which 10,000 events were evaluated.
For trypan blue quenching assays, ATCs were treated by Tf-PEI or PEI
polyplexes at N/P 20 or LF lipoplexes for 24 h. Each sample was divided into two
halves; one half was washed once with 0.4% trypan blue to quench the
extracellular fluorescent signal then washed with cold PBS/2 mM EDTA three
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times, the other half was only washed three times. Samples were resuspended in
400 µl PBS/2 mM EDTA and analyzed with an Attune® Cytometer (Life
Technology) as described above.
For the competition cellular uptake study, 400,000 Jurkat cells were seeded
in 96 well plates at a concentration of 4×106 cells/ml. Subsequently, Tf was
dissolved in growth media as a Tf stock solution (20 mg/ml), and predetermined
amounts of Tf stock solution and growth media were added into the cell
suspension to achieve desired Tf concentrations (0, 0.1, 2 mg/ml) at a fixed cell
concentration (2×106 cells/ml). The cells were then incubated with free Tf for 30
min and transfected afterwards with Tf-PEI or PEI at N/P ratio 15 for 4 h. Cellular
uptake was quantified using flow cytometry as described above. The experiment
was conducted in duplicate.
3.2.9 Confocal Laser Scanning Microscopy
Jurkat cells were seeded in 96 well plates as described above and
transfected with Tf-PEI and PEI polyplexes formulated with 50 pmol siRNAAF488 at N/P ratio of 15. LF was included as control. After 24 h incubation, cells
were transferred to 1.5 ml tubes and washed once with PBS followed by fixation
with 4% paraformaldehyde (PFA) solution in PBS (Affymetrix, Thermo Fisher)
for 20 min. After fixation, the cells were washed with PBS and the nuclei were
stained with 5 µM of DRAQ5 (Invitrogen, Thermo Fisher) for 5 min followed by

71

washing the cells with PBS. The cell pellet was resuspended in 20 µl Fluoromount
mounting medium (Southern Biotech, Birmingham, AL, USA), and the cell
suspension was dropped on slide and covered with a coverslip (Fisherbrand,
12CIR. -1). Slides were imaged by a Leica TCS SPE-II laser scanning confocal
microscope (Leica, Wetzlar, Germany), and the images were exported from the
Leica Image Analysis Suite (Leica).
3.2.10 In vitro GAPDH gene knockdown
For gene silencing experiments, 400,000 ATCs or Jurkat cells were seeded
in a 96 well plate and triplicates of samples were treated with Tf-PEI, PEI or LF
polyplexes/lipoplexes prepared with 50 pmol for ATCs or 100 pmol for Jurkat
cells for 24 h using either hGAPDH siRNA or scrambled siRNA at N/P 15. Cells
were harvested and processed to isolate total RNA using the PureLinkTM RNA
mini kit (Life techonologies) according the manufacturer’s protocol with DNase I
digestion (Thermo scientific). Synthesis of cDNA from total RNA and PCR
amplification were performed with Brilliant III ultra-fast SYBR® green QRT-PCR
master mix kit (Agilent Technologies, Santa Clara, CA) using a Stratagene Mx
3005P (Agilent Technologies). Cycle threshold (Ct) values were determined by
MxPro software (Agilent Technologies). A standard curve including 5 points was
made from a 1:5 serial dilutions of an untreated sample and assigned
concentrations of each point (1, 0.2, 0.004, 0.0008, 0.00016) were plotted vs. their

72

corresponding Ct values. The gene expression of GAPDH was normalized by the
expression of β-actin. Hs_GAPDH_2_SG primers for GAPDH and Hs_ACTB_2SG primers for β-actin (Qiagen, Valencia, CA) were used in experiment.
3.2.11 Cytotoxicity assay
For measuring the biocompatibility of polyplexes, 8,000 A549 cells were
seeded in a sterile, white 96 well plate (Corning) at a concentration of 40,000
cells/ml for 24 h. Polyplexes were prepared with Tf-PEI, 5k PEI and 25k PEI with
50 pmol scrambled siRNA at different N/P ratios (1, 3, 5, 7.5, 10, 15, 25, 30, 40)
and diluted with 5 % glucose to a final volume 40 µl. The polyplexes were then
mixed with 60 µl of growth media, old media in the well plate was removed, and
100 µl media containing polyplexes was added and incubated for 24 h. The release
of lactate dehydrogenase (LDH) from the cells was determined using a CytoToxONE™ kit purchased from Promega (Madison, WI) following the manufacturer’s
protocol. The “no cell” control served as 0% LDH release and cells treated with
lysis buffer represent 100% LDH release. Experiments were conducted in
triplicate.
3.2.12 Cellular distribution of polyplexes in a murine asthma model
All animal experiments were approved by a Wayne State University
Institutional Animal Care and Use Committee. Balb/c mice were purchased from
Charles River Laboratories (Boston, MA) and used at 5 weeks’ age. The murine
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asthma model was established as described before

75a

. Briefly, animals were

sensitized by intraperitoneal (i.p.) injection of 0.2 ml suspension of ovalbumin
(OVA) and Al(OH)3 (10 µg OVA and 2 mg Al(OH)3) on day 0 and day 14 (Figure
13 A). On days 24, 25, and 26, mice were challenged by inhalation of aerosolized
1% OVA for 1 h to establish experimental asthma while mice that inhaled saline
were used as healthy control group. On days 35, 36, 37 and 38, mice were
intratracheally (i.t) instilled (under ketamine/xylazine anesthesia) with 50 µl TfPEI or PEI polyplexes, prepared with 750 pmol Alexa Fluor 647 (Life
technologies) labeled siRNA at N/P 7.5, or free siRNA-AF647 as control. On days
36, 37 and 38, before the i.t. administration, a second series of daily OVA or saline
challenges was performed. On day 39, noninvasive lung function of animals was
determined by whole-body plethysmography. Changes in the delayed pause in
breathing as an indicator of altered bronchial responsiveness to increasing aerosol
challenge concentrations of β-methacholine was monitored (Buxco Electronics
Inc., Wilmington, DE)
ketamine/xylazine

124

. On day 40, all animals were sacrificed under i.p.

anesthesia,

exsanguinated

and

perfused

Bronchoalveolar lavage fluid (BALF) and BALF cells were collected
cell suspensions were prepared as reported before
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with
125

PBS.

and lung

. BALF cells and lung

suspension cells were counterstained with PerCP-Cy 5.5 labeled anti-CD45 (30F11, ebioscience), PE-Cy7 labeled anti-CD4 (GK1.5, eBioscience), a primary anti-
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prosurfactant protein C antibody (proSPC) (1:100, abcam), pacific blue labeled
goat anti-mouse IgG secondary antibody (1:100, Life Technologies), pacific
orange labeled anti-F4/80 (invitrogen), APC-Cy7 labeled anti-CD19 (MB19-1,
molecular probes), and PE labeled anti-CD49d (R1-2, Molecular Probes)
antibodies following the manufacturer’s protocols. Cell differentiation was
performed on a BD LSR II flow cytometer (BD bioscience). The staining strategy
was shown in Table 2. The different cell populations of macrophage/monocytes
(F4/80+), T cells (CD4+, F4/80-), eosinophils (CD4-, CD49d+), and epithelial
Type II pneumocytes (proSPC+) were gated, and the MFI of siRNA-AF647 in all
different cell populations was quantified. To quantify cellular uptake of polyplexes
in T cells only, lung suspension cells were stained with a PE-Cy7 labeled antiCD4 antibody. T cells were gated based on morphology, and the MFI of siRNAAF647 was quantified within CD4+ cells by an Attune® Cytometer (Life
Technology). The concentration of interleukin-5 (IL-5) and interleukin-13 (IL-13)
in BALF was determined by the mouse cytokine 20-plex panel (Invitrogen) using
a Bio-Plex® System (Bio-Rad Lab., Hercules, CA) following the manufacturer’s
protocol. Interleukin concentrations below the detection limitation were reported
as 0 pg/ml.
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Table 2 Strategy to differentiate cellular populations of BALF cells
CD45(PerCP CD4(PE-Cy5.5)
Cy7)
Macophage/
Monocytes
B cells
Dendritic
cells
T cells
Eosinophils
Type II
pneumocytes

+
+

ProF4/80
SPC(Pacific (Pacific
Blue)
Orange)

+

CD19
(APCCy7)

CD49d(PE)

+

+
+

+

+

+
+
+

+

+

3.2.13 Statistics
All results are given as mean value ± standard deviation (SD). One-way
ANOVA with Bonferroni posthoc post-test and calculation of area under the curve
(AUC) were performed in GraphPad Prism software (Graph Pad Software, La
Jolla, CA).
3.3 Result and Discussion
3.3.1 Synthesis Outcome
Transfection efficiency and toxicity of PEI are often correlated to its
molecular weight

126

. Here, low molecular weight PEI (5k Da) was chosen to

decrease potential toxicity and non-specific transfection efficacy. Holo-Tf
preferentially binds to TfR

57b

and has been reported as a targeting ligand for

various diseases involving TfR overexpression using lipid-based
based delivery systems carrying pDNA

44, 128

127

or polymer-

, siRNA 129 or oligonucleotides

93

for

anti-sense therapy. To target ATCs, holo-Tf was conjugated to PEI to increase the
intracellular internalization efficiency. As shown in Figure 3, holo-Tf and 5k PEI
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were reacted with the bifunctional crosslinker SPDP, respectively, and PEI-SPDP
was activated by the reducing reagent DTT. Activated PEI-SPDP* (see Figure 3)
was conjugated to Tf-SPDP to yield Tf-PEI. The final concentration of Tf was
determined by UV absorbance at 280 nm, and the concentration of PEI was
assessed by TNBS assay. The resulting molar ratio of Tf to PEI was approximately
1.5: 1. Due to the difference of molecular weights between Tf (80 kDa) and LMW
PEI (5 kDa), higher coupling degrees were not expected and could in fact be
disadvantageous for the interaction between PEI amines and siRNA phosphate
groups.

Figure 3 Synthesis scheme of transferrin-coupled polyethylenimine (Tf-PEI).
Transferrin (Tf, left side) and PEI (right side) are reacted with N-succinimidyl 3(2-pyridyldithio)-propionate (SPDP) in separate reactions. PEI-SPDP is activated
by dithiothreitol (DTT) and coupled with Tf-SPDP to form a disulfide bond and
the resulting Tf-PEI.
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3.3.2 siRNA condensation of Tf-PEI
The siRNA condensation efficiency of a polymer is an important property
to evaluate the suitability of a carrier for siRNA. To determine whether the
presence of Tf would affect the ability of PEI to condense siRNA, the
condensation efficiency of Tf-PEI was determined by SYBR® Gold assays, and
unmodified 5k PEI was used as a control. SYBR gold is a nucleic acidintercalating fluorescent dye. When siRNA is condensed by polymer and becomes
inaccessible to SYBR gold, consequently a decrease of fluorescence is observed.
As shown in Figure 4, PEI can completely condense and protect the siRNA at N/P
5 which was consistent with previous reports

75b

. On the other hand, both human

and mouse Tf-PEI condensed siRNA to 80% at N/P 5, and complete condensation
of siRNA was observed at N/P 7.5. The difference may be due to steric hindrance
of Tf which impacts the interaction between siRNA and the primary amines in PEI.
It also needs to be taken into consideration that by coupling Tf to PEI, a few
primary amines would be expected to no longer be available for interaction with
siRNA. However, the influence of the Tf modification on condensation efficacy of
the conjugate is limited, with full condensation still achievable at a comparably
low N/P ratio of 7.5.
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siRNA Condensation Efficiency

Free siRNA (%)

100

PEI
Human Tf-PEI
Murine Tf-PEI

80
60
40
20

0
0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0

N/P ratio

Figure 4 SYBR gold assay of PEI and Tf-PEI. The siRNA condensation efficiency
of PEI and Tf-PEI was measured by SYBR gold assay at different N/P ratios: 0,
1.25, 2.5, 3.75, 5, 7.5, 10, 15, 20. Fluorescence of free siRNA (N/P= 0) represents
100% free siRNA. (Data points indicate mean ﹢/﹣ SD, n= 2-3; Green square:
PEI polyplexes, orange circle: human Tf-PEI, yellow triangle: murine Tf-PEI)
3.3.3 Hydrodynamic diameter and zeta potential
Optimal physicochemical properties of polyplexes such as size and surface
charge can facilitate efficient siRNA delivery in vitro and in vivo. Therefore, TfPEI or PEI polyplexes, prepared with the same amount siRNA in HBS buffer at
different N/P ratios, were fully characterized for size, polydispersity index (PDI)
and zeta potential by dynamic light scattering and laser Doppler anemometry. As
shown in Figure 3.3 A, Tf-PEI formulations demonstrated small sizes ranging
from 72 to 197 nm and PDIs ranging from 0.24 to 0.39. In comparison, PEI
formed larger particles of 1133 nm to 1595 nm in size with PDI of approximately
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0.3. Both formulations demonstrated acceptable size distributions with PDIs
mostly below 0.3 indicating homogeneous morphology and little aggregation
which is an important factor for successful transfection. Size of polyplexes is
another key factor for efficient transfection, and small sizes (<200 nm) of the TfPEI polyplexes could ensure higher stability and better intracellular uptake
efficiency especially into ATCs compared with large PEI polyplexes (>1000 nm)
130

. Considering that Tf is a very soluble glycoprotein, it is possible that Tf

decorates the surface of Tf-PEI polyplexes and a resulting steric stabilization of Tf
contributes to the much smaller size of the particles

128

. Consistent with this

hypothesis, it has been reported that low molecular weight PEI tends to form large
particles with siRNA

131

and a tendency of aggregation of PEI has been observed

when preparing polyplexes in high ionic strength buffers such as HEPES buffered
saline 128.
Zeta potentials of both Tf-PEI and PEI polyplexes increased with
increasing N/P ratio (Figure 5 B). Tf-PEI polyplexes displayed negative charges
in the range of -20 to -7 mV which is in agreement with the assumption that the
negatively charged Tf may shield the positive charges of PEI and is located on the
surface of the polyplexes, resulting in an overall negative zeta potential 132. On the
other hand, except at N/P 2 where the zeta potential was -28.6 ± 3.9 mV, all PEI
formulations showed slightly positive charges in the range from 8.5 mV to 26 mV.
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Due to the relatively “rigid” structure of short duplex siRNA and the fact that not
all positively charged groups in PEI are sterically available to interact with siRNA,
most of the siRNA may be on the surface of the polyplexes at a low excess of
polymer, i.e. N/P 2. This could explain why a negative charge was observed at N/P
2. At higher N/P ratios, excess amount of PEI more efficiently interacts with the
negative charges of siRNA resulting in positive zeta potentials of the polyplexes.
Positive zeta potentials of polyplexes may hamper their penetration through lung
mucus and surfactant which have negative charge

75a

and also increase their

chance of non-specific delivery via adsorptive endocytosis. Additionally, multiple
pulmonary administrations of positively charged nanoparticles can increase local
and systemic toxicity, while in comparison, anionic nanoparticles are well
tolerated

133

. Therefore, we hypothesize that Tf-PEI polyplexes would be a more

efficient and safe pulmonary administrated system than PEI.
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Figure 5 Size and zeta-potential of Tf-PEI and PEI. (A) Hydrodynamic diameters
(left x-axis) and polydispersity indices (PDI, right x-axis) and (B) zeta-potentials
of Tf-PEI and PEI polyplexes formulated with 50 pmol siRNA in HEPES buffered
saline at different N/P ratios :2, 5, 7.5, 10, 15, 20. (Data points indicate mean ﹢/
﹣ SD, n=3)
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3.3.4 Stability of polyplexes in the presence of lung surfactant
The instability of polyplexes in the blood stream limit their suitability for
systemic administration. To overcome this challenge, pulmonary delivery is
favorable for the treatment of lung diseases due to the large application area, the
absence of serum proteins, and the reduced nuclease activity

75b

. However, there

are other biological barriers associated with using the airway route that need to be
overcome to deliver siRNA to the lung. If epithelial cells in the upper airway are
to be targeted, polyplexes need to penetrate a mucus layer before they reach the
epithelium. In asthma therapy, polyplexes are mostly expected to be delivered to
the deep lung, where the alveolar surface is covered by lung surfactant which
presents another barrier 75a. To investigate the stability of polyplexes in the lung, a
modified SYBR® Gold assay was performed in the presence of lung surfactant
Alveofact® or mucin and released siRNA was quantified. Tf-PEI polyplexes
demonstrated higher stability compared with PEI polyplexes at increasing
concentrations of mucin (0.0005 - 0.5 mg/ml) (Figure 6 A). Similarly, at low
concentrations of surfactant (0.0005 - 0.05 mg/ml), the ability of Tf-PEI to retain
siRNA was also better than that of PEI. Only 1% siRNA release from Tf-PEI
polyplexes but 4.3% from PEI polyplexes was observed at 0.05 mg/ml. At a
concentration of 0.25 mg/ml, PEI and Tf-PEI polyplexes released 10.9% and 10.2%
siRNA, respectively. As described above, there are indications that Tf is located
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on the surface of the polyplexes and consequently shields PEI/siRNA from
interaction with surfactant or mucin. In contrast, at the highest concentration of
surfactant (0.5 mg/ml), PEI more efficiently retained siRNA than Tf-PEI (Figure 6
B). While 13.5% of siRNA were released from PEI, 16.2% of siRNA were
released from Tf-PEI polyplexes. High concentration of surfactant may induce
structural changes in Tf, as a result, the ability to retain siRNA in the polyplex
simply depends on electrostatic interaction between siRNA and PEI. It is expected
that Tf-PEI polyplexes would release more siRNA since unmodified PEI
demonstrated slightly better ability to condense siRNA compared with Tf-PEI. In
2009, we reported also that PEGylated PEIs release siRNA more efficiently than
unmodified PEI

22

. It should be noted that in 2009, 25 kDa PEI was described,

whereas here we used 5 kDa PEI which showed slightly lower stability in presence
of surfactant and mucin compared to 25 kDa PEI complexes. However, the studied
concentrations of surfactant, of which predominant composition is phospholipids
(up to 70% being dipalmitoyl phosphatidylcholine (DPPC))

134

, are much higher

than that in a reported simulated lung fluid (0.02% (w/v) DPPC), used for
dissociation tests of inhaled pharmaceutical formulations

135

. At physiological

surfactant concentrations, Tf-PEI polyplexes therefore seem to exhibit enhanced
stability compared to PEI polyplexes. This observation could lead to beneficial
stability after aerosol deposition in the peripheral airways. On the other hand, 91%
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and 97% of siRNA, respectively, were released from Tf-PEI and PEI polyplexes at
a very high concentration of 0.5 mg/ml mucin. In comparison, complexes of
PEGylated 25 kDa PEI which mediated highly efficient gene knockdown in the
lung showed about 30% siRNA release at mucin concentrations as low as 0.33
mg/ml

22

. Instability of siRNA polyplexes at exaggerated mucin concentrations

therefore seem not to hamper efficient gene knockdown at physiological
conditions. While surfactant is only present in the alveolar region, mucus lines in
the upper and bronchial airways where the polyplexes are expected to mediate
their therapeutic effects. Based on our experiments, mucus stability of future
nanocarriers should be optimized. However, it is possible that stability in presence
of surfactant plays a more important role in vivo where Tf-modification of the
polyplexes was advantageous. Therefore, we hypothesize that Tf could protect the
polyplexes for sufficient stability during pulmonary administration.

Figure 6 Stability of Tf-PEI and PEI polyplexes. Stability of Tf-PEI and PEI
polyplexes at N/P 7.5 was determined by modified SYBR gold assay after 20 min
incubation with increasing concentration of (A) mucin and (B) lung surfactant
(0.005-0.5 mg/ml). Free siRNA represents 100% siRNA release. (Data points
indicate mean ﹢/﹣ SD, n=3; Green square: siRNA release from PEI polyplexes,
orange circle: siRNA release from Tf-PEI polyplexes)
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3.3.5 Determination of expression of TfR
To confirm the expression of TfR on human ATC

136

, human PBMCs were

activated by anti-CD3 antibody (OKT3), and the expression of TfR was quantified
by flow cytometry over time. On day 0 (Figure 7 A), the TfR expression was at a
basal level in PBMCs whereas the TfR expression increased dramatically from
day 1 to day 5 after activation. T lymphocytes undergo rapid differentiation,
proliferation, and up-regulate TfR (CD71) to meet their high consumption of iron
118

. The TfR expression level slowly decreased after day 5 post-activation, but a

clearly increased level of TfR expression compared to day 0 was maintained up to
day 14 post-activation. This observation may be due to the fact that T cells are
activated very early and that activation also leads to proliferation137

118, 137

. It is

possible that a) the rate of proliferation and differentiation of T cells slows down
after 5 days post-activation and that b) a percentage of activated T cells becomes
apoptotic resulting in lower TfR levels compared to earlier time points. However,
the activated status of T cells maintains a relatively high consumption of iron
compared to the resting status

118

.To characterize the lymphocyte population in

PBMCs after activation and to confirm the high expression of TfR on T cells, on
day 6 post-activation, activated PBMCs were immunologically counter-stained
with antibodies against CD3 and CD71 (TfR). Of the total cell population,
approximately 90% of the cells were CD3 positive, and within this population,
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more than 60% cells were TfR and CD3 dual positive cells confirming activation
stimulates T cells to overexpress TfR (Figure 7 B). Overexpression of TfR was
also observed in Jurkat cells (Figure 7 C). These results suggest the possibility to
target primary ATCs or Jurkat cells, as a surrogate T cell line, via TfR targeting
strategy.

Figure 7 TfR expression in ATCs and Jurkat cells. (A) Human peripheral blood
mononuclear cells (PBMCs) were activated by anti-CD3 antibody (OKT3) and
stained with anti-CD71 antibody to determine the expression of CD71, namely
transferrin receptor (TfR), on different post activation days. The median
fluorescence intensity (MFI) of CD71 of cells were quantified by flow cytometry.
(Data points indicate mean ﹢/﹣ SD, n=1-3; Compared with D0, *, p< 0.05, **, p
< 0.01, ***, p<0.005). (B) ATCs were counterstained by CD71-PE and CD3-PECy7 antibodies on day 6 post-activation. (C) Jurkat cells were stained with antiCD71 antibody (TfR) or isotype antibody. The MFIs of antibody-stained of cells
were quantified by flow cytometry. (Data points indicate mean ﹢/﹣ SD, n=2;
One-way ANOVA, ***, p<0.005).
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3.3.6 In vitro cellular uptake of polyplexes
To determine the targeting efficiency of Tf-PEI, primary ATCs were
transfected for 24 h and the cellular uptake was quantified by flow cytometry. TfPEI polyplexes were formulated with Alexa Fluor 488 labeled siRNA (AF488siRNA) at different N/P ratios (5, 7.5, 10, 15, 20). Unmodified PEI polyplexes and
lipofectamine 2000 (LF) served as positive controls, and treatment with free
siRNA and an untreated group were also included as negative controls. Initially,
cellular uptake was determined at low N/P ratios (N/P= 5 & 7.5, Figure 8 A) at
which 100% siRNA condensation was achieved by unmodified PEI but 80% and
100% condensation was achieved by Tf-PEI conjugates. Tf-PEI polyplexes can
target ATCs, and significantly higher cellular uptake was observed compared with
unmodified PEI at both N/P ratios, although only 80% siRNA were encapsulated
inside Tf-PEI polyplexes at N/P 5 (Figure 5). These results were in line with our
previously published results

91

. Moreover, ATC-selective delivery of Tf-PEI

polyplexes was confirmed at higher N/P ratios (N/P 10, 15, 20) (Figure 8 B).
Increased cellular uptake of both PEI and Tf-PEI was observed with increasing
N/P ratios from 10 to 20. Tf-PEI polyplexes achieved 3.2 fold, 4.5 fold and 4.1
fold higher cellular uptake compared to PEI polyplexes at N/P 10, 15, 20,
respectively. Most importantly, Tf-PEI achieved 1.8 fold more efficient cellular
uptake at N/P 20 than LF mediated siRNA delivery. PEI polyplexes can non-
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specifically associate on the cell surface due to electrical interaction between their
positive surface charge and negative charge of cellular membranes and induce
adsorptive endocytosis. This mechanism contributes to non-targeted cellular
uptake. However, PEI polyplexes are not efficiently taken up by primary ATCs.
These results agree with a previous report from our group which focused on the
observation that Tf-PEI can selectively deliver siRNA to ATCs overexpressing
TfR but not resting T cells which are TfR negative 91. To estimate the percentage
of extracellular fluorescence resulting from polyplexes that are bound but not
internalized, 0.4% trypan blue quenching treatment was performed on ATCs
treated by Tf-PEI (N/P 20), PEI (N/P 20), LF and free siRNA. As shown in Figure
8 C, the MFI slightly decreased in all trypan blue treated groups except the LF
group. This result suggests that only a limited amount of extracellular fluorescence
is associated with the surface of the cells but most of the fluorescent polyplexes
were taken up intracellularly. The slightly increased MFI of the LF treated group
(Figure 8 C) could be explained by the fact that apoptotic cells with a damaged
cell membrane are stained completely by trypan blue and therefore no longer are
detected by flow cytometry. As it is known that LF has a strong cytotoxic effect,
especially on primary cells, it is possible that the MFI was skewed to only viable
cells which seem to have a slightly higher MFI. To validate our results in a cell
culture model, transfection experiments were also performed in Jurkat cells, which
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are often used as a T cell model cell line. Jurkat cells are an immortalized
lymphoma cell line, however, and not as hard-to-transfect as primary T cells. In
agreement with the results obtained in ATCs, cellular uptake of Tf-PEI polyplexes
in TfR-overexpressing Jurkat cells (Figure 7 C) was also significantly higher than
that of PEI polyplexes (Figure 8 D). It needs to be noted, however, that the
transfection efficiency of LF in Jurkat cells is higher than that of Tf-PEI
polyplexes. The cellular endocytosis profile and molecular membrane composition
of this immortalized cell line is expected to differ significantly from primary
ATCs. Additionally, their viability under transfection is expected to be higher than
that of ATCs which do not withstand the cytotoxic effects of commercially
available transfection reagents. These characteristics may contribute to efficient
transfection of Jurkat cell with LF, while primary ATCs are especially difficult to
transfect cells 98a and benefit from active targeting.
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Figure 8 Cellular uptake of Tf-PEI and PEI in ATCs and Jurkat cells. MFI was
determined by flow cytometry to evaluate the cellular uptake in primary human
activated T cells (ATCs) of Tf-PEI, PEI and lipofectamine 2000 (LF)
polyplexes/lipoplexes prepared with 50 pmol Alexa Fluor 488 labeled siRNA
(AF488 siRNA) at low N/P ratios (5 and 7.5). (B) Cellular uptake of Tf-PEI, PEI
and LF in ATC at high N/P ratio (10, 15 and 20). (C) Cellular uptake in ATCs of
Tf-PEI, PEI and LF polyplexes at N/P 20 with or without trypan blue (TB)
quench. (D) Cellular uptake in Jurkat cells of Tf-PEI, PEI and LF at different N/P
ratios (5, 10 and 20). (Data points indicate mean ﹢/﹣ SD, n >2; One-way
ANOVA, **, p < 0.01, ***, p<0.005).
For the competition assay, Jurkat cells were transfected with Tf-PEI and
PEI polyplexes in the presence of different concentrations of free Tf. As shown in
Figure 9, the cellular uptake of Tf-PEI polyplexes in Jurkat cells can be inhibited
by the presence of free Tf and this inhibition depended on the concentration of free
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Tf. The higher concentration of free Tf (2 mg/ml) can achieve significantly
stronger inhibition compared to the lower concentration (0.1 mg/ml). However,
free Tf has no effect on the uptake of PEI polyplexes. This result suggests that the
selective delivery of Tf-PEI polyplexes to Jurkat cells was mediated by the
targeting ligand. In primary cells, this effect is even stronger, as published in 2013,
where almost no uptake is mediated by PEI or Tf-PEI in cells that do not express
the receptor 60.
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Figure 9 Free Tf competition assay. The cellular uptake in Jurkat cells of Tf-PEI
or PEI polyplexes at N/P ratio 15 in presence of free Tf (0.1 and 2 mg/ml) was
determined by flow cytometry (Data points indicate mean ﹢/﹣ SD, n= 2; Oneway ANOVA, **, p < 0.01).
3.3.7 Confocal Laser Scanning Microscopy (CLSM)
To determine the cellular distribution of polyplexes, Jurkat cells were
transfected with Tf-PEI, PEI and LF carrying siRNA-AF488 at N/P ratio of 15 for

92

24 h and a control, only treated with the according amount of free siRNA, was
included. The cellular distribution of siRNA was observed by CLSM (Figure 10).
As shown in Figure 10 A, negligible amounts of green dots (siRNA-AF488) can
be observed suggesting that free siRNA cannot be efficiently delivered into the
cells without carrier. The receptor-mediated cellular uptake of Tf-PEI/siRNA
resulted in an even distribution of siRNA within the cytoplasm of the cells (Figure
10 D), while delivery with PEI or LF resulted in punctuated distribution (Figure 10
B and C). The point-shaped distribution of siRNA in the transfected cells could be
a sign of endosomal entrapment of the LMW-PEI complexes.

Figure 10 CLSM images of Jurkat cells. CLSM images of Jurkat cells transfected
by Tf-PEI, PEI, LF and free siRNA-AF488 at N/P 15. The nuclei were stained
with 5 µM of DRAQ5. (green: siRNA-AF488; blue: nucleus).
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3.3.8 In vitro transfection efficacy
Next, we investigated whether the significantly higher internalization of TfPEI polyplexes could induce a corresponding fdownregulation of a targeted gene.
Therefore, ATCs or Jurkat cells were transfected by Tf-PEI and PEI polyplexes
prepared with siRNA against GAPDH or scrambled siRNA at N/P 15, and LF was
included as additional positive control. GAPDH gene expression was normalized
by β-actin gene expression and quantified via real time PCR (RT-PCR). As shown
in Figure 11 A, GAPDH expression in ATCs treated with Tf-PEI/ siGAPDH
polyplexes was 2 fold less than after transfection with PEI/siGAPDH. Moreover,
significant downregulation of GAPDH expression was observed in TfPEI/siGAPDH group compared with Tf-PEI/scrambled siRNA group and
untreated control. In contrast, there was no significant difference of GAPDH
expression among PEI/siGAPDH, PEI/scramble siRNA treated cells and the
untreated group. Unmodified PEI polyplexes can undergo endocytosis mediated
by electrostatic interaction between their positive surface charge and the negative
charge of the cellular membrane as demonstrated in cellular uptake study.
However, this limited internalization was not sufficient to induce significant
sequence-specific gene silencing compared with receptor mediated endocytosis.
LF was too toxic for primary ATCs, and it was impossible to isolate sufficiently
intact RNA after transfection. Therefore, no viable results were obtained in ATCs
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and experiments were repeated in Jurkat cells. A similar outcome of GAPDH
knock down was observed in Jurkat cells (Figure 11 B). CLSM images of Jurkat
cells transfected with Tf-PEI and PEI polyplexes and LF lipoplexes (Figure 10)
revealed the possibility that Tf-PEI could mediate more efficient endosomal
escape and release siRNA into cytoplasm. This observation, taken together with
the less efficient uptake of non-targeted polyplexes (Figure 8) could be one reason
for the lack of gene knockdown. According to the efficient uptake results, LF
mediated the most efficient gene knock down in Jurkat cells, which, however, is
not representative for the transfection of primary ATCs.
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Figure 11 GAPDH Knockdown in ATCs and Jurkat cells. (A) GAPDH gene
knockdown efficiency of Tf-PEI and PEI polyplexes at N/P 15 was validated in
ATCs. (B) GAPDH gene knockdown efficiency of Tf-PEI, PEI or lipofectamine
2000 (LF) was measured in Jurkat cells. Tf-PEI or PEI were formulated with
siRNA against GAPDH (siGAPDH) or scrambled siRNA (siNC). GAPDH
expression was normalized with beta-actin expression and quantified by real time
PCR. (Data points indicate mean ﹢/﹣ SD, n =3; One-way ANOVA, **, p < 0.01,
***, p<0.005).
3.3.9 Cytotoxicity assay
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Biocompatibility of polyplexes is one of the most important considerations
before the in vivo application. The potential toxicity of PEI may induce membrane
damage and cells apoptosis. Therefore, an assay to determine the cellular
membrane integrity would be idea to determine the potential toxicity of Tf-PEI
polyplexes. Tf-PEI polyplexes are proposed to be administrated pulmonarily,
therefore, A549 cells, a lung epithelial cell line, was used in this study. A549 cells
were treated with Tf-PEI, 5k PEI and 25k PEI polyplexes containing scrambled
siRNA (N/P ratio: 1, 3, 5, 7.5, 10, 15, 20, 25, 30 ,40). And the LDH release from
cells with damaged membranes was determined. As shown in Figure 12, high
molecular weight PEI (25k Da), which served as a positive control can cause
cytotoxicity, started to cause LDH release from N/P 7.5. As the N/P ratio of 25k
PEI increased, increasing LDH release was observed until N/P 30. At N/P 40 of
25k PEI, less LDH release compared to N/P 30 was measured which may be due
to cell killing by high doses of 25k PEI polyplexes at early time points resulting in
less cells available for the measurement of LDH release at the end point. On the
other hand, Tf-PEI and low molecular weight PEI (5k) polyplexes treatment didn’t
induce any increase of LDH release at all tested N/P ratios compared to the
untreated control. This result indicated the high biocompatibility of both 5k PEI
and Tf-PEI polyplexes. The toxicity of PEI strongly depends on the molecular
weight. Low molecular weight PEI (< 10k Da), which is used in this study,
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demonstrates a better safety profile compared to higher molecular weight PEI (i.e.
25k Da). The positive charge of PEI also contributes to toxicity. As shown in
Figure 5 B, Tf-PEI polyplexes have slightly negative surface charge which may
also contribute to the low cytotoxicity of Tf-PEI polyplexes.
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Figure 12 LDH release from A549 treated with polyplexes. LDH release from TfPEI, 5k PEI and 25k PEI polyplexes treated A549 cells was determined by
CytoTox- ONE. The “no cells” control represents 0% LDH release, and cells
treated with lysis buffer represent 100% LDH. (n = 3)
3.3.10 In vivo delivery of polyplexes
To further validate the possibility of pulmonary delivery of siRNA to ATCs
via Tf-PEI, a murine model of allergen-induced asthma-like inflammatory reaction
was established as shown in Figure 13 A. Animals were i.t administrated on 4
consecutive days with Tf-PEI or PEI polyplexes prepared with Alexa Fluor 647
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labeled siRNA (siRNA-AF647), and administration of free siRNA-AF647 was
included as negative control on day 35-38 (Figure 15 A). On day 39, lung function
of

animals

was

determined

by

PenH

assay.

Overall,

the

airway

hyperresponsiveness (AHR) of asthmatic groups of animals was slightly higher
than in corresponding saline-exposed, healthy groups of animals (Figure 15 B).
Additionally, according to the AUC of airway responsiveness against
methacholine concentration curve, mice within the asthmatic group treated with
PEI/siRNA polyplexes showed the highest AHR which was significantly higher
than within the corresponding healthy control. On the other hand, there is no
significant difference between asthmatic mice treated with Tf-PEI/siRNA
polyplexes and their corresponding healthy control group (Figure 13 C). This data
may suggest that the treatment with positively charged PEI/siRNA polyplexes
could have intensified the pre-existing lung inflammation in the asthmatic animals
but not the treatment with Tf-PEI/siRNA polyplexes, which are shielded by the
negatively charged glycoprotein.
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Figure 13 Murine asthma model. (A) Establishment of a murine asthma model.
Balb/c mice were sensitized by i.p injection of Al(OH)3 and ovalbumin (OVA)
twice and challenged twice by inhalation of 1% OVA aerosol for 1 h daily for 3
consecutive days to induce airway inflammation. Animals treated by inhalation of
saline served as healthy control. Polyplexes with 750 pmol Alexa Fluor 647
labeled siRNA (siRNA-AF647) were prepared with Tf-PEI or PEI at N/P 7.5 and
applied intratracheally (i.t.), and free AF647 siRNA served as negative control.
Lung function was determined on day 39. Bronchoalveolar lavage fluid (BALF),
BALF cells and lung cells suspension were analyzed on day 40. (B) Airway
hyperresponsiveness of methacholine-challenged mice after 4 consecutive days of
treatment with free siRNA, PEI or Tf-PEI polyplexes. (C) Airway responses of
animals were represented by AUC of airway responsiveness against methacholine
concentration curve. (Data indicated as mean +/- SEM, n> 3)

Figure 14 Differentiation of BALF. Strategy to differentiate cellular populations in
BALF cells by flow cytometry.
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On day 40, BALF, BAL cells and lung cells were collected and processed
for determining concentration of IL-5 and IL-13, or for immunostaining,
respectively.

BAL

cell

populations

were

differentiated

following

the

immunostaining strategy shown in Figure 14 and Table 2. As shown in Figure 15
A, Tf-PEI polyplexes uptake in T cells was significantly higher than that in B cells
and eosinophils. More importantly, cellular uptake of Tf-PEI polyplexes in T cells
was 1.3 and 1.5 fold higher than that in macrophages and type II pneumocytes,
one type of alveolar cells, respectively. It has to be taken into account that lung
resident macrophages serve as first line of cellular defense in the deep lung

138

by

actively phagocytosing foreign particles, which may result in a significant amount
of polyplexes being cleared. Additionally, the large interaction surface of type II
pneumocytes with aerosolized particles also increases their possibility to associate
with polyplexes. Considering that activated macrophages have elevated levels of
TfR

139

also and epithelial cells express TfR as well

140

, Tf-PEI polyplexes

demonstrated very efficient T cell-targeted delivery. In lung suspension cells,
uptake of Tf-PEI polyplexes in T cells was 1.7 fold higher than PEI polyplexes in
asthmatic animals (OVA group). Furthermore, cellular uptake of Tf-PEI
polyplexes in T cells from asthmatic animals was significantly higher than in
healthy animals (saline), which demonstrated minimal cellular uptake similar to
free siRNA treatment group (Figure 15 B). Tf-PEI and 5k PEI polyplexes didn’t
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show toxicity toward A549 cells at N/P ratios ranging from 1 to 40 as assessed by
LDH release assay (Figure 12). However, as suggested above, intratracheal
administration, especially of positively charged polyplexes could induce additional
inflammation. To evaluate the potential pro-inflammatory effects of polyplexes,
IL-5 and IL-13 were determined by a mouse cytokine 20-plex panel. As shown in
Figure 15 C, overall, IL-5 levels were higher in all asthmatic groups, which can be
explained by the allergic inflammation induced by the OVA-sensitization and
challenge. However, asthmatic animals treated with PEI polyplexes demonstrated
significantly higher secretion of IL-5. On the other hand, no significant difference
of secretion of IL-5 in Tf-PEI polyplexes and free siRNA treated OVA-sensitized
animals was observed compared with healthy animals. Additionally, the levels of
cytokines in OVA-sensitized animals treated with targeted polyplexes was not
significantly different from untreated OVA-sensitized animals (data not shown).
The same secretion profile was observed in IL-13 (Figure 15 D). These results
agree with the airway hyperresponsiveness results (Figure 3.11 B and C) and
suggest that the Tf-shielding of Tf-PEI polyplexes efficiently reduces the proinflammatory effect of PEI polyplexes in asthmatic animals. It is worth noting that
the repeated treatment with low molecular weight PEI was tolerated very well in
healthy animals (Figure 15 C and D). These results are in line with previous
reports 51, 120.
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Figure 15 Biodistribution and biocompatibility of Tf-PEI and PEI. (A) Cellular
uptake of Tf-PEI polyplexes in different BALF cell populations from OVA
sensitized-animals and (B) Cellular uptake of Tf-PEI polyplexes, PEI polyplexes
and free AF647 siRNA in the T cell population of the lung cell suspensions from
asthmatic and healthy mice was quantified by flow cytometry. (C) IL-5 levels in
BALF and (D) IL-13 levels in BALF were determined by the mouse cytokine 20plex panel. (n>3, *, p< 0.05, **, p < 0.01, ***, p<0.005)
3.4 Conclusion
This study is the first attempt to deliver siRNA selectively to activated T
cells for asthma therapy. Tf-PEI polyplexes exhibited desired physicochemical
properties and achieved selective delivery of siRNA to ATCs followed by
successful induction of gene knockdown. Such selectivity was also confirmed in a
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murine asthma model. Our present work demonstrates the possibility to
specifically deliver siRNA to ATCs via targeting TfR. Although repeated
administration of a Tf conjugate of low molecular weight PEI was well tolerated
in healthy animals and no toxicity was observed in our study, clinical application
of PEI or its conjugates is still limited by concern of any possible toxicity.
Therefore, after having established an efficient targeting strategy for primary T
cells in the present paper, our next studies will be devoted to developing a more
biocompatible polymer to replace PEI. Subsequently, therapeutic effects of
downregulating clinically relevant genes such as the Th2 transcription factor
GATA-3 will be determined.
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CHAPTER 4 POST-TRANSCRIPTIONAL REGULATION
OF THE GASC1 ONCOGENE WITH ACTIVE TUMORTARGETED SIRNA-NANOPARTICLES
Please note that part of the content of this chapter is from a research article,
“Post-transcriptional regulation of the GASC1 oncogene with active tumortargeted siRNA-nanoparticles”, was published in Molecular Pharmaceutics (S.
Movassaghian, Y. Xie, et al., 2016). The authors of this article include Sara
Movassaghian, Claudia Hildebrandt, Rayna Rosati, Ying Li, Na Hyung Kim,
Denise Conti, Sandro RP da Rocha, Zeng-Quan Yang, Olivia M Merkel and me.
Sara Movassaghian and me are joint first authors of this research paper.
4.1 Introduction
Basal-like breast cancer (BLBC) accounts for the most aggressive types of
breast cancer and currently cannot be treated specifically. Therefore, investigation
of new targets and treatment strategies is more than necessary. One possible new
group of targets are ‘epigenetic enzymes’ (e.g. a histone modifying and DNA
methylating enzymes) as the causative links between genetics and epigenetics in
cancer development are well documented

141

. There is also an increasing

appreciation that epigenetic aberrations that are often directly caused by genetic
defects resulting in loss- or gain-of-function of epigenetic-regulators contribute
significantly to cancer onset, severity and progression

142

. Specifically, a genetic

alteration in the gene encoding an ‘epigenetic enzyme’ can lead to changes within
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the histone code 143, which is involved in both tumorigenesis and cancer stem cellgenerated hierarchies in multiple tumor types 143.
The possibility of reversing epigenetic codes may provide new targets for
therapeutic intervention. In the present work, we focused on therapeutically down
regulating a recently discovered gene which was first identified and cloned as a
novel cancer gene by Yang et al.

144

. The gene amplified in squamous cell

carcinoma 1 (GASC1- also referred to as JMJD2C/KDM4C) encodes a nuclear
protein that catalyzes lysine demethylation of histones
several cancers, including breast cancer
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144

and is involved in

. Thus, down regulation of GASC1

expression represents an excellent therapeutic approach but is currently not
possible in a cell specific manner. Moreover, recent findings clearly established
that the GASC1 gene is amplified in approximately 15% of breast cancers

146

, and

its overexpression is more prevalent in basal-like breast cancers (BLBC)
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.

Besides, GASC1 overexpression is correlated with a poor prognosis and induces
transformed phenotypes

146b

. Previous studies have demonstrated that therapeutic

interference with GASC1 using an shRNA-based approach inhibits proliferation of
breast cancer cells in vitro and in vivo

146b 108

. However, in these studies, viral

vectors were used to express shRNA for GASC1 knock down. Besides the
immunologic challenges and safety issues viral vectors bear, viruses do not
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transduce cells in a specific manner. However, targeting can be achieved with
chemically engineered artificial viruses 147.
Human breast carcinomas represent a heterogeneous group of tumors that
are diverse in their behavior, outcome, and response to therapy. Breast cancer is
generally classified in four main groups based on their expression of estrogen
receptor (ER), progesterone receptor (PR), and Her2/neu receptor (HER2): two of
the main groups are ER+ and include luminal A (ER+, PR+, and HER2-) and
luminal B (ER+, PR+ and HER2+) subtypes, and two groups are ER-, HER2
overexpressing (ER2-, PR-, HER+) and basal-like (ER-/low, PR-/low, HER2-/low) 148.
Among the different types of breast cancer, basal-like breast cancers
(BLBC) are particularly aggressive and are associated with high histological grade,
prevalence of younger patient age, poor prognoses, and often relapse rapidly

148

.

The treatment for BLBC consists of standard chemotherapy regimens as no
effective molecularly-targeted therapies have been developed 149.
Failure in the current conventional therapies for BLBC patients urges the
development of novel strategies to achieve favorable outcomes.
Therefore, siRNA against GASC1, the newly identified oncogenic histone
modifying enzyme holds promise as a potential therapy of BLBC. Nanoparticles
offer an unprecedented opportunity in rational drug and gene delivery by
enhancing therapeutic efficacy and reducing side effects through overcoming
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major obstacles in cancer therapy such as nonspecific biodistribution with
consequent dose-limiting toxicity and multidrug resistance (MDR)

150

. Up-

regulation of TfR expression in a wide variety of cancers, its function and highly
efficient recycling pathway, provides a gate for intracellular gene and drug
delivery to BLBC in a tumor-specific manner

151

. Thus, Tf-PEI could potentially

deliver siRNA in a targeted way to BLBC overexpressing TfR.
In this chapter, we evaluated two Tf-SPDP-PEI and Tf-SPDP-PEG-PEI
conjugates, which were conjugated using two different linkers, SPDP and PEG 4SPDP, in different breast cancer cell lines or immortalized breast cell line. We
identified a new siRNA sequence that efficiently reduces GASC1 expression if
delivered intracellularly. Efficiency of GASC1 silencing was determined in BLBC
cells overexpressing GASC1, and the inhibition of proliferation was investigated.
To the best of our knowledge, this is the first report of developing a BLBCtargeted delivery system with a newly identified siRNA for therapeutic GASC1
gene knock down. Therefore, our approach is promising for therapeutic targeting
of hard-to-treat BLBC and could result in new receptor mediated therapy options
for BLBC.
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4.2 Materials & Methods:
4.2.1 Materials
Polyethylenimine (PEI, MW 5 kDa) was obtained from BASF (Lupasol
G100, Ludwigshafen, Germany). N-succinimidyl-3-(2-pyridyldithio) propionate
(SPDP), a PEGylated SPDP (PEG4-SPDP), Lipofectamine® 2000, trypsin,
penicillin/streptomycin,

4(2(hydroxyethyl))-1-piperazine

ethanesulfonic

acid

(HEPES), heparin sodium (140,000 U/g), were purchased from Thermo Fisher
Scientiﬁc (Waltham, MA, USA). Anti-human CD71 (transferrin receptor) PE was
acquired from (eBioscience, CA, USA). Dithiothreitol (DTT) was purchased from
Alfa Aesar, MA, USA. SYBR Gold dye and CellTiter-Blue® were obtained from
Life Technologies (Carlsbad, CA, USA). RPMI-1640 medium (1X) with 2.05 mM
L-glutamine, Ham's F-12 Medium, trypan blue (0.4%, sterile ﬁltered) was
purchased from HyClone (GE Health Care, Pittsburgh, PA, USA). Human holo
Transferrin (80 kDa) was obtained from Calbiochem (Billerica, MA, USA).
Dulbecco’s phosphate buﬀered saline (PBS), fetal bovine serum (FBS), D (+)glucose, 2-mercaptoethanol, dimethyl sulfoxide (DMSO, ≥99.7%), sodium
bicarbonate (NaHCO3) were purchased from Sigma-Aldrich (St. Louis, MO, USA).
DNase I reaction buﬀer and DNase/RNase-free water were purchased from Zymo
Research (Irvine, CA, USA). Hs_GASC1 primer (forward and reverse) and
sequences V4, V6, and V7 (self-designed siRNA against GASC1 using the
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GENtle software by Magnus Manske) were ordered from Invitrogen (Life
Technologies, Carlsbad, CA, USA). Commercially available GASC1 specific
siRNA was purchased from Qiagen (Valencia, CA, USA) for sequences A, B, C
and D. SMART pool and sequences E, F, G and H (Table 3) were purchased from
Dharmacon (Thermo Fisher, Waltham, MA, USA).
Table 3 Sequence of siRNA
Sequence
name
MISSION®
siRNA
Negative
Universal
Control
Negative
Control #1

hGAPDH

IDT

hGASC1

V4

hGASC1

V6

hGASC1

V7

hGASC1- A

Hs_KDM4C1

hGASC1- B

Hs_JMJD2C3

hGASC1- C

Hs_JMJD2C4

hGASC1-D

Hs_JMJD2C5

hGASC1- E

J-004293-12

Sequences

5’GGUCGGAGUCAACGGAUUUGGUC[dG][dT
]
3’UmUmCCmAGmCCmUCmAGmUUmGCmCU
mAAACCAGCA
5’-ACCGAAGACAUGGACCUCU[dT][dT]
3’-[dT][dT]UGGCUUCUGUACCUGGAGA
5’-CAGAAUUUAUCAGAUCAUA
3’-[dT][dT]GUCUUAAAUAGUCUAGUAU
5’-GUGAAGAUUUCAAUGGAUA[dT][dT]
3’-[dT][dT]CACUUCUAAAGUUACCUAU
5’-CGAAGCUUCCAGUGUGCUA[dT][dT]
3’-[dG][dG]GCUUCGAAGGUCACACGAU
5’-GAUAUUAAUGGGAGCAUAU[dT][dT]
3’-[dG][dT]CUAUAAUUACCCUCGUAUA
5’-CCAGAAGUUCGAUUCACUA[dT][dT]
3’-[dA][dG]GGUCUUCAAGCUAAGUGAU
5’-CAUCGGAGGGAAAGACUAA[dT][dT]
3'-[dA][dT]GUAGCCUCCCUUUCUGAUU
5’-GAGAAGUCGUCCAAGUCAAUU
3’-UUCUCUUCAGCAGGUUCAGUU
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hGASC1- F

J-004293-11

hGASC1- G

J-004293-10

hGASC1-H

J-004293-9

5’-GCAUAUAUGAUGAGGGUGUUU
3’-UUCGUAUAUACUACUCCCACA
5’-ACGAAGAUUUGGAGCGCAAUU
3’-UUUGCUUCUAAACCUCGCGUU
5’-AUUACAUGCUUUCGACAUAUU
3’-UUUAAUGUACGAAAGCUGUAU

* Deoxyribonucleotides are presented in parentheses with the letter d, and 2’Omethylated ribonucleotides are denoted with the letter m. The letter p indicates an
additional phosphate.
4.2.2 Cell lines characteristic and culture conditions
The non-tumorigenic human mammary epithelial cell line MCF10A and
human breast cancer cell line HCC1954 were purchased from the American Type
Culture Collection (Manassas, VA, USA). The COLO824 cell line was obtained
from DSMZ (Germany), and the cell lines SUM102, SUM225, SUM52, SUM149
were a kind gift from Dr. Stephen P Ethier (Department of Pathology and
Laboratory Medicine, Medical University of South Carolina). The COLO824 and
HCC1954 cell lines were retained and grown in RPMI-1640 cell culture medium
supplemented with 10% fetal bovine serum. MCF10A and SUMs cell lines were
cultured in a special DMEM/F12 media, containing 1% EGF (10 ng/ml), 0.1%
hydrocortisone (1µg/ml), and 0.5% insulin (5 µg/ml). The cell lines characteristics
are shown in Table 4.
4.2.3 Transferrin receptor expression study
Selected breast cancer cell lines were used to evaluate transferrin receptor
expression levels (CD71, TfR) by flow cytometry. Of each cell suspension,
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200,000 cells were transferred into an Eppendorf tube and spun down (350g for 5
min). The cell pellet was washed with PBS containing 2 mM EDTA. Afterwards,
PE-labeled CD71 antibody and its corresponding isotype control were each added
to assigned cell samples and incubated for 30 min at 4°C before analysis by flow
cytometry (Attune acoustic focusing cytometer Life Technologies, Carlsbad, CA).
Blank cells were not stained with any antibody. The excitation wavelength of 488
nm and an emission filter at 585 nm/42 nm were used. Cell gating and data
analysis in the Attune cytometric software were performed using cell morphology
and mean fluorescence intensity (MFI), respectively. The mean values and
standard deviation (SD) of experiments with n=3 are shown.
Table 4 Different breast cell line model and their specifications
Cell line
HCC1954
COLO824
MCF10A
SUM102
SUM225
SUM149
SUM52

Cell Source
Grade III invasive ductal
carcinoma
Mammary gland
carcinoma
Mammary glandimmortalized
Intraductal
carcinoma/microinvasion
Chest wall recurrence of
ductal carcinoma
Invasive ductal
carcinoma
(inflammatory)
Pleural effusion

Subtype

PR

ER

Her2/neu

GASC1

Basal

-

-

+

+++

Basal

-

-

-

+++

-

-

-

-

Basal

-

-

-

-

HER2+

-

-

+

-

Basal

-

-

-

+

Luminal

-

+

-

-

111

4.2.4 Specific binding of transferrin to the corresponding receptor
To analyze the specificity of transferrin binding to TfR, Tf was
fluorescently labeled with FITC (Invitrogen™, life Technologies). Bovine serum
albumin (BSA) was used as a control. Transferrin and BSA were dissolved in 0.1
M of NaHCO3. A ten-fold molar excess of FITC (dissolved in DMSO) was
incubated with transferrin and BSA overnight at 4°C. The protein-FITC
conjugates were subsequently separated from unbound FITC by gel permeation
method (Sephadex G25 M, GE Healthcare PD-10 columns) using 20 mM HEPES150 mM NaCl buffer. The BCA protein assay (Thermo Scientific) was used to
measure the final concentration of transferrin and albumin after purification. The
presence of FITC was found to not impact the measurements at the applied
concentrations. After purification and characterization of the labeled (glyco-)
proteins, HCC1954 and MCF10A cell lines (60,000 cells in 24 well plates) were
incubated with different amounts of FITC-transferrin or FITC-BSA (20, 200 and
400 pmol) for 4 h at 37°C and 5% CO2. Flow cytometry was used as described
above to measure the binding of Tf-FITC or albumin-FITC to the cells with the
emission filter set to 530/30 nm bandpass.
4.2.5 Conjugation synthesis and characterization
Two different heterobifunctional crosslinking agents, namely (Nsuccinimidyl-3-(2- pyridyldithio) propionate (SPDP) and a PEGylated SPDP
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(PEG4-SPDP) containing four ethylene glycol units were used to conjugate
transferrin to a 5 kDa LMW PEI as described before 20. PEI (1 mg/ml) was reacted
with SPDP or PEG4-SPDP (20 mM) in DMSO stirring at room temperature
overnight (1:10 molar ratio relative to amines present). The intermediate products
were purified by ultrafiltration using Amicon® Ultra 4 ml filters (MWCO 3000)
and Vivaspin centrifugal ultra-filters (10,000 MWCO) as described

61

. The

conjugates were separated from uncoupled Tf-SPDP by ion exchange FPLC via
ÄKTA prime plus (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA) as reported
152

. The products (Tf-PEI and Tf-PEG-PEI) were preserved at 4ºC until use. The

degree of SPDP coupling onto PEI was determined as previously reported by
spectrophotometric detection of release of the pyridine-2-thione group

47

. The

characterization of the final products was performed by spectrophotometric
detection of transferrin at 280 nm compared to standard curve
quantification of PEI amines in using a modified TNBS method

153

152

and

in presence of

the respective amount of transferrin as described by Germershaus et al. 152.
4.2.6 Preparation of siRNA-polymer nanoparticles
For preparing nanoparticles based on electrostatic interaction resulting in
the formation of polyelectrolyte complexes, or polyplexes, the PEI/siRNA charge
ratios (defined as N/P ratios) were calculated based on PEI nitrogen (N) groups
per siRNA phosphate (P) groups.

75b

. Polymer (1 mg/ml) and siRNA (100 μM)
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stock solutions were diluted with a 5% glucose solution (pH 7.4, prepared with
RNase free water). Equal volumes of PEI or modified PEI and siRNA solutions
were mixed to result in the respective N/P ratio, vortexed for 30 s, and incubated
for 20 min at room temperature before use.
4.2.7 Analysis of hydrodynamic diameters and zeta (ζ)-potentials
The hydrodynamic diameters and zeta potential of polyplexes prepared with
40 pmol siRNA and polymer at N/P 7 were measured in PBS using a Zeta sizer
Nano ZS (Malvern Instruments Inc., Westborough, MA, USA) and the refractive
index and viscosity settings for water. Dynamic light scattering (DLS) was
detected at 25°C at an angel of 173°. Results from triplicate samples are shown as
Z average in nanometers ± SD. Samples were then diluted with 700 μL of PBS
buffer for ζ-potential measurements. Results of three independent measurements
are given in millivolts ± SD.
4.2.8 Atomic force microscopy
Polyplex morphology was determined using atomic force microscopy
(AFM). For image acquisition, a drop of polyplexes prepared at N/P 7 was
incubated for 5 min on freshly cleaved mica surface. Excess solution was rinsed
off with deionized water, and the mica was dried and imaged at room temperature
using a Pico LE atomic force microscope (Molecular Imaging, Agilent
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Technologies) with a Si3Ni4 V-shaped cantilever in contact mode as described
before 75b.
4.2.9 SYBR Gold condensation assays
The capacity of the Tf-PEI and Tf-PEG-PEI to condense siRNA at different
N/P ratios (0-20) was evaluated in SYBR Gold assays, and PEI (5 kDa) was used
as control. Formulations with 50 pmol of siRNA per well were placed in 96-well
plate, vortexed and incubated at room temperature for 20 min. Fluorescence
(Ex/Em: 495/537 nm) was measured after 10 min of incubation with a 4x SYBR
Gold solution using a Synergy 2 microplate reader (BioTek, Winooski, VT, USA).
4.2.10 Stability of siRNA/PEI complexes - heparin dissociation assays
Polyplex formulations with 50 pmol of siRNA per well prepared at N/P 7
were incubated with a fixed heparin concentration (0.2 IU) over varying periods of
time (5-180 min). Fluorescence was measured with a Synergy 2 microplate reader
(BioTek Instruments) after adding a 4x SYBR Gold solution (Ex/Em: 495/537
nm). The mean values of three fluorescence intensity measurements of SYBR
Gold dye only (0) and of three samples of SYBR Gold intercalating with free
siRNA (1) were used for normalization and calculation of the relative stability of
the polyplexes. Results of triplicate samples are shown as mean values ± SD.
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4.2.11 Quantiﬁcation of cellular siRNA uptake by flow cytometry
Cells were seeded with 80,000 cells per well in 24-well plates 24 h before
they were transfected with polyplexes prepared with 50 pmol of Alexa Fluor 488labeled siRNA per well at N/P 7. Negative controls included untreated cells and
cells treated with free Alexa Fluor 488-labeled siRNA. PEI (5 kDa) was used as a
positive control for comparison. After 4 h of transfection with 100 μL of
polyplexes, 1 ml of medium was added and cells were incubated at 37°C and 5%
CO2 for another 24 h. The cells were washed with PBS and trypsinized.
Intracellular fluorescence from siRNA was detected using an Attune® Acoustic
Focusing Flow Cytometer (Thermo Fisher Scientific, Carlsbad, CA) and
corresponding software. For the distinction between internalized and surfacebound siRNA, trypan blue (0.4%) was used to quench surface-bound fluorescence.
Data were analyzed after gating for 10,000 viable cells, and median fluorescence
intensity (MFI) values are given for three independent studies.
4.2.12 Confocal laser scanning microscopy
HCC 1954 cells were seeded in 8 well chamber slides at a density of 25,000
cells per well (Permanox® Slide, Nunc, Thermo Fisher Scientific) and allowed to
grow for 24 h at 37°C in 5% CO2. Polyethylenimine (PEI), Lipofectamine (LF) or
Tf-PEI polyplexes made with Tye563-labeled siRNA (Ex/Em: 543/563 nm) were
used to transfect cells as described earlier. Subsequently, the cells were washed
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with PBS and fixed using 3% paraformaldehyde (Affymetrix, Cleveland, OH,
USA) for 30 min, followed by nuclei staining with DAPI (Ex/Em: 405/470 nm).
Finally, the cells were embedded using Fluorsave reagent (Calbiochem, Merck,
Darmstadt, Germany) and covered with a coverslip. The images were recorded
with a Zeiss LSM 780 microscope (Zeiss, Oberkochen, Germany). Representative
pictures are shown in Figure 24 (100X magnification).
4.2.13 Cytotoxicity of polyplexes
Cells (HCC1954, COLO824, SUM102 and MCF10A) were seeded at a
density of 10,000 cells in a 96-well plate (Thermo Scientific) and incubated for 24
h at 37°C and 5% CO2. Polyplexes containing 50 pmol of siRNA were added to
the cells, and plates were incubated for 24 h at 37°C. Subsequently, CellTiterBlue® reagent was added directly to each well, the plates were incubated at 37°C
for 2 h to allow the cells to convert resazurin to resorufin.

The obtained

fluorescence was measured at Ex/Em 560/590 nm. The percentage of cell viability
and proliferation was calculated as the ratio between the fluorescence of a sample
and the untreated control cells as follows: ([A] test/ [A] control) ×100%. Results
are shown as the mean value ± SD of triplicate samples.
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4.2.14 Knockdown measured by qRT-PCR and western blot
HCC1954 cells were seeded with 500,000 cells per well in 6-well plates
(Corning Incorporated) and were incubated for 24 h before transfection. at 37°C
and 5% CO2. PEI, Tf-PEI, and Tf-PEG-PEI polyplexes were prepared with 100
pmol of GASC1 siRNA at N/P 7 in a total volume of 100 μL and were added to
900 µL of cell culture medium per well. The cells were incubated with the
polyplexes for 4 h before 2 ml of fresh medium were added to each well. The cells
were then incubated for an additional 24 for PCR or 72 h for Western Blot
analysis. Lipofectamine (LF) (0.5 μL/10 pmol of siRNA) was used as a positive
transfection control. Cells were transfected with samples in fresh medium and
subsequently cells were washed with PBS and lysed with lysis buffer (PureLink
RNA mini, Ambion, Fisher Scientific, USA). Total RNA was then isolated from
cells according to the manufacturer’s protocol with supplementary DNase I
digestion; mRNA was mixed with qScript™ cDNA SuperMix kit (Quanta
Biosciences, Gaithersburg, MD, USA), then converted into cDNA through a
reverse transcription reaction for real time PCR (eppendorf Mastercycler gradient,
Hauppauge, NY, USA). Primers set for GASC1 genes were ordered from
Invitrogen (Life Technologies). A PUM1 primer (Qiagen, Valencia, CA, USA)
was used for normalization. Semi-quantitative RT-PCR was performed using the
FastStart Universal SYBR Green Master (ROX) using a Bio-Rad iCycler Thermal
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Cycler (IQ 5™ multicolor read thermal PCR). Results are given as the average of
n =3 ± SD.
For measuring protein levels after transfection of the HCC1954 cell lines
with modified PEI formulations, western blot analysis was performed after protein
extraction of the transfected cells following a 7 day in vitro incubation based on
previous protocol optimization. The cells were lysed in RIPA buffer containing
protease inhibitor cocktail (Calbiochem, CA, USA). Samples were sizefractionated by 7.5% SDS-PAGE (XCell SureLock™ Mini-Cell) and the blot was
transferred to Immunobilon-PVDF membranes (Millipore, Bedford, MA, USA).
The blot was then incubated in blocking buffer (5% milk, 0.1% Tween in TBS
buffer) at room temperature for 1 h and subsequently incubated with rabbit antiJMJD2C antibody (Bethyl Laboratories, Inc. Montgomery, TX, USA) in
precooled blocking buffer overnight at 4 °C. After washing in TBS/0.1% Tween,
The blot was incubated with horseradish peroxidase (HRP)-labeled anti-rabbit
secondary antibody at room temperature for 1 h. After washing with TBS/0.1%
Tween, the blot was developed by enhanced chemiluminescence (Thermo
Scientific SuperSignal™ West Pico, MA, USA), and visualized with a hyblot CL
film (Denvilla, NJ, USA).
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4.2.15 Therapeutic effects of GASC-1 gene knockdown on cell proliferation
Therapeutic effects on cell proliferation were measured in MTT assays after
transfection with siRNA against GASC1 or a scrambled control. In 24-well plates
(Corning Incorporated), HCC1954 cells were seeded at a density of 8,000 cells per
well and incubated for 24 h at 37°C and 5% CO2. Polyplexes were prepared with
50 pmol of GASC1 siRNA or a scrambled negative control siRNA, and the cells
were transfected on days 1, 3, and 6 after seeding. MTT assays were performed as
described above on days 2 and 10 after seeding. The results are shown as mean
values ± SD of 3 independent measurements in comparison to proliferation of
untreated cells.
4.2.16 Statistical analysis
Results from all experiments represent at least three independent
measurements and are presented as mean value ± SD as analyzed by Graph Pad
Prism 6.0 software (GraphPad Software, La Jolla, CA, USA). Statistical tests were
either one or two way ANOVA with a Bonferroni post hoc analysis (significance
level 0.05). Significantly different results are indicated with an asterisk (*) in
figures. Corresponding significance values are: * P < 0.05, ** P < 0.01, *** P <
0.001 and **** P < 0.0001.
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4.3 Results
4.3.1 Screening for TfR expression levels
Transferrin receptor expression levels were determined via flow cytometry
in a series of breast cell lines which were characterized as GASC1 positive or
negative breast cell line to select a valid cell line model and its controls for the
targeted siRNA delivery

146b

. The receptor expression of TfR (CD71) was

compared to the MCF10A cell line, an immortalized, non-transformed epithelial
cell line, showing no GASC1 amplification 146b. The expression was verified using
a PE-labeled anti-CD71 antibody. Non-specific binding of the antibody was
precluded based on experimental results using an isotype IgG (negative control)
and non-treated cells (blank). PE-labeled CD71 antibody and its corresponding
isotype control were each added to assigned cell samples. Figure 16 depicts that
MCF-10A cells bear only basal levels of TfR whereas the expression level in
HCC1954 cells was almost 9-fold higher than in MCF10A. Therefore, HCC1954
cells were selected as cell model to verify GASC1 knock down via targeting the
internalizing transferrin receptor. Screening of TfR expression levels in other
breast cancer model cell lines showed that GASC1-amplified COLO824 cells
present higher TfR expression levels than SUM102, SUM52 (p < 0.001) and
MCF10A (p < 0.0001) but TfR levels were not significantly different between
COLO824, SUM149, and SUM225 cell lines (P > 0.05). Therefore, all three of
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those cell lines could be used as another valid cell culture model for therapeutic
GASC1 knockdown.

Figure 16 TfR expression in different breast cell lines. Screening of TfR
expression levels in different cancer cell lines compared to MCF 10A cells. Using
flow cytometry, TfR over-expression on the breast cancer cell line HCC1954 was
verified, which also shows a comparably high GASC1 amplification. The
transferrin receptor expression (CD71, TfR) was compared to the MCF-10A cell
line, an immortalized, non-transformed epithelial cell line, showing no GASC1
amplification. The expression was verified by using a PE-labeled anti-CD71
antibody and non-specific binding of the antibody was precluded based on results
with an isotype control. Data are expressed as the mean ± SD (n = 3), ns: nonsignificant, **** p < 0.0001.
4.3.2 Specific binding of Tf to transferrin receptor
To confirm the endocytosis activity of Tf receptors on cell lines determined
to overexpress the receptor, HCC1954 and MCF10A cell lines were incubated
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with FITC-labeled transferrin in comparison to FITC-labeled albumin. The same
amount of transferrin (20 pmol) as used in the Tf-PEI uptake experiment was
chosen, and results were compared to higher amounts of transferrin or albumin
(200 and 400 pmol). Quenching of non-internalized Tf or albumin was achieved
by trypan blue treatment. Figure 4. clearly shows that a 2.3-fold increase in Tf
internalization is detectable in the HCC1954 cell line compared to albumin after
incubation with 20 pmol FITC-labeled proteins. Meanwhile, FITC-transferrin
showed an almost 3-fold higher internalization in HCC1954 cells compared to
MCF10A for the same amount of transferrin. There was no significant difference
in the uptake of FITC-Tf in the MCF10A cell line compared to FITC-albumin (p >
0.05). A notable increase in MFI of the HCC1954 cell line was detected with
increasing the amount of FITC-transferrin from 20 to 200 and 400 pmol (p <
0.0001), however this was not the case for FITC-albumin (p > 0.05). The MFI in
MCF10A cell lines with basal levels of TfR, however, did not change with
increasing the amount of transferrin from 20 to 200 pmol or 200 to 400 pmol (p >
0.05).
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Figure 17 Cellular binding of Tf. Comparison of FITC-Transferrin or FITCAlbumin internalization in HCC1954 (lower left bar graph) and MCF10A (lower
right bar graph) cell lines at different concentrations of transferrin and albumin via
flow cytometry. Data are expressed as the mean ± SD (n = 3), ns: non-significant,
**** p < 0.0001.
4.3.3 Development of transferrin-PEI conjugate
Coupling procedures for the synthesis of Tf-PEI conjugates are illustrated
in Figure 18. SPDP and its PEGylated form (PEG4-SPDP) with a 25.7 Å ethylene
glycol spacer are amine- and sulfhydryl- reactive heterobiofunctional cross linkers
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that produce disulfide-containing linkages which are stable extracellularly but can
be cleaved intracellularly 154. This design was chosen to prevent premature release
of the targeting ligand but will mediate release of the nanoparticle from Tf and the
recycling TfR inside the cell.

Figure 18 Schematic illustration of transferrin crosslinking with PEI by SPDP.
4.3.4 Physicochemical properties of the nanoparticles
Based on DLS and zeta potential measurements, both Tf-PEI and Tf-PEGPEI more efficiently formed dense polyplexes with siRNA than non-modified 5
kDa PEI (Figure 19). Tf-PEI/siRNA and Tf-PEG-PEI/siRNA complexes at N/P 7
were compactly packed with 30 and 140 nm hydrodynamic diameters, respectively,
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and narrow size distributions (PDI: 0.1). However, PEI/siRNA exhibited larger
mean diameter of 700 nm with somehow broader distribution (PDI: 0.4). In
addition, the zeta potentials of Tf-PEI (-0.6 ± 0.07 mV) and Tf-PEG-PEI (-0.01±
0.04 mV) complexes with siRNA were lower than those of PEI (39.9 ± 7 mV)
complexes, implying that most of the positively charged portion of PEI in was
shielded by Tf in the Tf-modified polyplexes. These results reveal that modified
PEI produced significantly smaller and more compact structures with siRNA
compared to PEI at the same N/P ratio.

Figure 19 Size and zeta-potential of Tf-PEI, Tf-PEG-PEI and PEI polyplexes.
Hydrodynamic diameter (nm) and zeta potential (mV) of siRNA polyplexes made
with PEI, Tf-PEI, and Tf-PEG-PEI at N/P ratio of 7 at room temeprature. Data are
expressed as the mean ± SD (n = 3).
The same trend was observed via AFM imaging which showed the
tendency of PEI polyplexes to aggregate into particles of several hundred
nanometers in size, whereas the morphology of the Tf-PEI complexes was more
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homogenous, the size distribution was narrow, and the particles didn’t show any
aggregation tendency (Figure 20). In additional experiments, the capacity of PEI
and the modified PEI polymers to condense siRNA at different N/P ratios was
evaluated by SYBR Gold condensation assays. In these experiments, free
(unbound) siRNA is accessible to the intercalating dye SYBR Gold. The free
siRNA is thus subsequently quantified on the basis of fluorescence emitted after
SYBR Gold treatment. Results were compared to PEI (5 kDa) as a control (Figure
21). PEI and Tf-PEI showed better siRNA condensation at N/P ratios 1-5, but all
formulations showed similar condensation efficiency at N/P ratio of ≥ 7.

Figure 20 AFM images of Tf-PEI and PEI polyplexes. AFM topography of siRNA
polyplexes made with PEI (left) and Tf-PEI (right) at N/P ratio of 7 and imaged
after drying at room temeprature.
A heparin-induced decomplexation stability test was performed to
determine the stability of the polyplexes. The release profiles of siRNA from all
polyplexes reached a maximum siRNA release after 30 min of incubation and then
leveled off over the remaining incubation time (Figure 21). After 30 min of
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incubation with 0.2 IU heparin, PEI and Tf-PEG-PEI displayed around 50% and
85% of siRNA release, respectively, but Tf-PEI showed only 25% of siRNA
release at that time point (Figure 22). The siRNA release from Tf-PEI polyplexes
initially increased, then decreased gradually and remained unchanged (7%) until
the end of the experiments (180 min) (Figure 22).
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Figure 21 SYBR Gold assay of Tf-PEI, Tf-PEG-PEI and PEI. Condensation
efficiency of Tf-PEI and Tf-PEG-PEI complexes with siRNA measured by SYBR
Gold assay at different N/P ratios (1-20) compared to polyethylenimine (PEI 5
kDa). Results are given as the average of three measurements ± SD. (n = 3).
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Figure 22 Heparin assay of Tf-PEI, Tf-PEG-PEI and PEI. Release profile of
siRNA from transferrin modified polyplexes (N/P 7; 50 pmol siRNA/well)
compared to polyethylenimine (PEI 5 kDa) as a function of time (0-185 min) with
heparin concentration of 0.2 IU per well. Results are shown as relative mean
fluorescence ± SD. (n = 3).
4.3.5Cellular uptake of the nanoparticles
Cellular uptake of polyplexes with 50 pmol of Alexa Fluor 488-labeled
siRNA (N/P 7) was quantified in different cell lines (GASC1 positive and GASC1
negative) by flow cytometry. Trypan blue staining was employed on half of the
samples to differentiate between surface bound and internalized siRNA. The
results were compared to cells that were not treated with trypan blue, while cells
treated with trypan blue are indicated with an asterisk in Figure 23. Overall, trypan
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blue treated cells showed slightly lower mean fluorescence intensities compared to
cells that did not undergo quenching of surface-bound siRNA, indicating that a
small fraction of the siRNA polyplexes was attached to the cell membrane and
was not taken up intracellularly. However, this difference was not significant in
any of the samples (p > 0.05). As can be seen in Figure 23, there is a significant
difference (p < 0.0001) in uptake of PEI/siRNA in GASC1 positive cell lines
(HCC1954 and COLO824) and GASC1 negative cells (MCF10A and SUM102).
Interestingly, PEI alone showed better uptake in MCF10A and SUM102 which
could be caused by higher endocytic activity of these two cell lines

155

. However

PEI conjugated transferrin (Tf-PEI and Tf-PEG-PEI) showed very high uptake in
the HCC1954 cell line which was expected due to the higher level of TfR
expression. The uptake efficiency of Tf-PEI polyplexes did not show any
significant differences between HCC1954 and SUM102 cell lines (p > 0.05),
although the TfR expression of HCC1954 cells is about 4 times higher than that of
SUM102 cells (Figure 16). The mean fluoresce intensity in HCC1954 cells treated
with Tf-PEI polyplexes was 2.5 and 10-fold higher than in MCF10A and
COLO824 cells, respectively. As can be seen in Figure 23, Tf-PEG-PEI/siRNA
polyplexes showed 2.6 times higher uptake in HCC1954 than in SUM102 cells.
Uptake efficiency of the conjugates containing the PEG-spacer was 3.6 and 6 fold
higher in HCC1954 than MCF10A and COLO824 cells, respectively (Figure 23).
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Figure 23 Cellular uptake of Tf-PEI, Tf-PEG-PEI and PEI. Comparison of siRNA
uptake with different formulations (Blank (untreated cells), PEI (positive control),
Tf-PEI, Tf-PEG-PEI) in GACS1 positive (HCC1954 and COLO824) and GASC1
negative (MCF10A and SUM102) cell line models after fluorescence quenching of
membrane bound nanoparticles with trypan blue (asterisks indicate cell samples
treated with trypan blue). Data are expressed as the mean ± SD (n = 3), ns: nonsignificant.
The intracellular uptake of the nanoparticles was then analyzed by confocal
microscopy (Figure 24). The images obtained revealed the presence of
concentrated fluorescence after 4 h of incubation with Tf-PEI conjugates. The
internalization was detected using a Tye 563 labeled siRNA (Figure 24). Higher
nanoparticle binding to the cell surface and cell entry of the Tf-PEI conjugate
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compared to LF and polyethylenimine was visible. Interestingly, PEI delivered
fluorescently labeled siRNA was not detected by microscopy which was consistent
with the flow cytometry results showing very poor uptake of PEI polyplexes in
HCC1954 cells.

Figure 24 CLSM images of Tf-PEI and PEI. Confocal microscopy images of
cellular interaction of different complexes with the HCC1954 cell line after 4 h
incubation with siRNA polyplexes. HCC1954 cells were seeded with 25,000 cells
per chamber and transfected with 25 pmol siRNA (Tye 563 labeled, indicated by
red color) for 4 hours. Cells were fixed and the nuclei stained with DAPI
(indicated by blue color). Representative pictures are shown (100X magnification).
A) Blank; and siRNA polyplexes with B) Lipofectamine; C) Tf-PEI (N/P 7); and
D) PEI (N/P 7).
4.3.6 Cytotoxicity
In order to test one aspect of biocompatibility of the nanoparticle systems
investigated here, the cytotoxicity of PEI and Tf-shielded polyplexes was analyzed.
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The rate of viability was assessed by CellTiter-Blue® assays which are based on
the ability of active mitochondria to convert a redox dye (resazurin) into a
fluorescent end product (resorufin). Neither the conjugate polyplexes (TfPEI/siRNA and Tf-PEG-PEI/siRNA) nor PEI/siRNA at N/P 7 appeared to have
any apparent cytotoxicity, and cell survival rates greater than 85% were
maintained for all treatments (Figure 4.25). There is a significant change in cell
viability observed alone in PEI treated COLO824 cells compared to Tf-PEI (p <
0.05). No significant differences in cytotoxicity amongst the different cells lines
were observed (p > 0.05).

Figure 25 Cytotoxicity of PEI, Tf-PEI and Tf-PEG-PEI polyplexes. Cytotoxicity
profile of siRNA polyplexes made with Tf-PEI or Tf-PEG-PEI measured by the
Cell Titer-Blue method compared to PEI/siRNA polyplexes. HCC1954, COLO824,
SUM102 and MCF10A cell lines were treated with polyplexes for 4 h and the
viability of cells was measured after 24 h. Cell toxicity is presented as impaired
cell viability as a percentage relative to control cells. Data are expressed as the
mean ± SD (n = 5). * P < 0.05.
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4.3.7 GASC1 knockdown optimization
To identify the amount of GASC1 knock-down on the mRNA level, several
transfection parameters were optimized and determined by RT-PCR. The primary
studies were performed with 9 commercially available siRNA sequences [(A-D)
and (E-H and mixed)] to screen their efficacy against GASC1 since no validated
sequences are available. LF was used as standard transfection agent. Figure 26
shows the GASC1 knock down efficiency in HCC1954 cells with the above
mentioned siRNA sequences. Among the different sequences, the strongest
relative reduction in GASC1 RNA was achieved with sequence “A”. However,
there was no significant difference between A and sequences C, D and E (p >
0.05). Based on this result, sequence “A” was applied for further optimization
experiments.
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Figure 26 optimization of GASC1 siRNA sequence. GASC1 gene knock down
optimization with different siRNA sequences [(A-D sequences from Qiagen) and
siRNA sequences E-H and pooled siRNA from Dharmacon]. Per well, 500,000
HCC1954 cells were transfected with lipofectamine2000 (LF) for 24 hours with
100 pmol of different siRNA sequences against GASC1. RT-PCR was performed
with specific GASC1 primers, normalization was carried out against the
housekeeping gene PUM1. (NC=scrambled siRNA; error bars reflect SD, n=3). *
P < 0.05 and ** P < 0.01.
Gene silencing efficiencies were investigated after 6, 17, 24, 48 h post
transfection (Figure 27). Clearly, the GASC1 mRNA level was reduced
significantly after 24 h but was not significantly further reduced 48 h post
transfection (p > 0.05). However, there was no measurable gene knock down
compared with the negative/non treated control at the 6h and 17 h time points.
Additionally, the GASC1 mRNA levels measured at 6 h and 17 h were not
significantly different as well as the levels measured at 17 h and 48 h post
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transfections with sequence “A” (Figure 27). The optimum transfection time point
of 24 h was then used to probe the effect of different siRNA doses (100, 150, 200,
250 pmol). However, the most efficient gene knockdown was already achieved at
100 pmol, so that further optimization was not successful.

Figure 27 GASC1 gene knock down optimization. GASC1 gene knock down
optimization with siRNA sequence A in HCC1954 cells at different time points
(A), or different siRNA concentrations 24 h post transfection (B).
Lipofectamine2000 (LF) was used as transfection agent and RT-PCR was
performed with specific GASC1 primers, normalization was carried out against
the housekeeping gene PUM1. (NC=scrambled siRNA; error bars reflect SD, n=3),
ns: non-significant,* P < 0.05, *** P < 0.001 and **** p < 0.0001.
As these sequences did not reach an acceptable and therapeutically relevant
level of knock down, we designed three new sequences of GASC1 siRNA (named
V4, V6 and V7) using GENtle software. Figure 28 A presents the results of mRNA
knock down with the newly-designed GASC1 siRNA duplexes. GASC1 siRNA
(V4, V6 and V7, 100 pmol) were used to transfect HCC1954 cells with LF, PEI and
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the different Tf-modified nanobioconjugates. hGAPDH siRNA was used as a
positive control. Among the different siRNA sequences, V7 showed the most
efficient mRNA reduction with LF which was comparable with the positive
control. Additionally, the Tf conjugate (Tf-PEI) also showed promising knock
down with sequence V7. There was no significant difference between the mRNA
knock down achieved with V7 when delivered with PEI or Tf-PEG-PEI. To verify
the result of the RT-PCR assay, we performed western blot analysis to quantify the
target protein levels. The analysis indicated that cells treated with the optimized
Tf-PEI polyplexes with GASC1 siRNA (N/P 7) expressed less GASC1 protein
compared to lysates of cells that were treated with scrambled control or nontargeted PEI/GASC1 siRNA complexes as was predicted based on the RT-PCR
results (Figure 28 B).
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Figure 28 RT-PCR and western blot of GASC1 knock down. (A) GASC1
knockdown of Tf-PEI with siRNA sequence V7 shows that the conjugate was able
to knock down mRNA levels of GASC1 more efficient than the commercially
available siRNA sequences in HCC1954 cells. (V4, V6 and V7 are self-designed
GASC1 siRNA sequences. NC=scrambled siRNA; PC=positive control siRNA
(hGAPDH), error bars reflect SD, n=3), ns: non-significant,* P < 0.05, ** P < 0.01,
*** P < 0.001 and **** p < 0.0001. (B) GASC1 protein knockdown in HCC1954
cells with Tf-PEI compared to PEI alone was confirmed by western blot. Alphatubulin was used as the loading control. Top row shows (A: PEI/ V7GASC1
siRNA, B: PEI/NC siRNA, C: Tf-PEI/V7GASC1, D: Tf-PEI/NC siRNA.
4.3.8 Therapeutic effects
To determine if this gene knockdown on RNA and protein level would
translate into a therapeutic effect, which would be reflected by a sequencedependent inhibition of cell growth, MTT assays were performed after either one
or multiple transfections. Even though a small effect on cell proliferation was
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observed 24 h after a single transfection (2 days after seeding the cells), a more
pronounced and clearly sequence-specific effect was observed after 3 transfections
on day 10 after seeding the cells (Figure 29). While the proliferation after 3
transfections with the negative control siRNA seemed to be slightly inhibited, the
proliferation of those cells was not significantly different from the untreated
control cells.

Figure 29 Inhibition of cell proliferation via GASC1 knockdown. Therapeutic
effects of GASC1 knockdown with Tf-PEI polyplexes on days 2 (D2) and 10 (D10)
after seeding measured as inhibition of proliferation of HCC1954 cells. V7 is a
self-designed GASC1 siRNA sequence; NC=scrambled siRNA; error bars reflect
SD, n=3).
4.4Discussion
Considering that epigenetics and genetics are accomplices in breast cancer
tumor development, much attention has been paid to the investigation of molecular
and biology insights which could lead to the design of more specifically tailored
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therapies (e.g. gene therapy)

156

. siRNA mediated RNAi has become a powerful

tool for its specificity and efficiency to knock down targets that cannot be readily
down regulated by conventional chemotherapy

157

. However, siRNA clinical

applications have been a very challenging task due to multiscale barriers,
including rapid excretion of siRNA, low stability in blood serum, nonspecific
accumulation in tissues, poor cellular uptake and inefficient intracellular release 157.
Several delivery strategies have been developed to address these issues

158

; Here,

we aimed to design a specifically targeted nanoparticle delivery system with
chemical modification and ligand decoration of the complexes to improve efficient
delivery of siRNA for the down regulation of GASC1 overexpression in target
cells. This strategy was chosen because GASC1 overexpression correlates with
poor prognosis in BLBC patients 144.
Low molecular weight polyethylenimine (PEI) has been researched
extensively as a safe and efficient nucleic acid delivery system based on its ability
to electrostatically complex siRNA molecules into nanoscale polyplex and hence,
to protect them from nuclease degradation 159. However, PEI alone is not a suitable
carrier for targeted gene delivery to specific cells

159b

. Meanwhile, TfR is cell

membrane-associated glycoprotein serving as the main port of entry for iron
through a clathrin/dynamin dependent endocytosis mechanism 160 and can be used
as a gate for delivery of PEI when conjugated to a ligand such as transferrin that
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selectively targets TfR on receptor expressing cells. Therefore, utilizing
knowledge about the physiological function of the transferrin–transferrin receptor
complex and the efficiency of its receptor mediated endocytosis provides the
rationale to develop transferrin-targeted anticancer modalities. Moreover, studies
have shown the elevated expression levels of TfR on cancer cells compared with
normal cells; which correlates with tumor stage and poor prognosis (The
Nottingham prognostic index (NPI))

135, 161

. Among the different ligand targeting

nanoparticles, there are four transferrin-conjugated nanoparticle delivery systems
currently in early clinical evaluation studies

162

. Our TfR screening study

confirmed distinct levels of TfR among breast cancer cell models (Figure 16), and
the cell line HCC1954 (overexpressing GASC1) posses the highest TfR expression
compared to the healthy breast cell line MCF10A (GASC1 negative control). The
results of the binding capacity of transferrin to actively endocytosing TfR were in
accordance with the transferrin receptor expression data and led to the assumption
that the fluorescently labeled Tf remained its binding capacity after FITC labeling
and was successfully internalized by the TfR in HCC1954 cells as a valid model
for over expression of TfR (Figure 17).
Here, we used functionalized linkers (SPDP or PEG4-SPDP) to couple the
targeting ligand transferrin to LMW-PEI (Figure 18). The effect of two different
linker types and different molar stoichiometries (Tf:PEI) on nanoparticle
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formation and efficacy were compared. The analysis of the prepared conjugates
revealed that a Tf:PEI molar ratio between 1.3-2 results in better condensation of
siRNA in the Tf-PEI polyplex which are considerably smaller than a ratio around
0.4 for Tf-PEG-PEI polyplex (Figure 19). The difference in transferrin coupling
degrees observed in this study was a result of using different linkers, i.e. SPDP vs.
PEG4-SPDP.

However, it is also possible that the presence of PEG in the

nanobioconjugate with the lower transferrin coupling degree interfered with dense
condensation of siRNA based on electrostatics. The presence of PEG in the
crosslinking agent may, however, benefit the ligand-receptor interaction of those
conjugates as the spacer provides longer distance of the ligand from the polyplex
and better solubility. Accordingly, this space may avoid steric hindrance of ligandreceptor binding by the bulky nanoparticle. However, it needs to be kept in mind
that the coupling of substances to the primary amines of PEI may reduce its charge
density and the proton sponge effect as well as the interaction with siRNA. Indeed,
excessive grafting influences the complexation efficacy, complex stability, and
complex architecture, and thus requires detailed analysis prior to application in
vivo 159b.
The extent of siRNA condensation with transferrin conjugates was
determined by measuring the change of the fluorescence intensity of SYBR Gold
as nucleic acid intercalating agent at different N/P ratios. Increasing the N/P ratios
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from 1 to 20 not only led to decreased amounts of free siRNA as shown in Figure
21, but also higher net positive charges of the polyplexes were obtained. This
higher net charge increases the ability of polymer to electrostatically interact with
negatively charged siRNA and to condense siRNA more efficiently. However,
higher positive charges of the nanoparticles also correlate with non-specific
toxicity and non-specific cell uptake. As shown by Plank et al., nanoparticles with
a positive surface charge can bind nonspecifically to the cell surface and, in
addition, activate the alternative complement system

163

. This interaction would

also lead to rapid nanoparticle uptake by the reticuloendothelial system (RES)
after in vivo administration, and as a consequence, rapid clearance of the
nanoparticles is expected. However, modification of the polymer surface reduces
this phenomenon

164

. In our experiments, the condensation efficiency for all three

formulations (PEI, Tf-PEI and Tf-PEG-PEI) reached a plateau at N/P ratio of ≥ 7,
indicating the ability of efficiently complexing with siRNA. The results in Figure
21 showed that the condensation ability of PEI was not compromised even after
modification with transferrin. Therefore, polyplexes with N/P ratio of 7 were
chosen as the optimal ratio for further experiments.
Particle size and zeta potential are key factors in the biological outcomes of
a drug delivery system as they govern the biodistribution proﬁle, their efﬁciency to
accumulate in tumors through the enhanced permeability and retention (EPR)
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effect and cellular uptake

165

. As a rough estimation, it is believed that the design

of rigid and spherical nanoparticles ranging in size from 10 to 200 nm improves
circulation half-life of nanoparticles and their uptake by tumors

166

. At the

aforementioned N/P ratio, Tf-modified polyplexes displayed very promising small
sizes with close to neutral zeta potentials (Figure 19). The latter property is of
particular interest for potential in vivo use, since a neutral surface charge reduces
nonspecific charge-based interactions and undesirable clearance by the RES such
as liver and spleen macrophages, and improves the blood compatibility. Thus,
small nanoparticles with close to neutral surface charge are expected to efficiently
deliver anti-cancer drugs to tumor sites 167.
The stability of polyplexes is another critical component which determines
the nanoparticles’ efficiency. The presence of competing anions in the cell
membrane or in serum is known to affect the stability of polyplexes which
determines their in vivo fate

168

. Since conjugation of Tf to PEI might influence

complex stability, this issue was addressed by incubating the complexes with the
competing model polyanion heparin

169

. Results confirmed the ability of modified

PEI (Tf-PEI) to protect the siRNA in the presence of polyanions even more
efficiently than PEI alone, however, Tf-PEG-PEI showed lower stability compared
to Tf-PEI and PEI alone (Figure 22). Our results reflect the enhanced stability of
Tf-shielded polyplexes (Tf-PEI) which also has been reported by others 132. Based
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on the zeta potential results, we hypothesize that Tf is located on the surface of the
nanoparticles and shields the PEI/siRNA from competing polyanions. The PEGcontaining complexes, however, exhibited compromised stability which may be
due to the less dense packaging of siRNA as hypothesized above. The peak of
siRNA release that was especially prominent for the Tf-PEI and PEI formulation
can be explained as an initial competition between bound siRNA and added
heparin for binding with PEI. After longer incubation, however, a new equilibrium
is reached, and possibly even ternary complexes of polymer, siRNA, and heparin
are formed. A part of the initially released siRNA seems to be condensed again at
45 min or 60 min after incubation resulting in lower fluorescence intensities. In
case of Tf-PEG-PEI, the siRNA was released almost quantitatively upon addition
of heparin and further incubation did not lead to a re-complexation of siRNA. The
weak condensation of siRNA by Tf-PEG-PEI therefore precludes any in vivo
administration of this formulation.
The Tf-modified PEI formulations are also expected to avoid nonspecific
cytotoxicity which is often caused by excess positive charges on PEI. This was
confirmed by the CellTiter-Blue® assay (Figure 25). We propose that this
modification of PEI could reduce the toxicity of the polymer backbone and also
enhance the stability of Tf-PEI complexes as well as the circulation of polyplexes
in vivo.
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Superior internalization of the delivered siRNA with Tf modified PEI in
GASC1 positive HCC1954 cell lines compared to PEI alone was confirmed by
flow cytometry and confocal microscopy images (Figures 23 and 24). These
interesting results implied that Tf-PEI/siRNA polyplexes undergo selective
cellular uptake through transferrin receptor-mediated endocytosis, and therefore
may exhibit increased therapeutic benefits through the ability to deliver high
concentrations of relevant siRNA to the tumor site

161

. However, it must be taken

into account that the final silencing effect depends also on the endo-lysosomal
escape and the efficient incorporation of siRNA to the RNA-induced silencing
machinery 170.
While the ligand choice depends on the receptor being targeted, an
additional consideration for targeting is the type of cell entry pathway that will be
induced after ligand-receptor binding. Therefore, the endocytic pathway which
may be used by the vector depends on the targeting ligand, cell type and vector
properties

171

. It was surprising that in COLO824 cells with relatively high levels

of TfR (Figure 16), no significant transfection was detected with PEI alone or
modified PEI (Figure 23). This could be related to the cell type which may have a
very low endocytic activity, but an accurate answer requires further investigations.
It has been proposed that the majority of receptor-ligand complexes (e.g.
Tf/TfR) enter cells by clathrin-mediated endocytosis

172

. Receptor binding
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typically triggers the localized accumulation of clathrin structures on the
cytoplasmic surface of the plasma membrane as it begins to invaginate, forming
clathrin-coated pits

172

. TfR undergoes clathrin-mediated endocytosis and may

enter two types of trafficking pathways

173

. In the first pathway, within 10 min

after uptake, the receptor undergoes rapid recycling from early endosomes to the
cell surface. In the second pathway, the receptor undergoes slow recycling to the
cell surface from the recycling compartment, which is slightly acidic

173

.

Importantly, studies showed that gene expression after delivery with nanoparticles
which enter cells through clathrin-coated endocytosis is comparably less efficient
than after delivery via other pathways, suggesting that this path is linked to
endosomolytic degradation of the cargo. Therefore, vectors utilizing this pathway
must incorporate a mechanism of release from either organelle

160

. Here, we used

PEI for its important buffering feature with regard to the intracellular fate of the
complexes. The so-called ‘proton sponge effect’ postulates a proton acceptor
function of PEI, leading to the buffering of low pH values in the
endosomal/lysosomal system and therefore reduced nuclease activity. The influx
of chloride counter ions and the resulting osmotic influx of water then causes
swelling and bursting of the endo-lysosomes, which eventually leads to release of
the endo-lysosomal contents 174. Therefore, as stated earlier, careful formulation of
vector assembly should be taken into account not to compromise this property
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through grafting with targeting moiety and reducing the accessible protonable
amine groups.
As reported by a study for Tf-targeted nanoparticles (lipoplexes), it is likely
that other yet unidentified cell surface components (nonreceptor endocytosis) also
mediate complex binding and uptake. This might be the reason for the rather high
transfection efficacies of Tf-PEI nanoparticles in SUM102 cells. The underlying
molecular mechanisms have yet to be investigated.
It has been also demonstrated that conjugation/linker chemistry may have a
signiﬁcant effect on transfection efﬁciency and speciﬁcity in vitro 175. In our study,
we used two structurally different conjugates (Tf-PEI and Tf-PEG-PEI) which
were comparable in physicochemical properties but different in transfection,
binding, and uptake efﬁciencies. As a result, the efﬁciency of PEI conjugates
strongly depends on the linker chemistry. The coupling of transferrin with SPDP
to LMW-PEI was most efﬁcient. In contrast, our second approach of using PEG
chains in the form of PEG4-SPDP showed that a slightly longer spacer may hinder
the proper presentation of transferrin, the condensation of siRNA, and/or have an
effect on proton sponge features of PEI. Introducing a cyclic RGD peptide as a
targeting moiety via direct coupling or PEG spacer linking to PEI studied by
Kunath et al. showed that only direct coupling of the peptide to PEI via SPDP
mediated efﬁcient and speciﬁc DNA transfection, while an RGD-PEG-PEI
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conjugate was inefﬁcient. The authors concluded that the use of a PEG spacer
seemed to impair targeting, possibly by not only shielding PEI, but also the RGD
ligand 176. In contrast, Moffatt et al. successfully utilized a PEG linker for coupling
an anti-PSMA antibody to PEI/DNA polyplexes

177

. Polyethylene glycol (PEG)

spacers are expected to preserve protein function by moving the targeting moiety
away from the surface, by providing ﬂexibility and reducing non-speciﬁc binding
of environmental biomolecules 178. In another study, antibody-PEI conjugates were
prepared with three different linkers (SPDP, SMCC, and IBFB 110001) to prepare
HER2 or CD90 targeted conjugates. Using these linkers, major differences in the
degrees of conjugation and in target cell speciﬁcity of the resulting conjugates
were found. Interestingly, none of the conjugates prepared with SPDP as a linker
showed target cell speciﬁcity. Because of signiﬁcant differences in the study
design, direct comparison of these results proved to be difﬁcult, however.
Optimization of GASC1 knockdown on the mRNA level was carried out by
initially screening commercially available GASC1 siRNA sequences. The results
revealed that three commercially available sequences (“A”, “C”, and “D” obtained
from Qiagen) were able to reduce the GASC1 mRNA levels to about 75% after
transfection with LF (Figure 26). While the general expression levels of GASC1
can not be compared to easy-to-knock down genes like the housekeeping gene
GAPDH, the reduction to 75% residual expression even with LF was not
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acceptable. Therefore, several parameters such as incubation time and siRNA
concentration were attempted to be optimized (Figure 27). Since the gene knock
down was not improved by this approach, new siRNA sequences (V4, V6 and V7)
were designed and transfected with LF, PEI and Tf-modified PEIs (Figure 28).
The gene knock down efficacy was determined via RT-PCR. Among all sequences,
V7 showed very promising results after transfecting HCC1954 cells with LF and
acceptable results after transfection with Tf-PEI/siRNA complexes (N/P 7, Figure
28A). This final formulation was therefore used to verify the protein knockdown
level in HCC1954 cells after 7 days of incubation based on a previously optimized
protocol. The western blot analysis confirmed the RT-PCR results (Figure 28B),
indicating that the combination of Tf-PEI with V7 siRNA is a promising
formulation for GASC1 gene knock down in BLBC.
The question whether GASC1 gene knock down would result in efficient
inhibition of cell proliferation was answered after optimizing the transfection
approach. As shown in Figure 29, a single transfection did not yet lead to efficient
inhibition of cell proliferation. This result is not surprising considering that
previous approaches using shRNA145a or small molecule GASC1 inhibitors also
required multiple treatments to inhibit cell proliferation.179 The results also imply
that GASC1 may have a long biologic half-life. Figure 29 shows that multiple
treatments with negative control siRNA can have a small but not significant
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impact on cell proliferation in comparison to untreated cells, whereas one single
treatment does not affect the cells, which is in line with the cytotoxicity results
shown in Figure 25.
4.5 Conclusions
The establishment of an efficient and cell type-specific gene delivery
system is a most challenging objective, which in the context of cancer therapy
ideally would allow for the specific introduction of a therapeutic transgene or
knock out in malignant cells. Tf-PEI demonstrated enhanced gene transfer
efficiency in BLBC cells overexpressing TfR compared to non-modified PEI.
Through inhibiting the epigenetically and therapeutically relevant target gene
GASC1 which is involved in multiple signaling pathways leading to tumorigenesis,
Tf-PEI nanoparticles treatment has revealed promising results regarding gene
silence efficiency and inhibition of breast cancer cell proliferation. However, it
remains to be shown whether these properties can be exploited for targeted in vivo
gene delivery after systemic administration.
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CHAPTER 5 TARGETED DELIVERY OF SIRNA TO
TRANSFERRIN RECEPTOR OVEREXPRESSING TUMOR
CELLS VIA PEPTIDE MODIFIED POLYETHYLENIMINE
Please note that part of the content of this chapter is from a research
article,“Targeted Delivery of siRNA to Transferrin Receptor Overexpressing
Tumor Cells via Peptide Modified Polyethylenimine”, was published in Molecules
(Y. Xie, et al., 2016). The authors of this article include Bryan Killinger, Anna
Moszczynska, Olivia M Merkel and me. I am the first author of this research paper.
I performed the experiments and wrote the manuscripts.
5.1 Introduction
TfR is overexpressed in many kinds of cancers due to their increased
consumption of iron but is expressed at a low level on most cells. Therefore, the
upregulation of TfR in cancer cells makes it a promising target for the selective
delivery of siRNA for cancer therapies

57b

. Several strategies have been explored

to target TfR, including the use of holo-Tf or monoclonal antibodies raised against
TfR 180 181 which were coupled to polymers 44, and liposomes

182

. We have shown

that Tf-PEI can efficiently deliver therapeutic siRNA to breast cancer cells
overexpressing TfR in Chapter 4. However, high concentrations of endogenous
Tf in blood plasma (25 µM) may competitively inhibit the uptake mediated by the
holo-Tf or the anti-TfR antibody

183

. Furthermore, holo-Tf (molecular weight

(MW) 80 kDa) and antibodies against TfR (e.g., the anti-human TfR antibody
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5E9,
MW= 30 kDa

180

) are relatively large, and therefore, may introduce steric

hindrance when the drug delivery system is synthesized. The stability of these
proteins will also need to be taken into consideration in terms of synthesis
conditions, storage, formulation, and expected shelf-life. A viable alternative to Tf
and TfR specific antibodies is the use of TfR binding peptides. Two peptide
sequences, HAIYPRH and THRPPMWSPVWP, discovered by phage display,
were reported to be able to non-competitively bind to human TfR with high
affinity and consequently trigger TfR internalization
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. The chemico-physical

properties of these peptides are more stable and their MWs are smaller than those
of holo-Tf and antibodies.
The aim of this study was to develop a siRNA delivery system to target TfR
overexpressing tumor cells. In this chapter, two TfR targeting peptides and bPEI
were successfully coupled via two different crosslinkers, namely PEGylated
succinimidyl 3-(2-pyridyldithio) propionate (PEG4- SPDP) and sulfosuccinimidyl
4-(N-maleimidomethyl) cyclohexane-1-carboxylate (sulfo-SMCC). The siRNA
and bPEI or peptide-bPEI polyplexes were characterized regarding size, zetapotential, and siRNA condensation efficiency. Selective delivery of siRNA using
peptide-bPEI was investigated in the TfR overexpressing cell line H1299 and low
TfR expressing cell lines A549 or H460. Gene knockdown efficiency of
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siRNA/peptide-bPEI polyplexes was measured both at the mRNA and protein
level in H1299 cells.
5.2 Materials and Methods
5.2.1 Materials
Branched 5k Da bPEI (Lupasol® G100) and 25k Da bPEI (Lupasol® HF)
were obtained from BASF (Ludwigshafen, Germany). Succinimidyl 3-(2pyridyldithio) propionate (SPDP), PEGylated succinimidyl 3-(2-pyridyldithio)
propionate (PEG4-

SPDP) and sulfosuccinimidyl 4-(N-maleimidomethyl)

cyclohexane-1-carboxylate (sulfo-SMCC) were purchased from Thermo Fisher
(Waltham, MA, USA). Dulbecco’s phosphate buffered saline (PBS), 1,4-DithioDL-threitol

(DTT),

dimethyl

sulfoxide

(DMSO),

HEPES,

ethylenediaminetetraacetic acid disodium salt dehydrate (EDTA), picrylsulfonic
acid solution (TNBS, 5% w/v), sodium pyruvate, sodium bicarbonate (NaHCO3)
and glucose were bought from Sigma-Aldrich (St. Louis, MO, USA). Human
holo-transferrin was obtained from EMD Millipore (Billerica, MA, USA).
Cysteine modified TfR binding peptide HAIYPRH (Cys-His-Ala-Ile-Tyr-Pro-ArgHis) was synthesized by BACHEM Americas (Torrance, CA, USA) and
THRPPMWSPVWP

(Thr-His-Arg-Pro-Pro-Met-Trp-Ser-Pro-Val-Trp-Pro-Cys)

was synthesized by the American Peptide Company (Sunnyvale, CA, USA).
Enhanced green fluorescent protein (eGFP) siRNA, amine modified eGFP siRNA,
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siRNA fluorescently labeled with Ty563 (siRNA-Ty563), human glyceraldehyde3- phosphate- dehydrogenase (GAPDH) siRNA and scrambled siRNA were
purchased from Integrated DNA Technologies (Coralville, IA, USA).
Table 5 Sequence of siRNA.
Name
Sequence
5´- pACCCUGAAGUUCAUCUGCACCACcg
eGFP siRNA
3´-ACUGGGACUUCAAGUAGACGUGGUGGC

GAPDH siRNA

5´- pGGUCGGAGUCAACGGAUUUGGUCgt
3´UUCCAGCCUCAGUUGCCUAAACCAGCA

Scramble siRNA

5´-pCGUUAAUCGCGUAUAAUACGCGUat
3´CAGCAAUUAGCGCAUAUUAUGCGCAUAp

* Indication of modified nucleotides: “p” denotes a phosphate residue, lower case
bold letters are 2´-deoxyribonucleotides, capital letters are ribonucleotides, and
underlined capital letters are 2´-O-methylribonucleotides.
5.2.2 Synthesis of Peptide–bPEI Conjugate
The HAIYPRH peptide (HAI) was coupled to bPEI using two different
crosslinkers, namely sulfo-SMCC and PEG4-SPDP. In the sulfo-SMCC
crosslinking approach, as shown in Figure 30 B, 1 mg of 25k bPEI was dissolved
in HEPES buffered saline (HBS) buffer (20 mM of HEPES and 150 mM of NaCl,
pH=7.2) at 1 mg/mL, and 1 mg of sulfo-SMCC was dissolved in water at 10
mg/mL. bPEI solution and sulfo-SMCC were mixed together and allowed to stir
for 4 h at room temperature (RT). bPEI-SMCC was purified using 10,000
molecular weight cut off (MWCO) centrifugal filters (Millipore) with HBS
containing 2 mM of EDTA buffer. The bPEI-SMCC solution was mixed with 1
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mg of HAI peptide dissolved in HBS containing 2mM of EDTA (5 mg/mL) and
stirred overnight at RT. The next day, free HAI peptide was removed from HAIbPEI using 10,000 MWCO centrifugal filters. In the PEG4-SPDP crosslinking
approach, as shown in Figure 30 A, 5 mg of 25k bPEI was dissolved in HBS
buffer at 5 mg/mL, and 2 mg of PEG4-SPD was dissolved in DMSO at 20 mM.
PEG4-SPDP was added drop-wise into the bPEI solution and stirred overnight at
RT. Meanwhile, 2 mg of HAI peptide was dissolved in HBS containing 2 mM of
EDTA buffer at 4 mg/mL and reduced by 10 molar excess DTT for 2 h. Reduced
HAI peptide solution was transferred to a 500–1000 MWCO dialysis tube
(Spectrum laboratories, Rancho Dominguez, CA, USA) and dialysis was
performed against HBS containing 2 mM of EDTA buffer overnight at 4 °C. The
next day, bPEI-SPDP was purified using 10,000 MWCO centrifugal filters with
HBS containing 2 mM of EDTA buffer and then mixed with the reduced HAI
peptide. The mixture was stirred for 24 h at RT followed by purification using
10,000 MWCO centrifugal filters with HBS. The concentration of HAI peptide in
the conjugate was measured spectrophotometrically at 280 nm. The concentration
of bPEI in the conjugate was determined by a TNBS assay

122

. Briefly, the

according amount of HAI peptide was added into bPEI serial dilution to generate
a standard curve in a clear 96-well plate (Corning, Corning, NY,USA). Then 30
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µl of 3 mM of TNBS solution was added to 100 µl of bPEI/HAI solution and the
absorbance at 405 nm was determined after 5 min.
5k bPEI (1 mg/mL) was dissolved in HBS buffer and mixed with 100 µl 20
mM of SPDP, stirred overnight, followed by purification via 3000 MWCO
centrifugal filters. THRPPMWSPVWP peptide (THR peptide) was reduced by 10fold excess TCEP HCl (Thermo Fisher) and purified using a PD10 column (GE
healthcare). THR peptide was mixed with bPEI-SPDP overnight while stirring at
RT. The concentrations of THR peptide and bPEI in conjugate were measured
spectrophotometrically at 280 nm and by a TNBS assay, respectively.
5.2.3 Fluorescent Labeling of PEI, Transferrin, Peptide and siRNA
bPEI was fluorescently labeled with fluorescein-5-isothiocyanate (FITC)
(Thermo Fisher). 15 mg of bPEI was dissolved in 0.1 M NaHCO3 (pH= 9) at 2.5
mg/mL, and 2 mg of FITC was dissolved in 200 µl of DMSO. The FITC solution
was added drop-wise to the bPEI solution and allowed to stir for 3 h at RT. Free
FITC was removed using 10,000 MWCO centrifugal filters, and bPEI-FITC was
stored in water. The bPEI concentration was determined by a TNBS assay as
described above, and the presence of FITC showed no interference with the
results, as reported before

47

. For the conjugates, 0.2 mg of FITC (1 mg/mL) in

DMSO was added dropwise into 2 mg of HAI-bPEI synthesized via the sulfoSMCC approach and allowed to react for 3 h with stirring. The concentration of
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bPEI in the conjugate was determined by a TNBS assay with a bPEI-FITC
standard curve. Holo human Transferrin was fluorescently labeled with Texas Red
modified with succinimidyl ester (Thermo Fisher) following the manufacturer’s
protocol. Cysteine modified THR peptide was fluorescently labeled with a Alexa
Fluor 488 modified with maleimide (Thermo Fisher) following the manufacture’s
protocol. Amine modified siRNA was fluorescently labeled with Alexa Fluor 488
modified with succinimidyl ester (Thermo Fisher) following the manufacturer’s
protocol, followed by purification using ethanol precipitation and silica spin
column binding as reported before 123.
5.2.4 Preparation of Polyplexes
To prepare the siRNA and polymer polyplexes, polymer was diluted with
5% glucose to different concentrations. An equal volume of polymer solution was
added to a predetermined amount of siRNA solution to yield different amine to
phosphate ratios (N/P ratios) and allowed to incubate for 15 min at RT before
measurement or transfection. The calculation to prepare polyplexes is based on the
following equation: m polymer (pg) = n siRNA (pmol) × MWprotonable (g/mol) × N/P × N
nucleotide

(MWprotonable of bPEI = 43.1 g/mol, N nucleotide of siRNA = 52).

5.2.5 . Measurement of Hydrodynamic Size and Zeta-Potential
Polyplexes were prepared with bPEI or HAI-SPDP-bPEI and 50 pmol of
siRNA at N/P 5 in 100 µl 5% glucose buffer as described above and were
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transferred to a disposable micro cuvette (Brand GMBH, Wertheim, Germany).
Size measurement was performed in three runs using a Zetasizer Nano ZS
(Malvern Instruments Inc., Westborough, MA,USA). Results were collected and
analyzed with the Zetasizer Software (Malvern) with settings of 173° backscatter
angle, 0.88 mPa*s for viscosity and 1.33 for refractive index. Subsequently, the
same polyplex solutions were diluted to 1 mL with water and transferred to a
folded capillary cell (Malvern). The zeta-potentials of polyplexes were determined
in three runs using a Zetasizer Nano ZS (Malvern).
5.2.6 siRNA Condensation Measured by a SYBR Gold Assay
SYBR Gold is a fluorescent dye which is used to stain nucleic acids. It
intercalates into siRNA and produces fluorescence. When siRNA is condensed by
polymer and becomes inaccessible for SYBR Gold, the fluorescence will decrease.
Polyplexes were prepared with bPEI or HAI-SPDP-bPEI and 50 pmol of siRNA at
different N/P ratios (1, 2, 3, 5, 7, 10) in 100 µl per well in a FluoroNunc 96 well
white plate (Thermo Fisher). Subsequently, 30 µl of 4 × SYBR Gold was added to
each well and incubated for 10 min in the dark. The fluorescence of SYBR Gold
was determined by a Synergy 2 multi-mode microplate reader (BioTek Instrument,
Winooski, VT, USA) with an excitation filter 485/20 nm and an emission filter
520/20 nm. The fluorescence of free siRNA (N/P= 0) represented 100% free
siRNA. The experiment was performed in triplicate.
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5.2.7 Cell Culture
NCI-H1299 cells (human non-small cell lung carcinoma) and A549 cells
(human non-small cell lung carcinoma) were purchased from ATCC (Manassas,
VA, USA). NCI-H460 cells (human large cells lung carcinoma) were a kind gift
from Dr. Larry H. Matherly (School of medicine, Wayne State University, USA).
H1299/eGFP is a H1299 cell line stably expressing the reporter gene eGFP.
H1299 and H460 cells were cultured in RPMI-1640 media (GE healthcare,
Buckinghamshire, UK) supplemented with 10% heat inactivated fetal bovine
serum (v/v) (Sigma), 1× penicillin/streptomycin (Corning), 1× GlutaMax (Thermo
Fisher), 10 mM of HEPES, 1.5 g/L of NaHCO3, 4.5 g/L of glucose and 1 mM of
sodium pyruvate. A549 cells were cultured in DMEM media (Corning)
supplemented with 10% fetal bovine serum (FBS) and 1× pen/strep. All cells were
maintained in a humidified atmosphere and 5% CO2 at 37 °C.
5.2.8 Immunofluorescent Staining
H1299, H460 and A549 cells were harvested from flasks and washed with
PBS. Each sample contained 100,000 cells and was resuspended in 10 µl of a 50fold diluted human Fc receptor binding inhibitor (eBioscience, San Diego, CA,
USA) for 5 min on ice. Subsequently, 20 µl of a 20-fold diluted phycoerythrin (PE)
labeled human CD71 antibody (OKT9, eBioscience) or 20 µl of a 20-fold diluted
PE labeled mouse IgG1 isotype control antibody (P3.6.2.8.1, eBioscience) were
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added to the samples and incubated for 30 min in the dark at 4 °C. Samples were
washed with PBS/ 2 mM of EDTA three times and were resuspended in 400 µl of
PBS/ 2 mM of EDTA. The median fluorescent intensity (MFI) of samples was
quantified using an Attune® Cytometer (Life Technologies, Waltham, MA, USA)
with an excitation laser 488 nm and emission filter 574/26 nm. Cell populations
were gated according to the forward and side scattering channel, and 10,000
events were collected. Data analysis was performed using the Attune® cytometer
software (Life Technologies). Experiments were conducted in duplicate.
5.2.9 Quantification of Cellular Uptake and Cellular Binding
For cellular uptake experiments, H1299, H460 and A549 cells were seeded
at the density of 50,000 cells/well in 24-well plates (Corning). After 24 h of
incubation, polyplexes were prepared with 50 pmol of siRNA-AF488 and bPEI,
HAI-SMCC-bPEI, HAI-SPDP-bPEI or THR-PEI at N/P=5. The cells were
transfected with polyplexes at the siRNA concentration of 125 nM for 4 h. To
reduce the potential cytotoxicity induced by concentrated polyplexes, fresh media
were added to dilute siRNA concentration to 50 nM followed by an additional 20
h of incubation. The cells were harvested and washed three times with PBS/2 mM
of EDTA. All samples were resupended in 400 µl of PBS/2 mM of EDTA, and
MFIs of samples were determined via an Attune® Cytometer (Life Technologies)
with an excitation laser 488 nm and emission filter 530/30 nm. In each sample,
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10,000 events were collected and data analysis was performed using the Attune®
cytometer software (Life Technologies). Experiments were conducted in triplicate.
For the cellular binding experiment, H1299 and A549 cells were seeded as
described above. After 24 h incubation, different concentrations (0, 0.1, 1, 2 µg/
ml) of THR peptide fluorescently labeled with Alexa Fluor 488 (THR-AF488)
were added into media and incubated for 1 h at 37 °C. The cells were harvested
and the MFI was quantified via flow cytometry as described above. Experiments
were conducted in duplicate.
5.2.10 Confocal Laser Scanning Microscopy
H1299 cells were seeded at the density of 50,000 cells/well in 24-well
plates with a 12 mm circle cover glass (Fisherbrand, 12CIR. -1) in each well and
were incubated for 24 h. To determine intracellular distribution of polyplexes,
fluorescently labeled polymer bPEI-FITC and HAI-SMCC-bPEI-FITC were
formulated with 50 pmol of siRNA-Ty563 at N/P= 5. Cells were transfected with
polyplexes at a siRNA concentration of 125 nM for the first 4 h and 50 nM for an
additional 44 h. Cells were washed with PBS and fixed with 4% paraformaldehyde
(PFA) solution in PBS (Affymetrix, Thermo Fisher) for 20 min at RT at different
transfection time points (1, 4, 24, 48 h). To investigate the co-localization of the
HAI peptide binding part with TfR, cells were incubated with 2 µg/mL of TfTexas Red and polyplexes formulated with bPEI-FITC or HAI—SMCC-bPEI-
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FITC and 50 pmol of siRNA at N/P= 5 for 1 h or 4 h. To determine the colocalization of THR peptide binding part with TfR, cells were incubated with 2
µg/ ml of THR-AF488 and Tf-Texas Red for 1 h. Slides were washed with PBS
and fixed with 4% PFA. After fixation, the nuclei were stained with 5 µM of
DRAQ5 (Invitrogen, Thermo Fisher) for 5 min and rinsed with PBS. Slides were
mounted with a Fluoromount mounting medium (Southern Biotech, Birmingham,
AL, USA). Slides were imaged by a Leica TCS SPE-II laser scanning confocal
microscope (Leica, Wetzlar, Germany), and the images were exported from the
Leica Image Analysis Suite (Leica).
5.2.11 In Vitro GAPDH Gene Knockdown
To determine mRNA level knockdown efficiency of polyplexes, silencing
of housekeeping gene GAPDH in H1299 and H460 was determined by real time
PCR (RT-PCR). Cells were seeded at the density of 50,000 cells/well in 24-well
plates for 24 h. bPEI, HAI-bPEI or THR-PEI were formulated with 50 pmol of
siRNA against GAPDH or scrambled siRNA at N/P= 5. Cells were transfected
with polyplexes at a siRNA concentration of 125 nM for the first 4 h and 50 nM
for an additional 20 h. Total mRNA was isolated from cells using the PureLink®
RNA mini kit (Life techonologies) following the manufacturer’s protocol in the
addition of DNase I digestion (Sigma). The brilliant III ultra-fast SYBR® green
QRT-PCR master mix kit (Agilent Technologies, Santa Clara, CA, USA) was used
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to reverse transcribe 100 ng of mRNA to cDNA and perform RT-PCR. RT-PCR
was conducted in a Stratagene Mx 3005p qPCR system (Agilent Technologies)
and cycle threshold (Ct) values were exported from MxPro software (Agilent
Technologies). Hs_GAPDH_2_SG primers for GAPDH and Hs_ACTB_2-SG
primers for β-actin (Qiagen, Valencia, CA, USA) were used in this experiment.
GAPDH gene expression was normalized to β-actin gene expression for
quantification and comparison, and the untreated group represented 100%
GAPDH expression. Experiments were conducted in triplicate.
5.2.12 In Vitro eGFP Knockdown
To determine the protein level knockdown efficiency of polyplexes,
silencing of reporter gene eGFP was determined by flow cytometry. H1299/eGFP
cells were seeded at the density of 50,000 cells/well in 24 well-plates for 24 h. On
the day of transfection, old media were replaced with 350 µl of fresh media with
or without 115 µM of chloroquine. Cells were transfected with 50 pmol of siRNA
against eGFP formulated with bPEI or HAI-bPEI at N/P= 5, 10 in total volume of
polyplexes of 50 µl. bPEI and HAI-bPEI polyplexes containing scrambled siRNA
at N/P= 10 were included as the negative control. Cells were transfected with 50
µl of polyplexes and incubated for 4 h with or without 100 µM of chloroquine. To
dilute the concentration of chloroquine and polyplexes, 600 µl of fresh media were
added, and cells were incubated for an additional 44 h. Afterward, cells were
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harvested and washed three times with PBS/2 mM of EDTA. Samples were
resuspended in 400 µl of PBS/2 mM of EDTA, and the MFIs were determined by
an Attune® Cytometer (Life Technologies) with an excitation laser 488 nm and
emission filter 530/30 nm. In each sample, 10,000 events were collected, and data
analysis was performed using Attune® cytometer software (Life Technologies).
Experiments were conducted in triplicate.
5.2.13 Statistics
Results were represented as mean +/- standard deviation (SD). All
statistical analysis used One-way ANOVA with Newman–Keuls multiple
comparison post-test in GraphPad Prism software (Graph Pad Software, La Jolla,
CA, USA).
5.3 Result
5.3.1 Synthesis of HAI-bPEI
HAI-bPEI conjugates were successfully synthesized using crosslinkers
sulfo-SMCC or PEG4-SPDP (Figure 30 A and B). To synthesize HAI-SMCCbPEI, sulfo-SMCC was first reacted with primary amines in bPEI, then the
maleimide group in bPEI-SMCC was reacted with sulfhydryl in the cysteine
modified HAI peptide. To synthesize HAI-SPDP-bPEI, PEG4-SPDP was first
coupled with bPEI. After purification, bPEI-PEG4-SPDP was coupled to DTTreduced cysteine-modified HAI peptide. The molar ratios of HAI peptide to bPEI
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were determined according to the absorbance at 280 nm and the 2,4,6trinitrobenzene sulfonic acid (TNBS) assay. The molar ratio of HAI peptide to
bPEI was 18.6 for HAI-SMCC-bPEI and 18.2 for HAI-SPDP-bPEI.
THR peptide was successfully conjugated to bPEI via crosslinker SPDP
(Figure 30 C). bPEI first reacted with SPDP while THR peptide was activated with
TCEP HCl. PEI-SPDP was coupled to reduced-THR peptide and yielded THRPEI. The molar ratio of THR peptide to bPEI is 0.4.
(A)
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(B)

(C)

Figure 30 Synthesis scheme of HAI-SPDP-PEI, HAI-SMCC-PEI and THR-SPDPPEI. (A) Synthesis approach of HAI-SPDP-bPEI.; (B) Synthesis approach of HAISMCC-bPEI. (C) Synthesis approach of THR-SPDP-bPEI. (bPEI: branched
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polyethylenimine;
PEG4-SPDP:
2-Pyridyldithiol-tetraoxatetradecane-Nhydroxysuccinimide; sulfo-SMCC: sulfosuccinimidyl 4-[N-maleimidomethyl]
cyclohexane-1-carboxylate; DTT: dithiolthreitol; SPDP: succinimidyl 3-(2pyridyldithio) propionate; TCEP: Tris (2-carboxyethyl) phosphine hydrochloride)
5.3.2 siRNA Condensation Efficiency of bPEI and HAI-bPEI
Cationic polymers, such as bPEI, can condense siRNA via ionic
interactions. The amount of uncondensed free siRNA can be quantified by
SYBR® Gold, an intercalating fluorescent nucleic acid staining dye. Therefore,
the condensation efficiency of bPEI and HAI-bPEI at different anime to phosphate
(N/P) ratios (1, 2, 3, 5, 7, 10) was examined by a SYBR Gold assay. As shown in
Figure 31, bPEI and HAI-SPDP-bPEI demonstrated similar condensation
efficiency. Increasing the N/P ratio resulted in less free siRNA. Both bPEI and
HAI-bPEI can achieve complete condensation of siRNA at an N/P ratio of 2 and
all N/P ratios above 2, respectively.
SYBR Gold assay
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Figure 31 SYBR Gold assay of PEI and HAI-SPDP-PEI. The siRNA condensation
efficiency of bPEI and HAI-SPDP-bPEI was determined by a SYBR® Gold assay
at N/P ratio 1, 2, 3, 5, 7 and 10. At N/P= 0, the fluorescence represented 100% free
siRNA. (Data points indicate mean +/- standard deviation (SD), n= 3.)
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5.3.3 Hydrodynamic Size and Zeta-Potential of PEI and HAI-PEI Polyplexes
The particle size of HAI-SPDP-bPEI and bPEI polyplexes formulated with
50 pmol of siRNA at N/P=5 was measured by dynamic light scattering (Figure 32
A). HAI peptide modified bPEI polyplexes, as expected, had a slightly larger
hydrodynamic diameter of around 144 nm with a polydispersity index (PDI) of
around 0.3. Unmodified bPEI polyplexes exhibited a hydrodynamic diameter of
around 117 nm with a PDI of around 0.2. The zeta-potential of HAI-SPDP-bPEI
and bPEI polyplexes were also determined. As shown in Figure 32 B, the zetapotentials of both polyplexes were slightly positive, and HAI-SPDP-bPEI
polyplexes demonstrated a lower positive surface charge (13.3 +/- 1.7 mV) than
bPEI polyplexes (17.2 +/- 9.2 mV).
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Figure 32 Size and zeta-potential of HAI-SPDP-PEI and PEI. (A) Hydrodynamic
diameters (left y-axis) and polydispersity index (PDI, right y-axis) and (B) zetapotential of bPEI and HAI-SPDP-bPEI polyplexes containing 50 pmol of siRNA
at N/P= 5. (Data points indicate mean +/- SD, n= 3.)
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5.3.4 TfR Expression
TfR expression levels in H1299, H460 and A549 cells were measured via
flow cytometry. Cells were immunostained with a fluorescently labeled anti-CD71
antibody, namely the anti-TfR antibody, and with an isotype control antibody. As
shown in Figure 33 A and B, median fluorescent intensity (MFI) across all three
cell lines was unchanged when stained with the isotype antibody, indicating that
little fluorescence was caused by non-specific binding of the antibody. On the
other hand, H1299 cells demonstrated a significantly higher MFI after being
stained with the anti-CD71 antibody compared with A549 and H460 cells.
Therefore, H1299 cells were considered as a TfR overexpressing cell model while
A549 and H460 cells were considered as TfR low expressing cell models for later
studies.
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Figure 33. TfR expression in H1299 and A549. (A) H1299 and A549 cells were
immunostained by the anti-CD71 antibody which binds to transferrin receptors
(TfR) and by the isotype antibody which served as a control of non-specific
binding. Median fluorescence intensity (MFIs) were quantified via flow
cytometry. (B) H1299 and H460 cells were immunostained by the anti- CD71
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antibody and by the isotype antibody (Data points indicate mean +/- SD, n= 2. ***
p <0.001).
5.3.5 Cellular Uptake of bPEI and HAI-bPEI Polyplexes
The bPEI modified by HAI peptide via two different crosslinkers—sulfoSMCC or PEG4-SPDP, HAI-SMCC-bPEI or HAI-SPDP-bPEI—were tested in this
study. The cellular uptake of HAI-SMCC-bPEI or HAI-SPDP-bPEI polyplexes
compared with bPEI polyplexes were determined in the TfR overexpressing cell
line H1299, and in TfR low expressing cell lines H460 or A549 via flow
cytometry. Cells were transfected by HAI-SMCC-bPEI, HAI-SPDP-bPEI or bPEI
polyplexes containing siRNA labeled with Alexa Fluor 488 at N/P= 5 for 24 h. As
shown in Figure 34 A, significantly stronger fluorescence was determined in
H1299 cells treated with HAI-SMCC-bPEI polyplexes than in A549 cells. On the
other hand, only a slightly stronger MFI was observed in H1299 cells treated with
bPEI polyplexes than in A549 cells. In A549 cells, cellular uptake mediated by
HAI-SMCC-bPEI polyplexes was only slightly higher than that mediated by bPEI
polyplexes, however, the difference between cellular uptake mediated by HAISMCC-bPEI and bPEI polyplexes was more significant in H1299 cells. A
comparison of the cellular uptake mediated by HAI-SPDP-bPEI and bPEI
polyplexes was performed in H1299 and H460, as shown in Figure 34 B, and a
similar cellular uptake profile was observed.
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Figure 34 Cellular uptake of PEI and HAI-SPDP-PEI. (A) The cellular uptake of
bPEI and HAI-SPDP-bPEI polyplexes was determined in TfR overexpressing cells
H1299 and TfR low expressing cells A549. Polyplexes were prepared with 50
pmol of siRNA fluorescently labeled with Alexa Fluor 488 at N/P= 5 and
transfected for 24 h. The MFIs were quantified by flow cytometry. (Data points
indicate mean +/- SD, n= 2. **, p <0.01, *** p <0.001). (B) The cellular uptake of
bPEI and HAI-SPDP-bPEI polyplexes was determined in TfR overexpressing cells
H1299 and TfR low expressing cells H460. (Data points indicate mean +/- SD, n=
3. *** p <0.001)
5.3.6 Cellular Binding and Cellular Uptake of THR Peptide and THR-PEI
The cellular binding of THR-AF488 was determined in H1299 cells and
A549 cells and quantified via flow cytometer. With increasing concentration of
THR-AF488, the MFI of H1299 cells overexpressing TfR increased dramatically
and was higher than the MFI of A549 cells expressing low level of TfR (5.6 a).
The cellular uptake of THR-PEI or PEI polyplexes was also determined in H1299
and A549. Cells were transfected by THR-PEI or PEI polyplexes formulated with
50 pmol siRNA-AF488 at N/P=5 for 24 h. The MFIs of cells were quantified by
flow cytometry. The cellular uptake mediated by THR-PEI polyplexes in H1299
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and A549 was similar. Moreover, non-modified PEI mediated higher cellular
uptake in both cell lines compared to THR-PEI (Figure 35 B).
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Figure 35 Cellular binding of THR peptide and cellular uptake of THR-PEI. (A)
The cellular binding of THR-AF488 with H1299 and A549 were quantified by
flow cytometry. (Data points indicate mean +/- SD, n= 3) (B) The cellular uptake
of bPEI and THR-bPEI polyplexes was determined in H1299 and A549 cells and
quantified by flow cytometry. (Data points indicate mean +/- SD, n= 2-3).
5.3.5 Imaging of Uptake by Confocal Laser Scanning Microscopy (CLSM)
To determine the sub-cellular distribution of polyplexes, H1299 cells were
transfected

by

HAI-SMCC-bPEI

fluorescently

labeled

by

fluorescein

isothiocyanate (HAI-SMCC-bPEI-FITC) and bPEI-FITC polyplexes containing
siRNA fluorescently labeled with Ty563 at N/P= 5 for 48 h. The cellular
distribution of polyplexes was observed at several time-points (1, 4, 24, and 48 h)
by CLSM (Figure 36). H1299 cells treated with HAI-SMCC-bPEI polyplexes
(Figure 36, lower panel) showed denser distribution of the red signal representing
siRNA-Ty563 than cells treated with bPEI polyplexes (Figure 36, upper panel). At
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24 and 48 h, bright yellow dots, representing co-localization of polymer-FITC
(green) and siRNA-Ty563 (red), were observed in both cells treated with HAISMCC-bPEI and bPEI polyplexes. There were some red dots (siRNA-Ty563)
evenly distributed in the cytoplasm of cells treated with HAI-SMCC-bPEI
polyplexes, however, siRNA-Ty563 was exclusively co-localized with bPEI
(yellow dots) and not present as free siRNA in cells transfected with bPEI
polyplexes.

Figure 36 CLSM of subcellular distribution of PEI and HAI-SMCC-PEI
polyplexes. Subcellular distribution of bPEI and HAI-SMCC-bPEI polyplexes in
H1299 was imaged by confocal microscopy. H1299 cells were transfected with
bPEI and HAI-SMCC-bPEI polyplexes prepared with 50 pmol of siRNA
fluorescently labeled with Ty563 at N/P= 5 for 1, 4, 24 and 48 h. The polymers
were fluorescently labeled with FITC and shown in green. siRNA-Ty563 was
shown in red, and DRAQ5TM stained nuclei were shown in blue.
To investigate the pathway of cellular internalization mediated by the HAI
peptide, H1299 cells were incubated with 2 µg/mL of transferrin which was
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fluorescently labeled with Texas Red (Tf-Texas Red) and HAI-SMCC-bPEI-FITC
or bPEI-FITC polyplexes formulated with non-fluorescently labeled siRNA at
N/P= 5 for 1 and 4 h. As shown in Figure 37, upper panel, after 1 h of incubation,
more yellow dots representing co-localization of Tf-Texas Red (red) and polymerFITC (green) were observed in cells treated with HAI-SMCC-bPEI polyplexes
than in bPEI polyplexes transfected cells. At 4 h (Figure 37, lower panel), there
was noticeably more co-localization between Tf and polymers in both bPEI and
HAI-SMCC-bPEI transfected samples when compared with samples at 1 h (Figure
37, upper panel). The intensity of the co-localization was stronger in samples
treated with HAI-SMCC-bPEI polyplexes than in bPEI polyplexes-transfected
cells (Figure 37, lower panel).
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Figure 37 CLSM of co-localization of Tf and PEI or HAI-SMCC-PEI. Colocalization of transferrin (Tf) and bPEI or HAI-SMCC-bPEI polyplexes in H1299
was imaged by confocal microscopy. H1299 cells were incubated with Tf
fluorescently labeled with Texas Red (Tf-Texas Red) and bPEI or HAI-SMCCbPEI polyplexes prepared with 50 pmol of siRNA at N/P= 5 for 1 and 4 h. The
polymers were fluorescently labeled with FITC and shown in green. Tf-Texas Red
was shown in red, and DRAQ5 stained nuclei were shown in blue. The arrows
pointing to the yellow dots represent co-localization spots of polyplexes and Tf.
To determine the co-localization of the cellular binding site of THR peptide
with TfR, H1299 cells were incubated with 2 µg/mL of Tf-Texas Red and THRAF488 for 1 h. As shown in Figure 38, red dots represented Tf-Texas Red evenly
distributed in the cells, but green dots represented THR-AF488 and formed large
aggregate on the cellular surface.
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Figure 38 CLSM of co-localization of Tf and THR peptide. 2 µg/mL of THRAF488 and Tf-Texas Red were incubated with H1299 for 1 h at 37 °C. The
cellular distribution of THR-AF488 and Tf-Texas Red was observed under
confocal laser scanning microscopy (CLSM).
5.3.6 In Vitro GAPDH Gene Knockdown
To investigate the selective delivery of siRNA with HAI-SPDP-bPEI or
HAI-SMCC-PEI, we next measured the efficacy of HAI-SPDP-bPEI or HAISMCC-PEI/ siRNA polyplexes to silence GAPDH in H1299 cells. Cells were
transfected with either HAI-SPDP-bPEI, HAI-SMCC-PEI or PEI polyplexes
containing siRNA against GAPDH (siGAPDH), or scrambled siRNA at N/P= 5
for 24 h. GAPDH gene expression was normalized to β-actin gene expression. As
shown in Figure 39 A, significantly higher GAPDH silencing was achieved by
siGAPDH/HAI-SPDP-bPEI polyplexes compared with the group treated with
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scrambled siRNA/HAI-SPDP-bPEI polyplexes, and with the untreated group.
However, there was no significant difference among siGAPDH/bPEI, the
scrambled siRNA/bPEI treated group, and the untreated group. On the other hand,
HAI-SMCC-PEI failed to mediate significant GAPDH knockdown compared to its
scramble siRNA control (Figure 39 B).
To further confirm the GAPDH gene silence mediated by HAI-SPDP-PEI,
the GAPDH knockdown experiment was conducted in H460 cells which expressed
low levels of TfR. As shown in Figure 39 C, there was no significant difference
regarding GAPDH expression among the HAI-SPDP-PEI polyplexes treated group,
PEI polyplexes treated group and untreated group.
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Figure 39 GAPDH knockdown in H1299 and H460. (A) H1299 were transfected
with bPEI or HAI-SPDP-bPEI. (B) H1299 were transfected with bPEI or HAISMCC-bPEI polyplexes. (C) H460 cells were transfected with bPEI or HAISPDP-bPEI polyplexes. All polyplexes were formulated with 50 pmol of siRNA
against GAPDH (siGAPDH) or scrambled siRNA at N/P= 5 and the cells were
transfected for 24 h. The expression of GAPDH was determined by RT-PCR and
normalized to the expression of β-actin. Untreated control represented 100% or 1
GAPDH/β-actin. (Data points indicate mean +/- SD, n= 3. ns, p > 0.05, **p <
0.01).
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5.3.7 In Vitro eGFP Knockdown
To further determine the gene silencing efficiency of HAI-SPDP-bPEI
polyplexes at the protein level, the in vitro knockdown efficiency of the reporter
gene enhanced green fluorescent protein (eGFP) by HAI-SPDP-bPEI polyplexes
was determined in a H1299 cell line stably expressing eGFP. Cells were
transfected with HAI-SPDP-bPEI or bPEI polyplexes formulated with siRNA
against eGFP (siGFP) or scrambled siRNA at N/P= 5 and 10 for 48 h with or
without chloroquine treatment, a drug reported to increase the endosomal release
of siRNA
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. The MFIs of eGFP in cells were quantified by flow cytometry. As

shown in Figure 40 A, there was no significant difference of MFI between cells
transfected with bPEI and HAI-SPDP-bPEI polyplexes containing siGFP without
chloroquine treatment at either N/P= 5 or 10. However, with additional
chloroquine treatment (Figure 40 B), HAI-SPDP-bPEI polyplexes achieved
significantly more eGFP knockdown compared with bPEI polyplexes at both
N/P=5 and 10. Both HAI-SPDP-bPEI and bPEI polyplexes containing scrambled
siRNA did not reduce the MFI of eGFP, indicating that the eGFP knockdown was
not contributed to by the polymer, but by the siRNA against eGFP released in the
cytoplasm.
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Figure 40 GFP knockdown in H1299. (A) H1299/eGFP cells were transfected with
bPEI and HAI-SPDP-bPEI polyplexes for 48 h without chloroquine treatment. (B)
H1299/eGFP cells, stably expressing eGFP, were transfected with bPEI or HAISPDP-bPEI polyplexes prepared with 50 pmol of siRNA against eGFP (siGFP) or
scrambled siRNA at N/P= 5 and 10 for 48 h with chloroquine treatment. The MFIs
of eGFP were quantified by flow cytometry. (Data points indicate mean +/- SD,
n= 3. ns, p > 0.05, *p < 0.05)
5.4 Discussion
The selective and efficient delivery of siRNA to tumors is hindered by
many biological barriers

95

. Numerous modifications of polymers have been

discovered to target tumor cells including folic acid
growth factor (EGF)
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19

, transferrin

20

, epidermal

and the tripeptide arginine-glycine-aspartate RGD

47

. In

this study, two human TfR binding peptides, HAIYPRH (HAI peptide) and
THRPPMWSPVWP (THR peptide), were tested for gene delivery in TfR positive
cells. Both peptides contain a distal cysteine to introduce an additional thiol group
for further modification. The THR peptide was first evaluated since it
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demonstrated a high affinity to TfR (1.5 × 10−8 M) compared to the affinity of
native ligand Tf to TfR of 2.8 × 10−9 M; in contrast, the affinity constant of the
HAI peptide was 4.4 × 10−4 M 184. The THR peptide was successfully coupled to 5
kDa bPEI via linker SPDP as shown in Figure 30 C. Despite the fact that the THR
peptide, which was fluorescently labeled with Alexa Fluor 488 (THR-AF488), did
preferentially bind to TfR overexpressing H1299 cells compared to TfR low
expressing A549 cells (Figure 35 A), the cellular uptake mediated by THR-bPEI
polyplexes in H1299 cells was lower than that of bPEI polyplexes and showed no
difference compared with A549 cells (Figure 35 B). It has been reported that the
THR peptide conjugated with a chelator for radiolabeling demonstrated negligible
uptake in a TfR positive cell line 187 and that THR modified gold nanoparticles did
not efficiently cross the blood brain barrier without the addition of a hydrophobic
peptide to facilitate membrane binding 188. Therefore, it is possible that the binding
cavity of the THR peptide to TfR is sterically very strict and only allows limited
modification in the peptide. Consequently, THR modified with a small fluorescent
probe, AF488 (MW= 720.66 Da), still demonstrated preferential binding to H1299
but THR conjugated to a large polymer, bPEI (MW= 5000 Da), cannot mediate
significantly higher cellular uptake in H1299 cells compared with A549 cells.
Another possible reason of low selective cellular uptake could be low receptor
internalization efficiency. Confocal imaging revealed that THR-AF488 can bind to
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the membrane of H1299 but little internalization was observed (Figure 38), and
the co-localization of THR-AF488 and Tf was absent. Thus, THR may not be an
optimal candidate for the TfR targeting of polyplexes.
The other peptide discovered in the same study, the HAI peptide,
demonstrated different properties during evaluation for polyplex targeting. Firstly,
the HAI peptide was successfully conjugated to 25k Da bPEI via two different
linkers: sulfo-SMCC and PEG4-SPDP. The coupling degrees were similar in both
approaches and were around 18 HAI peptides per bPEI. It has been reported that
protein/peptide modifications in polymer may result in less nucleic acid
condensation efficiency compared to the non-modified polymer due to the
introduction of steric hindrance 61, 189. The siRNA condensation efficiency of bPEI
and HAI-SPDP-bPEI was therefore determined by a SYBR Gold assay, and the
results demonstrated that HAI-peptide modification did not have any negative
impact on bPEI’s condensation of siRNA (Figure 31). Chemico-physical
properties of polyplexes are very important for successful and efficient siRNA
delivery. Therefore, bPEI and HAI-SPDP-bPEI polyplexes (N/P=5) were fully
characterized in terms of the hydrodynamic diameter, PDI and zeta-potential. As
shown in Figure 32 A, HAI-SPDP-bPEI and bPEI polyplexes had narrow size
ranges with PDIs of around 0.3, indicating that uniform polyplexes were formed
with little aggregation. HAI-SPDP-bPEI polyplexes were slightly larger than bPEI
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polyplexes which may be due to steric hindrance of the peptide during polyplexes
formation. However, both polyplexes resulted in very small sizes (100–150 nm).
These results suggested that both polyplexes may readily be taken up by cells

130

,

avoid rapid clearance from macrophages in the liver and spleen after systemic
administration, and could potentially easily accumulate in a tumor through the
EPR effect 24. Both polyplexes demonstrated slightly positive surface charge (<30
mV) (Figure 32 B). Since HAI-SPDP-bPEI and bPEI can completely condense
siRNA at N/P= 2 (Figure 31), it was expected that at N/P =5, an excess amount of
cationic polymer formulated with siRNA would result in positive surface charges.
HAI-SPDP-bPEI polyplexes exhibited a less positive charge than bPEI polyplexes
which may be due to the assumption that the conjugated HAI peptide locates on
the surface of the polyplexes and can shield some positive charge from bPEI.
Another possible reason for the reduced surface charge of HAI-SPDP-PEI is that
the SPDP coupling reaction consumed some of the primary amines in bPEI. A
slightly positive surface charge could facilitate the binding between polyplexes
and cellular membranes. Moreover, the HAI peptide located on the surface is
expected to increase the possibility to interact with TfR, suggesting that efficient
cellular uptake may be achieved by this formulation.
The TfR expression status of three different cell lines—H1299, A549 and
H460—was determined by flow cytometry after immunostaining with the anti-
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CD71 (TfR) antibody. Based on the results (Figure 33 A and B), H1299 cells
served as a TfR overexpressing cell model, and A549 and H460 served as TfR low
expressing cell models for later studies. The peptide mediated TfR selectivity was
investigated by confocal microscopy. HAI-SMCC-bPEI and bPEI were
fluorescently

labeled

with

FITC

(HAI-SMCC-bPEI-FITC,

bPEI-FITC

respectively), and polyplexes were formed with non-fluorescently labeled siRNA.
H1299 cells were incubated with Tf-Texas Red and the aforementioned polyplexes.
As shown in Figure 36, HAI-SMCC-bPEI polyplexes showed more binding (green
dots) on the cell surface and more co-localization (yellow dots) with Tf-Texas Red
(red dots) than bPEI polyplexes after 1 and 4 h of the co-incubation period,
indicating that the HAI peptide can mediate selective binding to TfR
overexpressing cells. Furthermore, HAI-SMCC-bPEI can achieve more colocalization with Tf, suggesting that HAI-SMCC-bPEI polyplexes may enter cells
via a TfR mediated pathway in a non-competitive manner as reported before
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.

The subcellular distribution of both polyplexes over time was observed under the
confocal microscope (Figure 36). H1299 cells were transfected with HAI-SMCCbPEI-FITC or bPEI-FITC polyplexes (green dots) containing siRNA-Ty563 (red
dots). HAI-SMCC-bPEI polyplexes clearly achieved more cellular binding on the
membrane than bPEI polyplexes during the first 1 and 4 h, suggesting that HAISMCC-bPEI preferentially bound to TfR overexpressing cells compared with
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bPEI polyplexes. At later time points (24 and 48 h), both bPEI and HAI-SMCCbPEI polyplexes formed bright yellow dots in vesicle like structures, indicating
that many of both types of polyplexes had accumulated and were trapped in
endosomes or lysosomes. However, it is worth nothing that more siRNA
distributed in the cytoplasm in the HAI-SMCC-bPEI treated group than in bPEI
transfected cells. According to the cellular uptake results (Figure 34 A), it is
possible that HAI-SMCC-bPEI polyplexes mediated higher cellular uptake in
H1299 cells than bPEI polyplexes, consequently more siRNA escaped into the
cytoplasm. The TfR specific cellular uptake mediated by the HAI peptide was also
confirmed by flow cytometry (Figure 34 A and B). Both HAI-SMCC-bPEI and
HAI-SPDP-bPEI polyplexes showed specific binding to the TfR overexpressing
cell line (H1299 cells) compared with TfR low expressing cells (A549 and H460).
Furthermore, both HAI peptide modified bPEI polyplexes mediated significantly
higher cellular uptake in H1299 cells compared with non-modified bPEI,
suggesting a specific interaction between the HAI peptide in the polymer and TfR
on the cell membrane.
The gene knockdown efficiency of the HAI peptide, modified bPEI and
non-modified bPEI was determined by RT-PCR, and the housekeeping gene
GAPDH was targeted. Surprisingly, HAI-SMCC-bPEI polyplexes did not mediate
efficient GAPDH gene knockdown, as shown in Figure 39 B, which did not agree
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with the cellular uptake result (Figure 34 A) and the confocal microscopy result
(Figures 35 and 36). It is possible that the HAI peptide modification reduced the
number of primary amines in bPEI and consequently reduced the buffering
capacity of bPEI. Furthermore, TfR rapidly recycles back to the cell surface after
internalization
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, therefore, HAI-SMCC-bPEI polyplexes that are still bound to

TfR are recycled back to the cell surface before siRNA can be released. To
address this problem, HAI-SPDP-bPEI was synthesized using a linker PEG4-SPDP.
PEG4-SPDP (25.7 Å) is longer than sulfo-SMCC (8.3 Å) which may make the
HAI peptide more accessible to TfR and increase the binding efficiency. Moreover,
it introduced a disulfide bond into the HAI-SPDP-bPEI conjugate which can be
reduced in the endosomal compartment
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and may facilitate the release of

bPEI/siRNA complexes from the HAI peptide/TfR complexes before TfR recycles
back to the cell surface. The GAPDH gene knockdown efficiency of HAI-SPDPbPEI polyplexes was determined in H1299 and H460 cells. In line with previous
cellular uptake results (Figure 34 B), HAI-SPDP-bPEI polyplexes can achieve
more efficient GAPDH gene knockdown in H1299 cells (Figure 39 A) compared
with bPEI polyplexes but not in H460 cells (Figure 39 C). These results revealed
that the introduction of a long and reducible linker into target moiety-polymer
conjugates may increase their transfection efficiency. Additionally, it was shown
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that the transfection efficiency of HAI-SPDP-bPEI polyplexes is highly dependent
on the TfR expression status of the targeted cells.
Next, the gene silencing efficiency of HAI-SPDP-bPEI polyplexes at the
protein level was investigated in H1299/eGFP cells. H1299/eGFP cells were
treated with HAI-SPDP-bPEI and bPEI polyplexes for 48 h, and the eGFP
expression was determined by flow cytometry. However, as shown in Figure 40 A,
there was no significant difference among the polyplexes treated groups and the
untreated group. Based on the confocal images (Figure 36), it is possible that most
polyplexes were trapped in the endosome and only a small amount of siRNA was
released into the cytoplasm. Therefore, mRNA level silencing can be observed
since mRNA is the direct target of siRNA. However, it is more difficult to achieve
protein level silencing. A sufficient amount of siRNA needs to be released into the
cytoplasm. Additionally, the silencing efficiency also depends on the half-life of
the targeted protein, and wild type GFP has a relatively long half-life (around 26
h) 192. To increase the release of siRNA from endosomes, H1299/eGFP cells were
transfected with HAI-SPDP-bPEI and bPEI polyplexes in media containing
chloroquine, which is a chemical that can dramatically increase the transfection
efficiency by disrupting the endosomal membrane
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. As shown in Figure 40 B,

significantly higher eGFP knockdown can be achieved by siGFP/HAI-SPDP-bPEI
polyplexes compared with siGFP/bPEI polyplexes in a dose dependent manner.
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5.5 Conclusion
In conclusion, our optimized HAI-bPEI conjugate has desired chemicophysical properties as a siRNA delivery vector. It can achieve selective delivery of
siRNA to TfR overexpressing tumor cells and efficient gene knockdown at the
mRNA level. This study demonstrates the feasibility to target TfR using HAI
peptide. However, results also indicate the need for further optimization of this
conjugate to achieve better endosomal escape.
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Gene therapy is thought to be a solution for various difficult to treat
diseases such as cancer. Small interfering RNA (siRNA) as a promising class of
anti-sense molecules can specifically silence disease related genes and has been
evaluated in different diseases. However, lack of safe and efficient siRNA delivery
systems limits the application of siRNA therapy in the clinic. Transferrin receptor
(TfR) is an essential transmembrane receptor involved in iron uptake. TfR is
universally expressed in most cells/ tissues but is upregulated in certain cells, for
example, many cancer cells and activated T cells (ATCs).

To overcome the

biological barriers and increase siRNA delivery efficiency, in this dissertation,
various TfR targeted siRNA delivery systems have been developed. Holo-Tf was
conjugated to PEI via reducible linker succinimidyl 3-(2-pyridyldithio) propionate
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(SPDP) or PEG4-SPDP to generate Tf-PEI. Tf-PEI was firstly evaluated for
potential therapy of asthma. Tf-PEI demonstrated satisfactory physicochemical
properties and can efficiently deliver siRNA to human primary ATCs ex vivo.
Furthermore, pulmonary administration of Tf-PEI in a murine asthma model
resulted in ATCs selective delivery of siRNA and minimum toxicity.
Gene amplified in squamous cell carcinoma 1 (GASC1) is an oncogene
overexpressed in basal like breast cancer (BLBC), an aggressive type of breast
cancer, and is an essential epigenetic factor involved in tumorigenesis. Tf-PEI
polyplexes containing siRNA against GASC1 gene were exploited as a potential
treatment of BLBC. Tf-PEI can selectively deliver siRNA to BLBC
overexpressing TfR and achieve efficient silencing of GASC1 gene leading to
inhibition of proliferation of BLBC.
Two TfR binding peptides, HAIYPRH (HAI) and THRPPMWSPVWP
(THR), as alternative TfR targeting moieties were conjugated with PEI via
reducible linker PEG4-SPDP or non-reducible linker sulfosuccinimidyl 4-[Nmaleimidomethyl]

cyclohexane-1-carboxylate

(SMCC).

Both

peptide-PEI

conjugates were investigated in lung cancer cells expressing low or high level of
TfR. HAI-PEI preferentially bound to cells overexpressing TfR while THR-PEI
didn’t demonstrate TfR selectivity. Reducible HAI-SPDP-PEI achieved better
gene silencing ex vivo than non-reducible HAI-SMCC-PEI. In conclusion, the
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present study described the feasibility to efficiently deliver siRNA to ATCs in
asthma and cancer cells via targeting TfR. These results could help the
development of siRNA therapies for asthma and cancer.
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